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resumo 
 
 
O uso inapropriado de antibióticos no tratamento de doenças infeciosas tem 
levado a um aumento da resistência de diversos microrganismos patogénicos, 
o que apresenta atualmente um problema de saúde pública e tem motivado a 
procura de estratégias alternativas para o controlo destes microrganismos. Por 
outro lado, a procura de novas moléculas ou novas combinações de moléculas 
para o combate ao cancro é um assunto em constante desenvolvimento. 
Na presente dissertação descreve-se o trabalho desenvolvido para a obtenção 
de conjugados de ftalocianina–sulfonamida e a avaliação da atividade dos 
novos compostos como fotossensibilizadores. Os conjugados foram 
idealizados com o intuito de promover um possível efeito sinérgico das suas 
unidades constituintes, nomeadamente propriedades antitumorais e/ou 
antimicrobianas. Para tal, desenvolveram-se métodos de síntese de 
sulfonamidas e de conjugados de ftalocianina–sulfonamida. Algumas das 
ftalocianinas obtidas foram testadas como fotossensibilizadores na eliminação 
fotodinâmica de células tumorais e de bactérias, utilizando-se as linhas 
celulares de carcinoma de células escamosas orais (HSC3) e de 
queratinócitos orais (HaCaT), e as bactérias Escherichia coli (Gram-negativo) 
Staphylococcus aureus (Gram-positivo) como modelos biológicos. Os 
resultados destes estudos revelaram que as ftalocianinas estudadas são muito 
promissoras como fotossensibilizadores para a inativação fotodinâmica de 
células tumorais e de microrganismos. Por outro lado, foi também 
desenvolvido um ensaio enzimático para avaliar a atividade dos novos 
compostos como inativadores da enzima anidrase carbónica, em particular a 
isoforma IX que se encontra sobre-expressa em células tumorais e é bem 
conhecida como reguladora do pH em processos de hipoxia e acidose 
metabólica. 
Este estudo vem dar mais um passo no conhecimento científico das 
ftalocianinas e evidencia o potencial das ftalocianinas sulfonadas na 
perspetiva do controlo de infeções e da tumorogénese. 
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abstract 
 
The inappropriate use of antibiotics in the treatment of infections has led to an 
increase in the resistance of several pathogenic microorganisms, which 
represents a major public health issue and triggered the search for novel 
antimicrobial drugs. On the other hand, the search for new molecules or new 
combinations of molecules for the fight against cancer is a subject in constant 
development. 
The present dissertation describes the work developed to obtain 
phthalocyanine–sulfonamide conjugates and the biological evaluation of these 
compounds as photosensitizers. These conjugates were designed to explore 
their antimicrobial and/or antitumor properties. 
Methods for the synthesis of sulfonamides and phthalocyanine–sulfonamide 
conjugates were developed. Some of the phthalocyanines obtained were tested 
as photosensitizers for the photodynamic inactivation of tumor cells and 
bacteria. HSC3 oral squamous cell carcinoma, HaCaT 'normal' keratinocytes, 
and the bacteria Escherichia coli (Gram-negative) and Staphylococcus aureus 
(Gram-positive) were used as biological models. 
The phthalocyanines studied proved to be very promising to be considered in 
future studies in the perspective of the photodynamic inactivation of tumor cells 
and microorganisms. On the other hand, an enzymatic assay was also 
developed to evaluate the activity of the compounds obtained as inactivators of 
the enzyme carbonic anhydrase, in particular the IX isoform that is 
overexpressed in tumor cells and is well-known as pH regulator in processes of 
hypoxia and metabolic acidosis. 
This study represents a contribution to the application of phthalocyanines, and 
in particular sulfonated phthalocyanines, in the control of infections and 
tumorigenesis. 
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Chapter 1 Introduction 
During the last decades photodynamic therapy (PDT) emerged as a promising 
and reliable technique for the treatment of different diseases, among which several 
forms of cancer. Its first application was the inactivation of tumor cells, but it has 
revealed much more relevance than initially thought. Nowadays, it is used in the clinical 
treatment of different oncological diseases as well as in the treatment of ocular diseases, 
atherosclerosis, and dermatological pathologies. Furthermore, particularizations of the 
technique have been developed, such as photochemical internalization (PCI) and 
photodynamic inactivation of microorganisms (PDI) (bacteria, fungi and virus) in living 
tissues, surgical equipment, surfaces and environmental matrices.1 In recent years, PDT 
has become a subject of intense investigation, making this technique still an interesting 
topic nowadays. 
Phthalocyanines (Pcs) are a class of tetrapyrrolic macrocycles of synthetic origin 
analogous to porphyrins (Pors). The latter were the first tetrapyrrolic macrocycles used 
as photosensitizers (PSs) in PDT. During the development of PDT and PDI different 
PSs have been studied. Pcs emerged as promising candidates due to their exceptional 
physico-chemical properties. In this sense, new and more effective Pc-based PSs have 
been developed for many applications extend beyond photodynamic therapy. They can 
be found in many materials science fields, surpassing Pors in a number of applications, 
making them one of the most highly studied macrocycle and coordination compounds.2 
This chapter intends to provide an overview on basic knowledge on Pcs. 
Due to the low solubility in common organic solvents, several functionalizations 
and metallations of Pcs have been studied in order to attain the most interesting 
properties, namely selectivity, transport across biological membranes, solubility in 
biological fluids, singlet oxygen production, as well as clearance after 
photoinactivation.3 Photobiological and photochemical properties of PSs must be very 
well-known for the proper functioning of this technique. Furthermore, it is also 
important to understand PDT and PDI main differences and similarities. 
During the last decades sulfonamides (SAs) have been used mainly as 
antimicrobials. However, they have also been successfully tested for other clinical 
purposes such as thiazide diuretics, loop diuretics, anti-arrhythmic agents, non-
nucleotide reverse transcriptase inhibitors, non-peptidic vasopressin V1a receptor 
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antagonists, and Human Immunodeficiency Virus 1 (HIV-1) protease inhibitors. 
Compounds containing SAs moieties can be found in pharmaceutical formulations for 
the treatment of inflammatory bowel disease (e.g. Sulsalazine®), in anticonvulsants (e.g. 
Sultiame®), in PDE5 inhibitor (Viagra®), and in COX-2 inhibitor (Celecoxib®).4 
As antimicrobial, SAs were initially used in the treatment of a variety of 
bacterial infections by inhibiting the enzyme dihydropteroate synthase (DHPS) in the 
folic acid pathway.4 However, the rapid development of resistance to SAs and the 
discovery of more potent drugs have limited their clinical use. Beyond that, SAs 
continue to be used in several clinical situations. 
In order to overcome resistance to antibiotics, observed not only for SAs but 
also to other antibiotics, efficient strategies to control microbial infections have been 
developed. One of them is PDI, which has proved to be effective in the inactivation of 
several pathogenic microorganisms, including multi-resistant bacteria, fungi and virus. 
Recently, SAs have been studied as antitumoral drugs. There are several targets 
for SAs with antitumoral activity, but the majority of the studies are concerned around 
the inhibitory effect of carbonic anhydrases (CAs) IX and XII and regulation of cell 
cycle at the G1 phase through inhibition of cyclin-dependent kinases (CDKs). 
Taking advantage of SAs potentialities as antitumor and antimicrobial agents 
and Pcs as PSs, the general objective of this work is to explore the additive effects 
between these two families of compounds. By coupling SA moieties to Pcs we expect to 
achieve more effective PSs. For that, a new group of PSs with a Pc backbone were 
designed, synthesized and tested in different bacterial models and in tumor cells, in 
order to gain knowledge on the biological pathways underlying the effects in target 
cells. 
1.1 Thesis outline 
This document was written in order to guide the reader along the different 
disciplines that this work is based upon. The basic components in which this work 
relays on are divided over the different experimental chapters. Since Pcs are transversal 
to the different works, as already mentioned, they will be addressed in this first chapter. 
In chapter 2, the study focused on the synthesis and optimization of new N-acyl 
Pc–SA conjugates is described. For that, an overview of click reactions and, in 
particular, sulfo-click reactions is made. Following, the synthesis of new Pc–SA 
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conjugates is described in chapter 3. In this third chapter not only the study of the 
synthesis of neutral Pc–SA conjugates is described, but also the synthesis of 
cationizable conjugates. Likewise, the encapsulation of neutral Pc–SA conjugates is 
presented. The synthetic strategies to obtain SAs are detailed. 
In chapter 4, the PDT of tumor cells using some neutral Pc–SA conjugates and 
the respective PVP-encapsulated conjugates is evaluated. For that, HSC3 oral squamous 
cell carcinoma and HaCaT ‘normal’ keratinocytes were used as cellular models. In 
addition, the properties of these neutral Pc–SA conjugates as inhibitors of the enzyme 
carbonic anhydrase (CA) were also accessed. The rationality on the use of the CA as a 
PDT target is explained as an introduction. 
The evaluation of neutral Pc–SA conjugates as PSs at 10 and 20 µM is 
addressed in chapter 5. The results obtained in the PDI of Escherichia coli and 
Staphylococcus aureus under white and red light, with neutral Pc–SA conjugates and 
the same compounds encapsulated in polyvinylpyrrolidone (PVP) micelles are 
discussed. In this chapter, basic concepts of PDI and biological functions of SAs are 
explained. 
1.2 Phthalocyanines 
Tetrapyrrolic macrocycles, such as heme and chlorophylls, are important in 
Nature, playing vital roles in biological systems responsible for oxygen transport, cell 
growth, light transformation into useful energy in plants, electron transfer chains in 
mitochondria and prokaryote cells, and in protective responses to oxidative damage. Pcs 
are synthetic tetrapyrrolic macrocycles that, while having a similar structure to natural 
Pors, are not found in Nature.3,5–7 
Pcs have four basic isoindole units connected through aza bridges, presenting an 
eighteen π-electrons aromatic cloud delocalized over an arrangement of alternated 
carbon and nitrogen atoms (Figure 1.1).3,8 
The word Pc is derived from the Greek terms for cyanine (dark blue) and 
naphtha (rock oil) and also from the phthalic acids, which were the first precursors used 
for the synthesis of these macrocycles. Professor Reginald P. Linstead, from the 
Imperial College of Science and Technology, was the first to use the term 
“phthalocyanine”, between 1933 and 1934.8–10 The first X-ray structure was 
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investigated by J. Monteath Robertson in the 1930's at the Davy Faraday Research of 
the Institution Laboratory Royal.8,10,11 
 
Figure 1.1: Structure and numeration of phthalocyanines. M is representing two protons 
or a metal ion. 
Metal-free and metallated Pc derivatives have recently attracted an increasing 
interest not only for the preparation of new dyes and pigments, but also as building 
blocks for the design of novel molecular materials, due to their outstanding electronic 
and optical properties.12 Furthermore, efficient singlet oxygen production, high stability 
in relation to  temperature and light, desirable spectroscopic features and low dark 
toxicity, make Pcs currently one of the most potent and promising PSs for application in 
PDT and PDI.8,10 
Pcs have been applied in a wide range of fields of medicinal3 and materials10,13 
sciences. They are applied in the treatment of cancer14–17 and photodynamic inactivation 
of pathogenic bacteria,18 virus19 and fungi,20 as well as in bone marrow purging, age-
related macular degeneration,21 atherosclerosis,22–24 theranostics,25 anti-oxidants,26 
tumor imaging,27–29 catalysis,30 chemical sensors,31–33 information storage and colorful 
liquid crystal systems, photovoltaic cells, semiconductors, non-linear transmission 
(NLT)34–36 and conductive polymers.8,10,11 On the other hand, the very low solubility of 
unsubstituted Pcs in common organic solvents and aqueous media has been the main 
limitation for their biological application.6 
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1.2.1 Historical background 
The first Pc was discovered accidentally in 1907 by Braun and Tcheriac,37 South 
Metropolitan Gas Company in London, during the chemical conversion of 1,2-
disubstituted benzene derivatives, in which they observed the formation of a small 
amount of an insoluble blue-green byproduct during the preparation of 2-
cyanobenzamide (Scheme 1.1).38 
 
Scheme 1.1: Accidental synthesis of Pcs.37 
Twenty years later, Diesbach and von der Weid, University of Fribourg, 
Germany, prepared, for the first time, a copper Pc in 23% yield by reacting 1,2-
dibromobenzene with copper(I) cyanide in refluxing pyridine (Scheme 1.2).3,8,10,39 
 
Scheme 1.2: Reaction performed by Diesbach and von der Weid. 
Diesbach and von der Weid tried to characterize this compound without success. 
Therefore, the credit of the discovery of these compounds was given to Scotish and 
Dyes Ltd., when in 1928, during the industrial preparation of phthalimide from phthalic 
anhydride, an impurity was formed. The production of this blue-green impurity resulted 
from the exposure of the phthalimide to the outer layer of the iron reactor. Normally, 
such impurity simply would be discarded. However, this accidental discovery occurred 
in a dye company (Scottish Dyes, Ltd., Grangemout, Scotland) and the blue-green 
product attracted immediate their interest. This dye company performed some initial 
studies revealing that the iron-containing byproduct was exceptionally stable and 
insoluble in the majority of the common organic solvents, acquiring potential 
applications as pigment. The first patent was issued to Dandridge, Drescher, and 
Thomas of Scottish Dyes Ltd., in 1929.8,10,11 
Pcs also turn out to have moderate cost of manufacture, good stability, tinctorial 
properties, and light absorption in the visible region of the spectrum. After 1938, several 
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companies like du Pont Company and Standard Ultramarine & Color Company started 
to produce copper Pc. Nowadays, there are a large number of companies all over the 
world producing Pcs and researchers have addressed themselves to the synthesis of 
substituted Pcs and determination of the physical and chemical properties of 
compounds.8,10,11 
Still, the evolution of Pcs chemistry has not only been aimed at finding synthetic 
strategies that provide increasingly sophisticated Pcs systems, but also similar 
structures. Pc analogues (Figure 1.2) have also been studied and it is possible to find a 
different variations of the basic structure of the Pc  macrocycle.10,39 
 
Figure 1.2: Analogues of phthalocyanine. 
1.2.2 Molecular structure and numeration 
According to the International Union of Pure and Applied Chemistry (IUPAC) 
numbering, the only atoms that cannot be numbered are the fusion carbons between the 
pyrrole ring and the benzene ring. Often the positions of the inner and outer carbons of 
the benzene rings are called alpha (α) and beta (β), respectively (Figure 1.1). 
In the center of metal-free Pcs there are two hydrogen atoms which can be 
replaced by metal ions. Metallated Pcs are usually called metallophthalocyanines 
(MPcs) (Figure 1.1). Also, the sixteen peripheral hydrogen atoms in the four benzene 
rings can be replaced by different groups or even halogens.40,41 
1.2.3 Physical and chemical properties 
Although the chemical and physical properties of Pcs can be easily modulated, 
they are very stable due to an extended network of conjugated electrons. This stable 
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electronic configuration makes this macrocycle unable to undergo many reactions than 
redox or substitution reaction, in which electrons or hydrogen atoms are exchanged 
respectively by suitable oxidizing/reducing agents or electrophilic/nucleophilic reagents. 
Additionally, other reactions like ring opening or additions are very rare because they 
would certainly lead to a disruption of the Pc skeleton. Yet, in some cases, reactions like 
acid-base or transformation of the metal ion M (Figure 1.1), do not alter the aromatic 
character of Pcs and can be used in metallated derivatives.8,10 
An important disadvantage of Pcs, especially for biological applications, is the 
extreme insolubility of their unsubstituted derivatives. The extreme hydrophobicity of 
the aromatic core and planarity of the molecules lead to stacking which results in highly 
stable crystal structures with high molecular lattice energies. These characteristics result 
in Pc aggregation. Aggregation is generally viewed as an association of molecules in 
solutions. In the case of Pcs aggregation is usually depicted as a coplanar association of 
rings progressing from monomer to dimer and higher order complexes, driven by non-
bonded attractive interactions. This leads to a perturbation of the Pc electronic structure, 
which is undesirable in some applications that take advantage of the optical or catalytic 
properties. Besides, separation, electronic spectra and characterization are also 
negatively affected.10 Even so, there are some techniques to diminish this aggregation 
tendency. The synthesis of axially substituted Pcs represent one of the most effective 
strategies, by not only diminishing aggregation but also by promoting solubility of the 
peripherally unsubstituted Pc compounds. Additionally, it is known that aggregation of 
Pcs may vary with solvent, addition of neutral disaggregating agents, presence of 
electrolytes, varying pH, and within micelles forming surfactants.8,10,11 
Pcs have been extensively studied as second-generation PSs for PDT.42–45 Due 
to the four additional peripheral benzene rings, they have absorptions at higher 
wavelengths compared with Pors, in the red visible region, allowing a deeper light 
penetration into tissues. 
In addition, the metal ions of Pcs also influence their photophysical properties. 
Commonly, Pcs containing a closed shell and diamagnetic metal centre, such as Zn2+, 
Al3+, and Ga3+ have higher triplet state quantum yields and longer lifetime.46 
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1.2.3.1 Aromaticity 
As already mentioned, Pcs are molecules whose planar aromatic character is 
provided by eighteen π-electrons delocalized over an alternate arrangement of atoms of 
carbon and nitrogen, obeying the Huckel’s rule.10 This unique electronic delocalization 
confers excellent electronic properties to the molecules. One of such properties is the 
high absorption capacity in the near-ultraviolet (UV) regions of the visible 
electromagnetic spectrum, similarly to Pors. However, in Pcs, the absorption bands of 
greater intensity are located in the visible range.3 
1.2.3.2 Solubility 
The major disadvantage of these compounds is their insolubility in water 
(aqueous media) and in most organic solvents. Unsubstituted Pcs only dissolve in 
solvents of high boiling point, such as quinoline, chlorobenzene or 1-chloronaphthalene, 
due to the natural tendency of the molecules to stack (π–π stacking). The only effective 
solvent is sulfuric acid at concentrations greater than 8 M, by inducing solubility via 
protonation of the aza nitrogens, thus modifying the properties of the macrocycle and 
severely limiting the applications of these solutions. For instance, protonation of the aza 
nitrogens causes a strong bathochromic shift of up to 80–120 nm in the Q band. 
However, physical, chemical, and electronic properties of Pcs can also be fine-tuned via 
the addition of suitable substituents and functional groups, which can enhance the 
solubility of these compounds.3  
However, in some applications, insolubility of unsubstituted Pcs is essential. 
That is the case of the use of Pcs as dyes for textiles, paints and inks, in which, contrary 
to what is observed for biological applications, insolubility of these compounds is 
crucial for theirs application as dyes, along with Pcs glue-green intense colors. 
1.2.3.3 Absorption spectra of phthalocyanines 
All Pc compounds absorb light on both sides of the blue-green region of the 
visible light spectrum. The extensively conjugated aromatic chromophoric system of 
Pcs generates intense bands in their absorption spectra. The spectrum of the metal-free 
Pc differs from the metal-containing ones. MPcs UV-Visible (Vis) spectra show a 
strong Q band while metal-free Pcs UV-Vis spectra show two Q bands. Q band split is 
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due to less symmetry of metal-free Pcs in relation to MPcs. In Figure 1.3 it is possible to 
observe differences in the absorption range of a metal-free Pcs and MPcs.47 
 
Figure 1.3: Absorption spectra of metal-free phthalocyanines (a) and 
metallophthalocyanines (b).48 
The strongest absorption band(s) (Q band(s)) in most Pcs lies in the visible 
region at wavelengths between (620–700 nm), while the weaker band (Soret or B band) 
is near 350 nm. The Q band(s) (red light region) is (are) responsible for the 
characteristic blue-green color of Pcs. The position of the absorption bands in Pc are 
affected by axial substitution, peripheral and non-peripheral substitution, solvent, 
aggregation, and extension of the conjugation.10 This effect is more pronounced in the Q 
band(s).49 
1.2.4 Synthesis of phthalocyanines 
Depending on the precursors used, Pcs can be synthetized by several methods. 
Pcs can be obtained via a metal-templated cyclotetramerization reaction from aromatic 
ortho-dicarboxylic derivatives like phthalic acids, Phts, phthalic anhydrides, 
phthalimides, diiminoisoindolines and o-cyanobenzamides (Figure 1.4). In Scheme 1.3 
some reactions examples by which Pcs can be obtained are described. 
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Figure 1.4: Precursors of phthalocyanines. 
The most used Pc precursors are Phts because of their capacity to render good 
yields and higher purity. There are a large number of commercially available substituted 
Phts bearing diverse functional groups. Others can be synthesized by different classical 
methods from inexpensive commercial available starting materials.8,10 
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Scheme 1.3: Examples of the possible strategies for the synthesis of metal-free 
phthalocyanines and metallophthalocyanines. 
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The fine-tuning of the properties of a Pc can be accomplished by one of two 
basic methods: in the first one, the substitution takes place directly on the pre-existing 
Pc; in the second method the substitution takes place in precursors of Pcs, leading to far 
cleaner reactions in terms of degree of substitution. The second method, by modulation 
of the precursors of Pcs, is the most used one. Through this method, a more precise 
modulation can be made, leading to a mono- or even to an octa-substituted Pc in the 
positions 2, 3, 9, 10, 16, 17, 23 and 24. In spite the fact that the potential sites for Pc 
substitution are well-known, these methods can lead to a formation of constitutional 
isomers (Figure 1.5), which are very difficult to separate. This was only accomplished 
for very specific Pcs using specially designed high-performance liquid chromatography 
(HPLC) columns.8,10 
Nucleophilic aromatic substitution is by far the most used reactions employed in 
the modification of substituted Phts. This reaction is successful when appropriate 
leaving groups are present in the Pht, due to the electron-withdrawing capacity of the 
dinitrile functionality. Many leaving groups have been used on substituted Pht 
synthesis. The most used and with best results leaving group for nucleophilic aromatic 
substitution reactions is NO2. Nevertheless, there are other leaving groups used in this 
type of reaction. Although the order of leaving group ability depends on the nature of 
the nucleophile employed during the reactions. The approximate order of leaving group 
ability is F > NO2 > OTs > Cl, Br, I.8–11,40 
The majority of the work around Phts as precursor of Pcs has been carried out 
using the NO2 group of both 3- and 4-nitrophthalonitrile as the leaving group and an 
alcohol as the nucleophile. Thiols and amines can also be used as nucleophiles. Usually 
this reaction is carried out in a dry polar aprotic solvent, such as dimethyl sulfoxide 
(DMSO) or dimethylformamide (DMF), using sodium or potassium carbonate as a base. 
In some cases, the dry potassium carbonate is added portionwise over time. Moreover, 
there are other solvents which can be used, such as dioxane, N-methyl-2-pyrrolidone 
and N,N-dimethylacetamide. Despite the fact that 3-nitro- and 4-nitrophthalonitrile are 
known to react with ammonia and primary and secondary amines to give the 
corresponding aryl amines, the number of works where these nucleophiles are used is 
small.8,9,50 From the few compounds synthesized by this reaction, 4-(phenothiazin-10-
yl)phthalonitrile can be highlighted, as well as a series of heteroarylphthlalonitriles, 
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where heterocyclic N-nucleophiles were used like benzotriazole, 3,5-diphenyl-1,2,4-
triazole, phthalazine and 4-quinazolinone (Figure 1.6).8–10,21 
 
Figure 1.5: Constitutional isomers for a tetrasubstituted phthalocyanine. 
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Figure 1.6: Phthalonitriles with amine groups. 
The most used conditions to obtain substituted Pcs via Phts consists on the 
reaction of one or two different Phts (that can previously be modified with the insertion 
of the desired substituents) in an alcohol, such as 2-dimethylaminoethanol (DMAE) or 
penta-1-ol in the presence of a metal ion (Li+, Mg2+, Al3+ or Zn2+). In some cases, a base 
catalyst such as 1,8-diazabicyclo(5.4.0)undec-7-ene (DBU) is required. Free-metal Pcs 
can be obtained by the treatment of LiPcs or MgPcs with trifluoroacetic acid and 
temperature, or by reaction of one or more different Pht(s), in the presence of  dioxane 
or with ammonia in DMAE.8–10 The statistical condensation of two different Phts leads 
to the formation of six different substituted Pcs (not including constitutional isomers) 
(Figure 1.7).8,10 When only one type of precursor is used in the reaction it can be 
obtained a mixture of constitutional isomers. In some cases, such as for di-, tri- or 
tetrasubstituted Phts, only one product is obtained. 
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Figure 1.7: During a mixed condensation reaction of two different substituted 
precursors can be formed six different phthalocyanines. A and B represent two different 
substituted isoindoline units. 
The specificities of cyclotetramerisation are still far from being fully understood. 
Nevertheless, there is a possible mechanism for the formation of Pcs (Scheme 1.4). 
Commonly, cyclotetramerisation reactions are highly exothermic and occur under harsh 
conditions. Thus, it is difficult to access Pc synthesis mechanism because the classical 
techniques for mechanistic elucidation cannot be applied readily. The mechanistic 
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option most accepted is based on isolated intermediates in Pc synthesis. All synthetic 
routes studied use an alcohol as solvent. 
 
Scheme 1.4: Intermediates involved in the formation of phthalocyanine. 
This reaction of cyclotetramerization is believed to involve a polymerization of 
the precursors, followed by coordination with the central atom leading to cyclization. 
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This process starts by the formation of the alkoxide due to the presence of an alcohol 
and the metal ion. The study of cyclotetramerization of Pht in the presence of metal ions 
such as Li+ or Na+ resulted in isolation of A and B. It is believed that solvents such as 
methanol and ethanol favor the formation of structure A, whereas larger alcohols are 
related with the formation of the structure B. Furthermore, it is probable that both 
structures are intermediates in Pc formation using pentan-1-ol as solvent at reflux. The 
intermediate C was obtained when 4-nitrophthalonitrile and lithium methoxide are 
reacted in methanol at 116 ºC. Intermediate D, which it is not more than two C units 
coordinated with a metal, was isolated when the reaction was carried out with NiCl2 and 
diiminoisoindoline in pentan-1-ol under reflux. Heating complex D gave NiPc with 
pentan-1-ol and pentanal release, giving rise to the Pc, throw complex E, which were 
isolated and characterized by single crystal X-ray crystallography.10 
In some cases, due to the presence of halogens or leaving groups in the 
precursors, a synthesis via alkoxide mediator, it is not recommended. Under these, the 
cyclotetramerization reaction is usually carried out at higher temperatures in a high 
boiling solvent, such as chlorobenzene, quinoline, nitrobenzene, or 1-chloronaphthalene 
can be used to obtain the desired Pcs. These methodologies can also be used when high 
reaction temperature is required to achieve the desired Pcs. 
1.2.5 Separation and purification of phthalocyanines 
The most used Pc separation method is chromatography. Due to strong tendency 
of Pcs to aggregate in solution, every chromatographic technique must be carefully used 
to prevent contamination with previous and forward compounds and consequently 
obtain pure fractions of Pcs. The aggregation phenomenon can be surpassed by using 
diluted solutions, addition of coordination solvents and by heating the eluent. Likewise, 
gel permeation chromatography can be used to separate Pcs from small precursors and 
byproducts, since this technique separate the compounds based on molecular 
exclusion.10 
Taking advantage of remarkable stability of Pcs and some of its unsubstituted 
metal derivatives, they can be purified by sublimation at temperatures up to 600 ºC in 
vacuum. This method is used to obtain ultra-pure materials. Another method of 
purification relying on the stability of Pcs is reprecipitation from concentrated sulfuric 
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acid into water or ice. However, it cannot be applied to substituted derivatives that can 
undergo hydrolysis or sulfonation.10 
1.2.6 Characterization of phthalonitriles and phthalocyanines 
Pcs are usually characterized by the classical methods such as elemental analysis 
(EA), infrared (IR), and UV-Vis spectroscopy. A particular and very important analysis 
is the position of the Q-band in the UV-Vis spectrum. This analysis allows the 
visualization and procurement of useful information of the influence of insertion of 
substituents on the Pc periphery and the insertion of central metal ions.10 
What is more, some structures of Pcs have been solved by single crystal X-ray, 
which is another important characterization method along with nuclear magnetic 
resonance (NMR). NMR is a useful technique for soluble derivatives since the analysis 
by this technique requires the solution of the desired compound in a deuterated organic 
solvent. However, Pcs are poorly soluble in many organic solvents and tend to 
aggregate in solution leading, frequently, to broad signals. Thus, good results are highly 
dependent on the choice of the solvent and on the use of low concentrations and high 
temperature. The chemical shift is strongly influenced by aggregation, which also has a 
direct relation with the concentration. This deviation can undergo a chemical variation 
up to 2 ppm. The electronic structure of the Pc ring creates a strong induced current and, 
consequently, a very intense anisotropic effect. Thereby, the protons directly linked to 
the ring are quite unprotected, and theirs resonances will occur at very high chemical 
shift values, in the region typical for aromatic protons. On the other hand, the inner 
hydrogens are rather protected, and as a result will have negative chemical shift values, 
appearing on the right of the tetramethylsilane (TMS) signal.10 
Finally, mass spectrometry (MS) is also a commonly used technique for the 
structural characterization of Pcs, especially  by matrix-assisted laser desorption 
ionization (MALDI).10 
1.2.7 Applications 
Since their accidental discovery in the beginning of the twentieth century, Pcs 
have been extensively studied in many fields. The first application as dyes for textiles, 
paints and inks was due to the dark green-blue color. Interesting physicochemical 
properties triggered the application in a wide range of techniques and processes like 
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catalysts for oxidation reactions, lubrication greases, molecular electronic devices and 
optical materials.2 
Guilherme Amaral and co-workers26 evaluated the possible anti-oxidant 
capacities of four MPcs and one metal-free Pc. The tests were carried out in lipid 
peroxidation assay. With this strategy, Amaral et al.26 were able to confirm, by the 
juxtaposition to a non-induced control, the capacity of these Pcs to protect from sodium 
nitroprusside-induced oxidative damage to supernatant from the homogenized liver, 
brain and kidney of mice. They were also able to observe that MPcs have a better anti-
oxidant capacity than metal-free Pcs. In this work it was observed that the approximate 
order of decreasing efficiency was MgPc, CuPc, FePc, ZnPc and, as the least efficient, 
metal-freePc. 
It is known that cationic Pcs form complexes with nucleic acids. The binding of 
positively charged oligonucleotide substituted Pcs with single- and double-stranded 
DNA (dsDNA) was investigated and it was shown that these Pcs interact with nucleic 
acids through an outside binding mode. These Pcs were investigated ultimately aiming 
at potential applications as nucleic acid molecular probes because only few molecules 
are available to image DNA.51,52 In addition, anionic Pcs have also been shown to 
interact with DNA, although not directly. As an example, some anionic Pcs are known 
to efficiently inhibit telomerase activity, even in the presence of excess dsDNA, due to 
their selective binding to telomere G-quadruplex.53 G-quadruplex is a four-stranded 
structure formed by guanine-rich sequences in which anionic compounds can selectively 
bind such as anionic Pcs. Yaku et al.53 reported for the first time the utilization of 
anionic Pcs comprising four sulfonic groups that bound telomere G-quadruplex with 
high selectivity, inhibiting telomerase activity. 
Another application of Pcs is the utilization of this macrocycle as cathode 
catalyst for oxygen reduction in microbial fuel cells (MFCs). MFCs are devices that use 
bacteria as the catalysts to oxidize organic and inorganic matter and generate current. 
Electrons produced by the bacteria from these substrates are transferred to the anode 
and flow to the cathode linked by a conductive material containing resistor.54 The 
development of oxygen reduction catalysts for fuel cells has been increasing and an 
efforts have been made to develop inexpensive non-noble metal electrocatalysts. Pcs 
and metalloPors have emerged as an important alternative for the substitution of 
platinum and other related oxygen reducing precious metals as cathode catalyst in fuel 
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cells.54–58 In this context, Yuan et al.56 investigated the utilization of amino-
functionalized multi-walled carbon nanotube-supported iron Pc as a catalyst for the 
oxygen reduction in an air-cathode single-chambered MFC. These nanotube-supported 
iron Pcs proved to be efficient for reducing conversion and showed maximum power 
density of 601 mWm-2. 
Recently, Pcs have been used as PSs in PDT and PDI. Examples of these 
applications, along with their basic concepts, will be addressed in the following 
chapters. 
1.3 Aim 
Considering the photosensitizing potential of Pcs to be used in the photodynamic 
inactivation of Gram-negative, Gram-positive and tumor cells, and the antibacterial and 
antitumor activity of SAs, the aim of this work is to obtain Pc–SA conjugates to be used 
as antimicrobial and antitumor compounds. The presence of SA moieties will give 
higher specificity to photosensitization due to specific selectivity to the folic acid 
pathway and to antitumor targets such as CA. It will increase the efficiency and 
specificity of the photodynamic therapy and reducing any toxic effects on non-target 
tissues. Examples of PSs, such as Pors coupled to the SAs are documented in the 
literature.59 For some of these PSs, the photodynamic effect was proven.60 Similarly, 
there is also information on the synthesis of sulfonated Pcs,61,62 but, as far as we are 
aware of, there is no reports on the utilization of Pc–SA conjugates as PSs. Thus, the 
synthesis of Pc–SA conjugates with antimicrobial and/or antitumor activity addresses a 
gap in scientific knowledge and will provide a scientific platform for application of 
sulfonated Pcs as a new tool in the control of tumorigenesis and infection diseases, 
including those caused by multiresistant microorganisms. For that, it was projected to 
develop new methods for the synthesis of Pc–N-acyl-SA conjugates and Pc–SA 
conjugates; and evaluate the biological activity of the synthesized compounds in 
bacteria and tumor cells. 
This work will be a contribution to circumvent microbial resistance to antibiotics 
which is observed worldwide. Moreover, it will also be an asset in developing 
interesting strategies against oncological diseases, particularly by increasing the 
selectivity of the compounds used in PDT. 
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Chapter 2  Synthesis of phthalocyanine–N-acyl-sulfonamide 
conjugates 
Look carefully to Nature and you will find that nucleic acids, proteins and 
polysaccharides are condensed polymers of small subunits (blocks) linked together by 
carbon–heteroatom bonds. In Nature there is an almost perfect biosynthesis efficiency 
involving reactions that occur in quantitative yields, few/no byproducts or side-reactions 
and are, in the majority of the cases, stereoselective.63 For instance, Nature links small 
molecules via carbon–heteroatom bonding in order to synthesize essential molecules for 
life like polypeptides, polysaccharides, or polynucleotides.64 From this idea, and ever 
since initial publications of Sharpless and co-workers,65 the area of click chemistry has 
turned into a field with exponential growth.66 One important click reaction is the sulfo-
click reaction, a variation of the Cu(I)-catalyzed alkyne–azide cycloaddition (CuAAC). 
With this information in mind, we decided to study the applicability of the sulfo-
click reaction67–70 in the construction of new PSs bearing N-acyl SA moieties. In this 
chapter it is described how it was carried out and the results obtained. 
2.1 Introduction 
Using new synthetic methods, as the principle of click chemistry, introduced by 
Sharpless and co-workers in 2001,65 new SA derivatives have been developed. Click 
chemistry involves chemical reactions that generate substances quickly in smooth 
reaction conditions and in high yield, by the addition of small blocks. This principle has 
aroused great interest, particularly in the synthesis of N-acyl SAs. Its applications are 
found in large aspects of drug discovery, combinatorial chemistry and target-template 
chemistry, drug delivery nanosystems, polymers and nanoparticle surface modification, 
and in proteomics and DNA research, using bioconjugation reactions.66 
The prime example of a click reaction, and the most studied, is the CuAAC. It 
has found applications in a wide variety of research areas, including materials science, 
polymer chemistry, and pharmaceutical science. This reaction is regioselective, forming 
only 1,4-disubstituted 1,2,3-triazoles, and can be performed at room temperature.66 
Beyond that, it produces the desired product in high yields and is faster than the 
uncatalyzed reaction. Another important aspect of the success of this reaction, related to 
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materials science and biotechnology, is that the starting azides and terminal alkynes are 
exceptionally stable and can be introduced in a wide range of macromolecules.71 
There are a few classes of chemical transformations that have click 
characteristics. In Figure 2.1 some examples of each class of click reactions are 
schematized. 
 
Figure 2.1: Examples of chemical reactions that fall within the framework of click 
chemistry. 
This category of reactions turns out to be an important tool in medical and 
materials science (especially in polymer material design72) by their versatility. This is 
especially important in living systems, because a critical aspect of any strategy of 
labelling a target biomolecule inside a living cell or organism by a chemical reaction is 
that the reaction must be chemoselective, and in particular bioorthogonal.66 
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As already referred, the sulfo-click reactions are a type of click reactions that 
lead to SAs. SAs, have interesting properties for application in medicine and 
veterinary.4,73,74 
Sulfo-click chemistry takes advantage of the combination of more than two 
components, falling in the category of a multicomponent reaction (MCR). Since it also 
requires Cu(I) as catalyst, it can be considered a variation of the CuAAC. Chang and co-
workers,69,75 from a modified Staudiger reaction of azides with phosphines, has drawn a 
new synthetic pathway in which sulfonylazides react with terminal alkynes in the 
presence of catalytic amounts of CuI and a base, to give rise to N-acyl SAs (Scheme 
2.1).70 This reaction is completely regioselective, occurs under very mild conditions and 
the products are obtained in high yields. Thereafter, they found that the best yields and 
shorter reaction times are obtained by using water as solvent, making this type of 
reaction surprisingly adequate for biological applications.69,75 The mechanism for this 
reaction is not yet fully identified, but there are some results pointing that this type of 
reaction develops a common ketenimide intermediate generated from the Cu-mediated 
intermolecular cycloaddition between azide and alkyne.69,75,76 
 
Scheme 2.1: Sulfo-click reaction. 
Although a detailed understanding of the mechanism of this reaction will require 
additional studies, Cassidy et al.67 proposed a mechanism similar to the copper(I)-
catalyzed triazole synthesis (Scheme 2.2). After acetylene activation by Cu catalyst, the 
formed (1,2,3-triazol-5-yl)copper species, which in a copper(I)-catalyzed triazole 
reaction normally undergoes proteolysis to release the triazole product, in this reaction, 
due to a strongly electron-withdrawing group at N1, elimination of a dinitrogen 
molecule occurs producing a transient Cu-alkynamide compound. This complex is then 
protonated to give the highly reactive ketenimine which is immediately trapped by 
water to form the N-acyl SA. There is an alternative route to ketenimine production 
through a ring-opening pathway, resembling the Dimroth rearrangement, forming a 
diazoimine derivative. 
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Scheme 2.2: Sulfo-click mechanism (see description in the text).67 
2.2 Results and discussion 
For the synthesis of Pc–N-acyl-SA conjugates, two synthetic routes can be 
followed as described in Figure 2.2. In the synthetic route A Pht–N-acyl-SA conjugates 
and Pc–N-acyl-SA conjugates are obtained from 4-(4-
azidosulfonylphenoxy)phthalonitrile. In synthetic route B 4-(3-
ethynylphenoxy)phthalonitrile is used as starting material. Results and details related 
with synthetic routes A and B will be described in sections 2.2.1 and 2.2.2, respectively. 
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Figure 2.2: Planned synthetic routes A and B. 
2.2.1 Synthetic route A - from 4-(4-
azidosulfophenoxy)phthalonitrile 
The first part of the work for the synthesis of Pc–N-acyl-SA conjugates, through 
synthetic route A, convey the synthesis of Pht–N-acyl-SA conjugates, taking advantage 
of the sulfo-click reaction, using as reagent a Pht with an azidosulfonyl group. The 
planned synthetic route to those compounds is described in Scheme 2.3. 
Firstly, 4-phenoxyphthalonitrile (1) was obtained by a nucleophilic aromatic 
substitution of the nitro group in 4-nitrophthalonitrile by phenoxide. The reaction was 
carried out in DMF under basic conditions with portionwise additions of potassium 
carbonate in order to avoid phenol oxidation. Then, the reaction mixture was left 
overnight at room temperature. The consumption of the 4-nitrophthalonitrile was 
verified by thin-layer chromatography (TLC) and the desired product was obtained by 
precipitation in cold water, filtered and washed several times with water and hexane. 
Finally, the product was crystallized from a mixture of chloroform/hexane (77.8% 
yield). 
Pht 1 was characterized by 1H NMR, 13C NMR and mass spectrometry (MS) 
using electrospray ionization (ESI) in positive mode. All spectra are in agreement with 
those described in the literature.77–82 The crystalline structure has also already been 
reported.79 
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Scheme 2.3: Planned route for the synthesis of phthalocyanine–N-acyl-sulfonamide 
conjugates from 4-(4-azidosulfophenoxy)phthalonitrile (3). 
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Then, we proceeded to the synthesis of the chlorosulfonyl derivative 2 by 
chlorosulfonation of the phenoxy group (Scheme 2.3). This conversion proved to be 
quite demanding. Pht 1 reacted with an excess of chlorosulfonic acid for 45 min at 0 ºC, 
following the conditions described by Carvalho et al.61,62 However, instead of the 
chlorosulfonated derivative, more than once, we obtained the product 4-(4-
sulfophenoxy)phthalonitrile (8) (Scheme 2.4), that was confirmed by 1H NMR spectrum 
where it showed a peak at δ 11.32 ppm, attributed to the proton of the sulfonic moiety 
and by ESI-MS analysis in positive mode, where we were not able to observe the 
isotopic pattern of the chlorine atom expected for the chlorosulfonyl derivative 2. 
 
Scheme 2.4: Synthetic procedure for the conversion of 8 into the chlorosulfonyl 
derivative 2 with the chlorinating agent TCT. 
So, in order to achieve the desired compound, we evaluated the applicability of 
2,4,6-trichloro[1,3,5]triazine (TCT) as chlorinating agent of reagent 8 (Scheme 2.4). 
The procedure consisted in the addition of TCT to a mixture of the sulfonic acid and 
triethylamine, all in equimolar quantities, in acetone. The reaction was carried out under 
microwave irradiation in a sealed tube at 80 ºC for 20 min as described by Luca et al.83 
and Blotny.84 However, with this procedure, we were also not able to verify the 
conversion of the sulfonic acid 8 into the corresponding chlorosulfonyl derivative 2. 
In addition, in a parallel reaction, we also verified whether we were in the 
presence of derivative 2 or 8. For that, the white powder afforded from the reaction of 
Pht 1 with chlorosulfonic acid, was reacted with diethylamine in acetonitrile at room 
temperature (Scheme 2.5).61,62 Yet, we did not afford the expected SA 9, confirming 
that we were in the presence of the sulfonic acid 8. 
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Scheme 2.5: Reaction of the white powder (from the reaction of phthalonitrile 1 and 
HSO3Cl) with diethylamine. 
As a parenthesis of our planned work, and to better understand the sulfo-click 
reaction, we decided to use the commercial chlorosulfonyl derivative 10 as a precursor 
to the N-acyl SA 12, in a two steps procedure, as shown in Scheme 2.6. 
 
Scheme 2.6: Planned synthetic route to N-((4-acetylphenyl)sulfonyl)-2-phenylacetamide 
(12). 
In the first step the chlorosulfonyl derivative 10 was reacted with sodium azide, 
in acetone at room temperature. 4-Acetylbenzenesulfonyl azide (11) was obtained in 
69.7% yield as a white powder. The structure of 11 was confirmed by 1H and 13C NMR. 
In the 1H NMR spectrum (Figure 2.3) it is possible to observe a singlet at δ 2.69 ppm, 
which corresponds to the protons at the acetyl group. In the aromatic region, an AB 
system with a peak at δ 8.05–8.09 ppm and another at δ 8.15–8.19 ppm is observed. In 
the 13C NMR spectrum (Figure 2.4) it is possible to observe the peak corresponding to 
the methyl group at δ 26.95 ppm, whilst the peaks for the carbons in the ortho and para 
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positions appear at δ 127.85 ppm and 129.38 ppm, and at δ 141.52 ppm and 141.94 ppm 
the other two carbons of the aromatic ring. Finally, the peak corresponding to the 
carbonyl group can be observed at δ 196.26 ppm. 
The 1H and 13C NMR spectra of azidosulfonyl derivative 11 is similar to the 
ones of the chlorosulfonyl 10 (data not shown), from which there is only a difference in 
the sulfonyl moiety. Therefore, there are no significant changes in the chemical shifts 
and multiplicities of the 1H NMR spectrum and 13C NMR spectrum of product 11 when 
compared to the reagent 10. Nonetheless, reagent 10 and product 11 have quite different 
retention factors (Rf) in TLC plates (silica gel, CH2Cl2/hexane (1:1) as eluent): 0.37 for 
10 and 0.21 for 11. Additionally, in ESI-MS spectrum the molecular ion (M+) of 
azidosulfonyl 11 at m/z 225.2 and [M+K]+ ion at m/z 264.2 was observed, confirming 
the success of the conversion of chlorosulfonyl reagent 10 into the azidosulfonyl 
derivative 11. 
 
Figure 2.3: 1H NMR spectrum of acetylbenzenesulfonylazide (11) in CDCl3. 
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Figure 2.4: 13C NMR spectrum of acetylbenzenesulfonylazide (11) in CDCl3. 
Next, in the second reaction described in Scheme 2.6, sulfonylazide derivative 
11 was used as reagent in a sulfo-click reaction with ethynylbenzene and Et3N in H2O 
following the procedure described by Cho et al. using CuI as catalyst.68,69 However, the 
N-acyl SA derivative was not obtained using these reaction conditions. 
After analyzing the results discussed in this section (synthetic route A), it was 
decided to change the synthetic route. As already explained, in the new synthetic route 
(Figure 2.2 - synthetic route B), the synthesis of ethynylphenoxy-Phts and the 
corresponding ethynylphenoxy-Pcs were studied. Then, the conversion of these 
compounds (ethynylphenoxy-Phts and ethynylphenoxy-Pcs) into N-acyl SA derivatives 
due to a sulfo-click reaction was evaluated. In the next section, the results and details 
about these conversions in the synthetic route B, will be discussed. 
At this point it is important to emphasize that all sulfo-click reactions reported in 
this section were carried out using CuI as catalyst. However, in the next section it is 
discussed the use of other Cu(I) sources in this type of reaction. 
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2.2.2 Synthetic route B - from 4-(3-ethynylphenoxy)phthalonitrile 
In the synthetic route B, 4-(3-ethynylphenoxy)phthalonitrile (13) was used as 
starting material for the synthesis of N-acyl SA precursors of Pcs in a sulfo-click 
reaction. The planned synthetic route is described in Scheme 2.7. Firstly, by a 
nucleophilic aromatic substitution with 4-nitrophthalonitrile and 3-ethynylphenol, 4-(3-
ethynylphenoxy)phthalonitrile (13) was obtained. Then, as described in Scheme 2.7, 
two pathways can be followed: Pht 13 can be used in a statistical condensation with 4-
tert-butylphthalonitrile to obtain Pcs with ethynyl groups; or 13 can be used in a sulfo-
click reaction with a sulfonylazide to obtain N-acyl SA 17. Then, the latter compound 
can be used in a statistical condensation with other Phts to produce the corresponding 
Pcs 18–20. In both cases the resulting compounds will be as Pc-acyl group-SA while 
synthetic route A (section 2.2.1) leads to compounds of type Pc-SA-acyl group. 
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Scheme 2.7: Planned route for the synthesis of metallophthalocyanine–N-acyl-
sulfonamide conjugates from 4-(3-ethynylphenoxy)phthalonitrile (13) 
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 (synthetic route B). 
The 4-(3-ethynylphenoxy)phthalonitrile (13) was obtained in 79.0% yield by a 
nucleophilic aromatic substitution between 4-nitrophthalonitrile and 3-ethynylphenol in 
DMF. The structure of the 13 was confirmed by 1H NMR and MS. In the 1H NMR 
spectrum (Figure 2.5) it is possible to observe the peak corresponding to the proton at 
the ethynyl group at δ 4.34 ppm. In the aromatic region, at δ 7.24–7.53 ppm the peaks 
of the protons in the ring bearing the ethynyl group are observed. Protons at the Pht ring 
appear at δ 7.86 ppm and δ 8.12 ppm. In the mass spectrum a peak at m/z 245.4 
corresponding to the [M+H]+ ion is observed. 
 
Figure 2.5: 1H NMR spectrum of the 4-(3-ethynylphenoxy)phthalonitrile (13) in 
DMSO-d6. 
Pcs 14–16 were synthesized via a statistical condensation of 4-(3-
ethynylphenoxy)phthalonitrile (13) and 4-tert-butylphthalonitrile in a ratio of 1:5. The 
statistical condensation was carried out in DMAE at 140 ºC, in the presence of zinc 
acetate (Scheme 2.7) obtaining three ethynylphenoxy ZnPcs (14–16) and t-BuZnPc. The 
four ZnPcs obtained were characterized by 1H NMR and MS. The spectra allowed to 
confirm that, besides tetra(tert-butyl)Pc, tri(tert-butyl)-mono(3-ethynylphenoxy)Pc 14 
and two di(tert-butyl)-bis(3-ethynylphenoxy)Pcs 15 and 16 were obtained (Scheme 2.7). 
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The 1H NMR spectrum of Pc 14 illustrates all proton resonances as multiplets 
for the α- and β-aromatic protons of the Pc macrocycle between δ 9.30 and δ 7.93–7.37 
ppm, corresponding to the 8 α-protons and 4 β-protons, respectively. Furthermore, the 
proton resonances of the phenoxy moiety appear in the same multiplet as the 4 β-
protons. Finally, the resonance of the acetylenic proton appears at δ 4.34 as a singlet 
(Figure 2.6a). 
Figure 2.6b illustrates, as an example, the 1H NMR spectrum of Pc 16. The 
protons of the Pc macrocycle appear between δ 9.31–8.80 and δ 7.80–7.44 ppm, 
corresponding to the 8 α-protons and 4 β-protons, respectively. At δ 7.80–7.44 ppm the 
resonance of the 8 protons of the phenoxy groups is also observed. The two acetylenic 
protons appear at δ 4.34 and 4.37 ppm as two singlets, probably due to conformational 
differences of the two ethynyl groups. 
The photochemical and photophysical properties of Pcs 14–16 were also studied. 
Figure 2.7 shows the UV-Vis spectra of Pcs 14–16 in chloroform. In all studied Pcs the 
absorption spectrum has a broad Soret band at λ 343, 348 or 345 nm, respectively, and a 
Q-band at 679, 678 or 679 nm, respectively (Table 2.1). Despite the structural 
differences of Pcs studied, a significant difference in UV-Vis spectra is not observed. 
Figure 2.8 shows the fluorescence spectra of Pcs 14–16 upon excitation at 590 nm in 
chloroform. These spectra reveal maxima at 679, 677 or 674 nm, respectively, and the 
quantum yields found for 14 (0.04), 15 (0.07) and 16 (0.09) (Table 2.1) are higher than 
the quantum yield of zinc hexadecafluoroPc used as reference (0.01).85 The emission 
spectra of Pcs 14–16 in chloroform is shown in Figure 2.8. 
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Figure 2.6: 1H NMR spectra of a) mono-substituted Pc 14 and b) di-substituted Pc 16 in 
DMSO-d6. 
The mass spectra of the Pc derivatives show the expected molecular ions (M+) at 
m/z 860.2 for Pc 14 and at m/z 980.2 for Pcs 15 and 16, and thus support the proposed 
structures. 
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Figure 2.7: Absorption spectra of Pcs 14–16 in chloroform. 
Table 2.1: Molar extinction coefficients (ε) and fluorescence quantum yields (Фf) for 
Pcs 14–16. 
Compounds 
Absorption 
λmax (nm) 
ε1 (M-1cm-1) ε2 (M-1cm-1) Фf (a.u.) 
14 343/679 1.2×10& 4.5×10) 0.04 
15 348/678 1.2×10& 5.1×10) 0.07 
16 345/679 1.5×10& 5.9×10) 0.09 
 
Figure 2.8: Emission spectra of Pcs 14–16 in chloroform. Excitation wavelength: 590 
nm. 
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Then, we studied the possibility of obtaining tetrakis(3-ethynylphenoxy)Pc 21 
via cyclotetramerization of Pht 13 in DMAE at 140 ºC in the presence of Zn(OAc)2 
(Scheme 2.8). With these reaction conditions the expected modification in the color of 
the reaction mixture from light yellow to blue-green was not observed, indicating that 
the Pc 21 was not formed. 
Drawing our attention to recent sulfo-click reactions67–69 in which sulfonyl 
azides react with terminal alkynes in the presence of catalytic amounts of copper(I), a 
base and water, we proceeded with the study aiming at the synthesis of Pht–N-acyl-SA 
conjugates and Pc–N-acyl-SA conjugates. 
 
Scheme 2.8: Synthesis of tetra-2-(3-ethynylphenoxy)phthalocyanine 21. 
To this end, the reaction of 4-(3-acetylenephenoxy)phthalonitrile (13) with 4-
acetamidobenzenesulfonyl azide (a commercial compound) was carried out in the 
presence of catalytic amounts of CuI and triethylamine, in water at room temperature 
(Scheme 2.9 - pink), following the conditions described by Cho et al.68,69 From this 
reaction resulted a variety of products from which it was possible to isolate two pure 
compounds. However, their 1H NMR spectra do not correspond to the desired structure. 
In order to verify if the products obtained result, or not, from the reaction of the sulfonyl 
azide with the cyano groups of the Pht, we also carried out the reaction of mono-2-(3-
acetylenephenoxy)Pc with the commercial sulfonyl azide. Again several products were 
formed but, unfortunately, we were unable to obtain the desired Pc–N-acyl-SA 
conjugates. 
In order to better understand the sulfo-click reaction we carried out the reaction 
of phenylacetylene with 4-acetamidobenzenesulfonyl azide under the same conditions 
used previously, using CuI as catalyst (Scheme 2.9 - blue), but in the presence of 
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sodium ascorbate and tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBAB), and 
in various solvents. From all these reactions, different compounds were isolated but 
their structures did not correspond to the desired compounds and, in the majority of the 
cases, in very low yields. Thus, we concluded that the reaction conditions for these 
transformations would not be the most appropriate. 
 
Scheme 2.9: Evaluation of different Cu(I) sources for the synthesis of N-acyl 
sulfonamide derivatives. 
With these results, we decided to explore different reaction conditions and, in 
particular, to study the use of different Cu(I) sources. 
Diverse copper(I) sources, such as CuI, CuBr, [Cu(CH3CN)4]PF6, and 
CuSO4/ascorbate, are reported as suitable catalysts for sulfo-click reactions. The pH 
value has also been described as having a pronounced effect on the outcome of these 
reactions: mildly basic conditions favor the conversion into N-acyl SAs.67,68,86 With this 
in mind, we proceeded to study different catalysts and reaction conditions in order to 
obtain the desired N-acyl SAs. For that, an exploratory work was conducted using 4-
acetamidobenzenesulfonyl azide and phenylacetylene as reagents and following the 
experimental conditions reported by Cassidy et al.,67 equimolar quantities of the two 
reagents were stirred in tetrahydrofuran (THF)/H2O (4:1) in the presence of 
ONC
NC
O
N3O2S
H
N
O
CuI
R1
H
N
S
O2O
H
N
O
[Cu(CH3CN)4]PF6
CuSO4·5H2O, sodium ascorbate
CuCN, 52.4%
CuI
[Cu(CH3CN)4]PF6, 47.3%
CuSO4·5H2O, sodium ascorbate
CuCN, 64.5%
CuI
[Cu(CH3CN)4]PF6
CuSO4·5H2O, sodium ascorbate
CuCN
17: R1 =
NC
NC
O
18
13
14
+
H
N
S
O2O
H
N
O
22
N3O2S
H
N
O+
O
H
N
S
O2O
H
N
O
N3O2S
H
N
O+
Pc
  
39 
 
CuSO4·5H2O (2 mol%) and sodium ascorbate (0.1 equiv.). After 34 hours the reaction 
was ended but the desired N-acyl SA was not formed. 
Following Govindaranju et al.86 conditions, phenylacetylene was reacted with 4-
acetamidobenzenesulfonyl azide in equimolar quantities in the presence of 2 mol% of 
Cu(CH3CN)4PF6, 2 mol% of the tertiary amine TBTA, 4 mol% sodium ascorbate and 1 
equiv. NaHCO3 in aqueous conditions. The desired derivative was obtained in 47.3% 
yield. The best result was attained when CuCN was used as catalyst, as disclosed by 
Cho et al.87 In this experiment copper(I) cyanide and 4-acetamidobenzenesulfonyl azide 
were poured in a boiling flask and then distilled water and ethynylbenzene were added. 
Finally, triethylamine was slowly added via syringe over one minute, at room 
temperature, and the reaction was then stirred while open to air for 4 hours at room 
temperature. From the reaction mixture a white solid was obtained in 64.5% yield. The 
structure of 22 was confirmed by its 1H NMR spectrum, and the results are in agreement 
with those described in the literature.87 
The procedure developed by Cho et al.90 using CuCN as catalyst turned out to be 
very promising. We used these conditions to study the synthesis of N-acyl Pht–SAs and 
the results were very interesting. For that, 4-(3-ethynylphenoxy)phthalonitrile was used 
as starting material in a sulfo-click reaction using CuCN as catalyst. The procedure used 
was similar to the one described for 22 and the expected Pht 17 was obtained in 52.4% 
yield (Scheme 2.9 - pink). The structure was confirmed by 1H NMR and MS. In the 1H 
NMR spectrum (Figure 2.9) the peaks corresponding to methyl and methylene protons 
are observed, respectively, at δ 2.09 and 3.60 ppm. The signal corresponding to H4 
appears at δ 6.69 ppm as a broad singlet due to the presence of H5 and H7 at meta 
distances. Protons H5 and H7 appear at δ 7.03-7.12 ppm as a multiplet. The signal of 
H2 appears at δ 7.32 ppm as a double doublet with coupling constants of J = 2.5 and 8.8 
due to the presence of H1 and H3 in the vicinity. At δ 7.40 ppm appears H6 as a triplet, 
and a multiplet is observed at δ 7.72–7.85 ppm corresponding to H1, H8 and H9 
(integrating to 5 protons). Finally, proton H3 appears at δ 8.09 ppm as a doublet. At δ 
10.39 and 12.24 appear the NH groups. 
Having Pht 17 in hand, we tried to convert it into Pc–N-acyl-SA conjugates. In 
that way, we attempted a statistical condensation of 17 and t-butylphthalonitrile in the 
presence of Zn(OAc)2 and using DMAE as solvent at 140 ºC (Scheme 2.7). However, 
again, only the tetra(t-butyl)Pc was formed. Since Pht 17 was not recovered, the absence 
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of the expected Pc–N-acyl-SA conjugate seems to indicate that this Pht probably 
decomposes at the temperature required for the condensation reaction (140 ºC). 
Considering the good results obtained in the sulfo-click reactions using CuCN as 
catalyst, as confirmed with the synthesis of compounds 17 and 22, we decided to apply 
these experimental conditions to the synthesis of Pc 18 (Scheme 2.9 - red). In fact, we 
carried out the reaction of Pc 14 with 4-acetamidobenzenesulfonyl azide, using CuCN 
as catalyst. A blue-green product was isolated and its structure was studied by 1H NMR 
and MS. In the 1H NMR spectrum, it was not possible to identify, without any doubt, 
the peaks corresponding to the methyl and methylene groups. That is, the results from 
the 1H NMR were inconclusive. Moreover, in MS analysis the ion or adduct 
corresponding to the desired compound was not found, leading us to conclude that we 
were not in the presence of the desired Pc. 
 
Figure 2.9: 1H NMR spectrum of 17 in DMSO-d6. 
2.3 Conclusions 
Taking into account the work published on sulfo-click reactions,67–70 we were 
interested to verify if this type of reaction could be used to prepare Pc–N-acyl-SA 
conjugates. In order to elucidate this question, two complementary synthetic routes were 
drawn. Route A involved the synthesis of SA-Phts and their conversion into Pcs while 
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route B involved the synthesis of Pcs bearing ethynyl groups and their reaction with 
sulfonyl azides. Although the disappointing results, route B allowed to better understand 
the scope and limitations of the chlorosulfonation and sulfo-click reactions when used 
in the transformation of Phts and Pcs. 
In the synthetic route B, we were able to synthetize, for the first time, a new 
Pht–N-acyl-SA conjugate (17) and also new Pcs with acetylene groups. 3-
Ethynylphenoxy-Pht 13 and zinc-ethynylphenoxy-Pcs 14–16 bearing one or two 3-
ethynylphenoxy groups and their photophysical properties, namely absorption and 
fluorescence spectroscopy were also studied. The structural analysis of these 
compounds by mass spectrometry and NMR spectroscopy was also reported. Besides, a 
new methodology for the synthesis of new ethynylphenoxy-Pcs was proposed and the 
applicability of sulfo-click reaction in Phts was demonstrated. The scope of sulfo-click 
reaction, in particular for Phts, was likewise disclosed. 
The new Pcs 14–16 are versatile substrates for further structural modifications. 
Particularly, in a collaboration with Professor Óscar Rodrigues, from the Federal 
University of Santa Maria, Rio Grande do Sul - Brazil, the coupling of azidothymidine 
(AZT) derivatives to zinc-ethynylphenoxy-Pcs 14–16 is under study. AZT is a well-
known antiretroviral used to prevent and treat HIV/acquired immune deficiency 
syndrome (AIDS) and, along with its derivatives, is also studied as an antioxidant and 
antitumoral drug.88 Therefore, these new Pcs would be suitable to be studied as new PSs 
in the inactivation of virus and cancer cells. This is an ongoing work. 
The differences between the results obtained by Eliana et al.61,62 and those 
described in this work can be related to structural differences among mono and 
disubstituted Phts. In the next chapter, new synthetic approaches to overcome this 
limitation will be discussed. 
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Chapter 3  Synthesis of phthalocyanine–sulfonamide 
conjugates 
Substitutions in the periphery of macrocycles such as Pcs with other organic 
groups are a commonly strategy to fine-tune the properties of these compounds for a 
specific application in materials or pharmaceutical sciences. In particular, in this work 
the aim is to synthesize Pcs to be used as potential PDT and PDI agents. 
SAs stand out as an interesting class of compounds with a wide range of 
applications in medicine. Moreover, SAs are still a first-line approach in the treatment 
of several infection diseases. Still, SA resistance is well-known and the synthesis of new 
SAs needs to be addressed. 
In this work, the synthesis of new Pc–SA conjugates was disclosed as a 
continuation of the work developed by Carvalho et al.62 For that, new synthetic 
approaches to obtain SAs and new methods to afford Pc–SA conjugates were studied 
and are described in this chapter. 
3.1 Introduction 
SAs are organic basis compounds containing a group -SO2NR1R2 used for 
different therapeutic purposes.4,74,89,90 SAs with inhibitory capacity of CA have been 
used to disrupt the growth of tumor cells in hypoxic conditions and acidification.73 
Additionally, Owa et al.90 synthesized SAs capable of regulating cell cycle at the G1 
phase through inhibition of cyclin-dependent kinase (CDK). Furthermore, the 
antimicrobial effect of SAs is carried out as competitive antagonists of p-aminobenzoic 
acid (pABA), which is a substrate of the enzyme DHPS, in the biosynthesis of folic 
acid. Antimicrobial SAs exhibit a broad spectrum of action, covering all groups of 
organisms which operate in the biosynthesis of folic acid.4 These antimicrobials were 
first introduced in the 1930s and were widely used on the treatment of several infections 
initiated by a number of pathogenic microorganisms, including Neisseria meningitidis 
and Pneumocystis carinii. 
Currently this class of synthetic antibiotics is still a first-line therapeutic option 
in human and veterinary medicine. They are commonly applied in the treatment of 
malaria (Plasmodium falciparum), toxoplasmosis (Toxoplasma gondii), eye infections 
initiated by Staphylococcus aureus and Candida albicans, urinary tract infections by 
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Escherichia coli, lymphogranuloma venereum by Chlamydia trachomatis, pulmonary 
infections caused by Nocardia and autoimmune borne diseases such as rheumatic fever, 
infections affected by Streptococcus pyogenes.4,74,89,90 
3.1.1 Historical background 
SA was the first antimicrobial drug and was responsible for the antibiotic 
revolution in medicine. The first commercially available antimicrobial SA was sold by 
the trademark ProntosilTM. This prodrug was developed in 1932 by Josef Klarer and 
Fritz Mietzsch at the Bayer Laboratories of the IG Farben conglomerate in Germany but 
only several years later the physician Gerhard Domagk found the exact compound that 
had remarkable effects on stopping some bacterial infections in mice. ProntosilTM 
turned out to be a strong protective agent against infections caused by streptococci, 
including blood infections, childbed fever, and erysipelas, and a lesser effect on 
infections caused by other cocci.91 
For several years in the late 1930s, the production of sulfa products was 
increased until the elixir sulfanilamide disaster in the fall of 1937. During this year at 
least 100 people were poisoned with diethylene glycol by improperly prepared 
sulfanilamide. In 1937 the S. E. Massengill Company, a pharmaceutical manufacturer, 
created a preparation of sulfanilamide using diethylene glycol as a solvent. Diethylene 
glycol is poisonous to humans but company's chief pharmacist and chemist was not 
aware of it. Since SA was the only effective antibiotic available in the years before 
penicillin, it continued to be used at the early years of World War II.92,93 
Thousands of molecules with SA backbone have been created with improved 
formulations, greater effectiveness and less toxicity. SAs are still widely used not only 
as antibiotics but also, for example, as antitumor and antidiabetic agents. 
3.1.2 Synthesis of sulfonamides 
The oldest and most commonly used method to obtain SAs involves the 
synthesis of a chlorosulfonated derivative by chlorosulfonation with chlorosulfonic 
acid.94,95 
The chlorosulfonic acid is a versatile reagent which is extensively used for the 
sulfonation or chlorosulfonation of aromatic compounds.95 Depending on the number of 
equivalents (equiv.) of acid used, the products obtained may be sulfonic acids, sulfones 
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or sulfonyl chlorides. Generally, for the sulfonation only one molar equivalent is 
necessary. This type of reaction is usually conducted in an inert solvent, for example 
chloroform, to avoid the formation of byproducts. However, if chlorosulfonation is 
desired, it is necessary to use a large excess of chlorosulfonic acid over the other 
reagent. This reaction can be carried out in the absence or presence of an inert solvent. 
The optimization of reaction conditions depends on the nature of the aromatic substrate 
which is sulfonated or chlorosulfonated (Schemes 3.1). 
 
Scheme 3.1: Sulfonation and chlorosulfonation of aromatic compounds with 
chlorosulfonic acid. 
There are few mechanistic evidences on this type of reaction. However, 
thermodynamic studies have shown that reactions with aromatic substrates using an 
equimolar amount of chlorosulfonic acid, quickly forms its sulfonated derivatives with 
release of hydrochloric acid. In the presence of excess reagent, sulfonated derivatives 
are slowly converted to the sulfonyl chloride with release of sulfuric acid. The 
formation of the intermediate sulfonic acid and sulfonyl chloride, under mild conditions 
(low temperature) using an excess of chlorosulfonic acid as solvent, may possibly be 
represented as shown in the Scheme 3.2. 
 
Scheme 3.2: Mechanism of the chlorosulfonation. 
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Over the last years, additional ways to get the sulfonyl chloride were developed. 
Chlorosulfonic acid may be used “alone” or in conjugation with thionyl chloride, 
phosphorous pentachloride (PCl5),96 or with phosphoryl chloride (POCl3).97 It is also 
possible to obtain the sulfonyl chloride by the oxidation of thiols with KNO3-SO2Cl2 
(2.5 equiv.) (Scheme 3.3).98 
 
Scheme 3.3: Oxidation of thiols to sulfonyl chlorides. 
In 200384 Blotny reported a new method for the preparation of sulfonyl chlorides 
that involved the treatment of a sulfonic acid or a sodium sulfonate with TCT (cyanuric 
chloride) in refluxing acetone under neutral conditions (Et3N or 18-crown-6, 
respectively) (Scheme 3.4).  
 
Scheme 3.4: Synthesis of sulfonyl chlorides using cyanuric chloride as chlorinating 
agent. 
During the last years, new strategies for the synthesis of SAs have been 
developed. SAs are really important as building blocks of pharmaceutical and bioactive 
compounds. Nowadays, as already mentioned, SAs can be obtained by the conventional 
reaction of sulfonyl chlorides with NH3 or amines, but can also be got by modification 
of the SA group, namely by catalytic cross coupling of SAs with organic halides99–104 
arylsulfinates,105 alkyl halides and thiourea,106,107 or alcohols.108 Additionally, they can 
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be prepared by aminosulfonation of hydrocarbons,109,110 or even by oxidation of 
sulfenamides,111 diazonium salts,112 Grignard reagents,113 sulfinates and amines102,114 
and sulfonylazides.115–117 They can also be obtained by transformation of heterocyclic 
compounds,118,119 modification of other SAs by N-alkylation/arylation99,102–104,108,120–127 
and by modification at carbon atoms.128–131 Herein, some recent examples will be 
described. 
Concerning the utilization of thiols as precursors for SAs synthesis, in 2010 
Taniguchi,132 by a dehydrocoupling of aryl thiols with amines using copper as catalyst, 
produced sulfenamides and SAs. Using the system CuI-bpy (10 mol %) as a catalyst 
under an oxygen atmosphere in DMSO, at 60 ºC, Taniguchi was able to obtain SAs 
(Scheme 3.5). The substrate scope of this reaction was studied in different aryl thiols 
and amines. The best result was obtained when thiophenol and tBuNH2 were used, and 
by the formation of N-(tert-butyl)benzenesulfonylsulfonamide in 90% yield with trace 
amounts of the respective sulfenamide and sulfinamide. Additionally, using aryl thiols 
and amines as reagents, Huang et al.133 reported the synthesis of SAs using cinnamic 
acid, Cu(II) as oxidant, under air condition, providing a novel and direct strategy via an 
oxygen-activated radical process. However, further studies on the mechanism must be 
taken in future work. 
 
Scheme 3.5: Synthesis of sulfonamides from thiols. 
Also using copper as catalyst Tang et al.114 developed a method for the 
construction of SAs in a copper-catalyzed oxidative coupling between sodium sulfinates 
and amines with 1 atm O2 or DMSO as the oxidant by in situ conversion of Cu(I) to 
Cu(II). This method proved to be efficient and robust for the synthesis of functional SAs 
in good yields and chemoselectivity. The reaction is carried out using CuBr2 as catalyst 
in DMSO (Scheme 3.6). Using various amines and sodium sulfinates, under these 
reaction conditions, the desired SAs were obtained in good yields (61–97%). 
Furthermore, mono-N-heteroaryl SAs have been synthetized using CuI as catalyst.102 
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Scheme 3.6: Synthesis of sulfonamides from amines and sodium sulfinates. 
In an interesting work from 2003, Burton et al.124 developed an efficient 
microwave-promoted palladium-catalyzed coupling of aryl-chlorides with SAs. After 
conditions optimization for the SA coupling, the best results were obtained using 
Pd2(dba)3 as catalyst, and an aminophosphine ligand, in basic conditions in 1,4-dioxane 
(Scheme 3.7).125 In a similar work, in order to reduce reaction temperatures and catalyst 
loadings was developed a Pd-catalyzed cross-coupling of methaneSA with aryl 
bromides and chlorides. After ligand screening, the best reaction conditions were 
[Pd(Allyl)Cl]2, ligand t-BuXPhos, in basic condition, using 2-MeTHF as solvent. Also 
using microwave heating, in a copper(I) catalyzed system, N-arylation of SAs with aryl 
halides, in basic conditions, have been performed.103 
 
Scheme 3.7: Palladium catalyzed N-arylation of sulfonamides with aryl chlorides. 
3.2 Results and discussion 
In this section, the results of the synthesis of Pc–SA conjugates are described. 
For that, the synthesis of Pht–SA conjugates is firstly addressed. So, in subsection 3.2.1 
is described the work developed for the synthesis of Pht–SA conjugates, from sulfonyl 
chlorides and from other sulfo sources. It is also addressed the synthesis of Phts with 
cationizable groups. Next, in subsection 3.2.2, the results obtained in the synthesis of 
neutral and cationic Pcs from the precursors previously obtained are discussed. 
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3.2.1 Synthesis of the precursors of phthalocyanine–sulfonamide 
conjugates 
The synthetic route to achieve the desired precursors is shown in Scheme 3.8. 4-
Nitrophthalonitrile and 2,4-dichlorophthalonitrile are converted to compounds 1 and 23, 
respectively, via a nucleophilic aromatic substitution with an excess of phenol at room 
temperature. Phenoxy-Phts 1 and 23 were obtained in good yields as described in the 
literature.61,62,77–82,134 Then, Phts 25, 28 and 29 were synthesized as described in a 
previous work61,62 and 9, 26 and 27 were obtained by modification of the same 
procedure that will be described in more detail in this section. 
4-Phenoxyphthalonitrile (1) has already been mentioned as starting material in 
chapter 2. For the synthesis of 4-(4-chlorosulfonylphenoxy)phthalonitrile (2) different 
synthetic strategies were tested. As described in chapter 2, we tried the 
chlorosulfonation with five equiv. of chlorosulfonic acid at room temperature and by 
using other chlorinating agents, such as TCT, but without success. In this chapter, we 
describe the successful conversion of 4-phenoxyphthalonitrile (1) into the 
corresponding chlorosulfonyl derivative 2. For that, a combination of chlorosulfonic 
acid and thionyl chloride was used.135 4-Phenoxyphthalonitrile was slowly added to 5 
equiv. of chlorosulfonic acid cooled in an ice bath. The addition is slow so that the 
temperature of the reaction mixture did not increase. The reaction mixture was stirred 
for 15 minutes at a temperature between 0 ºC and 5 ºC and then the temperature was 
allowed to rise to room temperature for more 15 minutes. After 30 minutes, thionyl 
chloride (2 equiv.) was added and the reaction was left for more 30 minutes at room 
temperature. After this time, the reaction mixture was slowly poured onto ice and the 
solid formed was filtered and washed with cold water. The compound was dried under 
vacuum at room temperature and used in the next reaction without further purification. 
In the following reaction the white powder obtained was dissolved in acetonitrile and 
the solution was cooled to 0 °C. Diethylamine was added slowly to the reaction mixture. 
The reaction mixture was then stirred at room temperature for 2 hours and poured into 
water ice. The resulting precipitate was filtered and washed with cold water. After 
recrystallization in CH2Cl2/Hexane and drying under vacuum at 60 ºC, a white powder 
was obtained in 78.0% yield. The structure of the desired Pht–SA conjugate 9 was 
confirmed by 1H NMR, 13C NMR and MS. 
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Scheme 3.8: Systematization of the synthetic route used to obtain precursors from sulfonyl chlorides.
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In 1H NMR spectrum (Figure 3.1), the signals corresponding to the methyl and 
methylene groups are observed at δ 1.18 and 3.29 ppm. In the aromatic region the 
resonances of the protons 8 and 9 appear as multiplets at δ 7.18 and 7.91 ppm, 
respectively Finally, the signals of protons H3, H5 and H6 emerged as a combined 
system in which H6 appear at δ 7.38 ppm as a doublet (J = 8.7), H5 at δ 7.31 ppm as a 
double doublet (J = 2.4 and 8.7) and H3 at δ 7.80 ppm as a doublet (J = 2.4). The 13C 
NMR spectrum (Figure 3.2) shows the carbons of the methyl and methylene groups at δ 
14.26 and 42.19 ppm, respectively. Between δ 110.35 and 138.09 ppm are observed the 
peaks corresponding to the aromatic carbons, in wich at δ 114.65 and 115.04 ppm are 
emerged the resonances of the nitrile groups. At the ESI-MS spectrum was observed a 
peak at m/z 355.3 corresponding to the molecular ion (M+). 
 
Figure 3.1: 1H NMR spectrum of 4-(4-(diethylaminosulfonyl)phenoxy)phthalonitrile (9) 
in CDCl3. 
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Figure 3.2: 13C NMR spectrum of 4-(4-(diethylaminosulfonyl)phenoxy)phthalonitrile 
(9) in CDCl3. 
Then we proceeded with the synthesis of SA derivatives 26 and 27. 4,5-
Bis(isopropylaminosulfonylphenoxy)phthalonitrile (26) was obtained in similar 
conditions for compound 9. In a boiling flask, with 4,5-bis(4-
chlorosulfonylphenoxy)phthalonitrile 24, 6 equiv. of isopropylamine were slowly added 
in acetone. The reaction mixture was stired for 1 hour under nitrogen atmosphere. Then, 
the reaction was quenched with cold water and the resulting precipitate was filtrated. 
After recrystallization in CH2Cl2/hexane a white powder was obtained in 23.0% yield. 
Figure 3.3 shows the 1H NMR spectrum of Pht 26 recorded in CDCl3. The 
resonances of the methyl and methine groups of the isopropyl group appear as a doublet 
and a multiplet at δ 1.12 and 3.45-3.58 ppm respectively. The multiplets at δ 7.05 and 
7.92 ppm are attributed to the resonances of protons 7 and 6, respectively. A singlet due 
to protons 3 is observed at δ 7.44 ppm. The 13C NMR spectrum (Figure 3.4) shows two 
peaks in the aliphatic region corresponding to the carbon atoms of the methyl and 
methine groups (δ 23.89 and 46.34 ppm). At the aromatic region is present the carbons 
from the three aromatic rings (δ 112.77–138.45 ppm) and the carbons of the nitrile 
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groups emerged at δ 114.23 ppm. At ESI-MS spectrum was observed a peak at m/z 
554.6 (M+). 
 
Figure 3.3: 1H NMR spectrum of 4,5-bis(4-isopropylaminosulfonylphenoxy) 
phthalonitrile (26) in CDCl3. 
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Figure 3.4. 13C NMR spectrum of 4,5-bis(4-(isopropylaminosulfonyl)phenoxy) 
phthalonitrile (26) in CDCl3. 
For SA derivative 27 the synthesis procedure was slightly different since 2-
aminothiazole is a solid. 4,5-Bis(4-chlorosulfonylphenoxy)phthalonitrile 24 reacted 
with 2-aminothiazole in acetonitrile in the presence of slowly added 4 eq. of 
triethylamine. After 2.5 hours at room temperature, under nitrogen atmosphere, water 
was added and the desired compound was extracted with dichloromethane and washed 
with water. The desired product was purified by chromatography over a silica gel 
column using a mixture of CH2Cl2/hexane (3:1) and crystallization from 
CH2Cl2/hexane. Compound 27 was obtained in 16.2% yield. 
The 1H NMR spectrum (Figure 3.5) shows two doublets δ 7.07 and 7.75 ppm 
corresponding to protons 10 and 11, respectively, from the thiazolyl group. Protons 6 
and 7 from the phenyl ring emerged at δ 7.35 and 7.56 ppm, and protons 3 appear at δ 
8.39 ppm as a singlet. The ESI-MS spectrum shows a peak at m/z 637.7 corresponding 
to the [M+H]+ ion. 
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Figure 3.5: 1H NMR spectrum of 4,5-bis(4-(thiazol-2-ylaminosulfonylphenoxy) 
phthalonitrile (27) in DMSO-d6. 
In addition, we also study the reaction of 4,5-bis(4-
chlorosulfonylphenoxy)phthalonitrile 24 with diisopropylamine, 3-amino-1,2,4-triazole 
and 4-(aminomethyl)benzenesulfonamide in order to obtain Pht–SA conjugate 30, 31 
and 32, respectively. Unfortunately, the reactions were not sucessful, probably due to 
low solubility of these amines in these reaction conditions or due to steric effects. 
Following the procedure of Trujillo et al.,136 in which 2,4-disubstituted oxazole 
sulfonyl chlorides are obtained by the treatment with N-chlorosuccinimide (NCS) in 
AcOH-H2O in good yield, we studied the extension of this reaction to Phts. For that 4-
(benzylthio)phthalonitrile (33) was obtained via a nucleophilic aromatic substitution 
with 4-nitrophthalonitrile and phenylmethanethiol at room temperature in DMF and in 
the presence of cesium carbonate (Scheme 3.9). The solid obtained was dried at room 
temperature in a desiccator. The desired Pht 33 was obtained at 86.1% yield. The 1H 
NMR spectrum (Figure 3.6) shows the diagnostic signal of the methylene group at δ 
4.25 ppm. In the aromatic region emerge a multiplet at δ 7.37–7.32 ppm corresponding 
to the protons of the benzyl group (H2’-H7’). Finally, at δ 7.35-7.61 it is observed the 
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characteristic signals of a 4-substituted Pht. The structure of the desired compound was 
also confirmed by ESI-MS in which it is observed a peak at m/z 251.1 corresponding to 
the [M+H]+ ion. 
Then, we attempted to convert compound 33 into the sulfonyl chloride 34 using 
NCS in AcOH-H2O. The reaction mixture was cooled with an ice-water bath and after 
10 minutes NCS (4 eq.) was slowly added in three portions. After stirring for 15 min at 
0 ºC and 2 h at room temperature the reaction was stopped. After the workup and 
separation by column chromatography the white powder obtained was characterized by 
1H NMR. In the 1H NMR spectrum of the isolated compound it is possible to verify the 
absence of signals corresponding to the benzyl group (data not shown), confirming that 
this group was cleaved. Finally, in order to confirm if we were in the presence of the 
expected sulfonyl chloride, the white powder was reacted with diethylamine (5 equiv.) 
in acetonitrile at room temperature. After 4 hours we were not able to observe any 
product in TLC so we decided to increase the temperature, firstly to 50 ºC and then to 
90 ºC. No SA could be obtained from this reaction. With these results we may conclude 
that the reaction with NCS did not afford the sulfonyl chloride 34.  
 
Scheme 3.9: Planned synthetic route for the synthesis of 4-(diethylaminosulfonyl) 
phthalonitrile (35). 
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Figure 3.6: 1H NMR spectrum of 4-(benzylsulfanyl)phthalonitrile (33) in CDCl3. 
Using TCT as chlorinating agent, disulfonate Pht 36 was tried to be converted 
into the sulfonyl chloride 24 by microwave irradiation in quick experiment. For that, 
compound 36 and TCT were dissolved in acetone in the presence of 2 equiv. of 
triethylamine and reacted in microwave at 50 W. After 20 minutes the reaction was 
ended with cold water. The isolated compound was the starting disulfonate Pht 36 and 
not to the desired sulfonyl chloride 24, indicating that this synthetic strategy was not 
successful in this transformation. 
 
Scheme 3.10: Chlorination of disulfonate phthalonitrile 36 with TCT. 
In parallel, other strategies for the synthesis of SAs, that do not use sulfonyl 
chlorides as intermediates, were evaluated. It was reported by Bahrami et al..137 that 
SAs may be synthetized in a mild and efficient way by the direct conversion of thiols 
into SAs in the presence of H2O2/ZrCl4 in acetonitrile at room temperature In order to 
evaluate the applicability of this reaction in our compounds, in a first approach, we used 
simple reagents like thiophenol with p-toluidine (Scheme 3.11) in order to obtain N-(p-
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tolyl)benzenesulfonamide 37. We obtained SA 37 in 98.6% yield, which is in line with 
what is described in the literature.137–140 1H NMR and MS spectra confirmed the 
structure of compound 37. This strategy was then extended to the synthesis of a new 
Pht–SA conjugate, using 4-aminophthalonitrile and thiophenol but the desired 
compound was not obtained probably due to the presence of the cyano groups that may 
reduce the reactivity of the amino group. 
 
Scheme 3.11: Synthesis of N-(p-tolyl)benzenesulfonamide (37) and extension of the 
synthetic conditions to the synthesis of a new phthalonitrile–sulfonamide conjugate. 
In order to obtain Pcs with SA and cationic groups, due to the cationization of 
Phts with amine groups, a study around the best synthetical strategy to obtain free amine 
groups substituted Phts, which could be cationization, was conducted. For that, we 
started by studying the possibility of obtaining 4,5-bis(2-
(dimethylamino)etoxi)phthalonitrile (38) via a nucleophilic aromatic substitution 
between the commercial 4,5-dichlorophthalonitrile and 2-(dimethylamino)etanol 
(DMAE) in DMF, from room temperature to 90 ºC (Scheme 3.12). Various 
experimental condition and temperatures were tested. In lower temperatures there was 
no reaction and at higher temperatures it was observed a formation of green byproducts 
that were very difficult to separate from other colorless compounds that were obtained 
in very low yields. This strategy to obtain cationic Pcs via dimethylaminoethoxy di-
substituted precursors proved not to be the most practical and straight way for this goal. 
In the literature it is possible to find some work about the synthesis of Phts and 
Pcs with 2-(dimethylamino)ethoxy and 2-(dimethylamino)ethylsulfanyl groups.141–147 
However, in those articles the focus was on the synthesis of mono-substituted 2-
(dimethylamino)ethoxy and not on the di-substituted Pht. Contrariwise, in the case of 
dimethylaminoethylsulfanyl substituted precursors the mono- and also di-substituted 
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precursors were already synthetized. To give an example, 2-
(dimethylamino)ethylsulfanyl mono- and di-substituted Phts and respective Ti(IV) Pcs 
in the neutral and cationized form were reported by Arslanoglu et al..146 In other work, 
the same group147 also describes the synthesis of 4-(2-
dimethylaminoethoxy)phthalonitrile and the corresponding tetra-substituted neutral and 
cationic Ti(IV) Pcs. 
 
Scheme 3.12: Synthetic approach to obtain 4,5-bis(2-(dimethylamino)etoxy) 
phthalonitrile (38). 
The strategy that proved to be viable was the utilization of Phts with pyridyl 
groups. Following the procedure described by Pereira et al.148 we obtained 4-
pyridylsulfanylphthalonitrile (39) and 4,5-di(4-pyridylsulfanyl)phthalonitrile (40) in 
76.2% and 53.5% yield, respectively. These pyridyl-Phts will be used in the next section 
as starting materials in a statistical condensation to obtain cationizable Pc-SA 
conjugates. 
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Scheme 3.13: Synthesis of 4-pyridylsulfanylphthanitrile (39) and 4,5-di(4-
pyridylsulfanyl)phthalonitrile (40). 
3.2.2 Synthesis of the phthalocyanine–sulfonamide conjugates 
Pcs Mg41, 41, Zn41, Zn44 and Zn45 were synthesized as described in 
previous works from our group.61,62 Pcs Mg42, Mg43, Mg44, Mg46, Mg47, 42–
45, Zn42, Zn43 and Zn46 will be described here in more detail. These Pcs were 
obtained following the same protocol used by Carvalho et al.62 Pcs Mg42, Mg43 
and Mg46 were prepared by cyclotetramerization of the corresponding Phts in the 
presence of magnesium pentoxide. First, magnesium turnings were added to 
pentan-1-ol and the suspension was heated to 150 °C with reflux. After the 
formation of the alkoxide (overnight), octan-1-ol was added to the suspension, 
followed by the respective Phts 26, 27 and 9. Then, the reaction mixture was 
stirred at 160 °C overnight. After cooling to room temperature, the mixture was 
added to a 5:1 methanol/water mixture and the resulting Pcs Mg42, Mg43 and 
Mg46 were isolated by filtration. These Pcs were then converted into the 
respective metal-free and ZnPcs (Zn42, Zn43 and Zn46) as described in the 
literature.62 The formation of the metal-free and Zn derivatives was confirmed by 
UV-Vis. UV-Vis absorption spectroscopic properties of Pcs 42, 43, 46, Zn42, 
Zn43 and Zn46 will be discussed in chapters 4 and 5. 
Pcs Mg42, Mg43 and Mg46 were characterized by 1H NMR and MS. 
Apart from the α and β protons of the Pc macrocycle, in 1H NMR spectrum of 
Mg42 (Figure 3.7) it is also observed the peaks corresponding to the methyl and 
methyne groups at δ 1.11 and 3.46 ppm, respectively, and at δ 7.02 and 7.87 ppm the 
peaks corresponding to the H1 and H2, respectively. As the 1H NMR spectrum of 
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Mg43 is concerned, the characteristic peaks of thiazolyl group emerge at δ 6.98 
ppm as a multiplet overlapped with the protons of the Pc macrocycle. 
Furthermore, the peaks at δ 7.47 and 7.71 ppm corresponding to the H1 and H2, 
respectively. Finally, the 1H NMR spectrum of Mg46 show unequivocally the 
signals corresponding to the protons of the methyl and methylene groups at δ 1.16 
and 3.26 ppm, respectively, and the peaks corresponding to the H1 and H2 (δ 7.81 
ppm) as a multiplet overlapped with the α protons of the Pc macrocycle. At δ7.15 ppm 
emerge the peak corresponding to the β protons of the Pc macrocycle. The structure of 
Pcs Mg42, Mg43 and Mg46 were also confirmed by MALDI-MS at positive mode in 
the presence of 2,5-dihydroxybenzoic acid (DHB) matrix. 
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Scheme 3.14: Systematization of the synthetic route used to phthalocyanine–sulfonamide conjugates. 
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Figure 3.7: 1H NMR spectrum of {2,3,9,10,16,17,23,24-[octakis(4- 
isopropylaminosulfonyl)phenoxy]phthalocyaninato}magnesium(II) (Mg42) in CDCl3. 
 
Figure 3.8: 1H NMR spectrum of {2,3,9,10,16,17,23,24-[octakis(4- (thiazol-2-
ylaminosulfonyl)phenoxy]phthalocyaninato}magnesium(II) (Mg43) in CDCl3. 
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Figure 3.9: 1H NMR spectrum of {2,9(10),16(17),23(24)-[tetrakis(4-
diethylaminosulfonyl)phenoxy]phthalocyaninato}magnesium(II) (Mg46) in CDCl3. 
Then, we started the study of the synthesis of cationic Pc–SA conjugates. For 
that, we planned three synthetic routes to obtain cationizable Pcs with N,N-
diethylaminosulfonyl groups (Figure 3.10). In the three synthetic routes, 4,5-bis(4-(N,N-
diethylaminosulfonyl)phenoxy)phthalonitrile (25) was used as starting material. 
In the first route (Figure 3.10 - blue), in a statistical condensation with 
magnesium turnings and pentan-1-ol, Pht–SA conjugate 25, 4-
pyridylsulfanylphthalonitrile (39) and octan-1-ol were added to the suspension after 
alkoxide formation. The suspension was heated to 160 °C and stirred overnight. 
From this reaction was obtained a mixture of Pcs as confirmed from TLC observations 
and from mass spectrometry analysis in which it was possible to observe the molecular 
ion (M+) at m/z 1318.6 of Mg47. 
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Figure 3.10: Planned route for the synthesis of cationic phthalocyanine–N,N-diethylaminosulfonamide conjugates.
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With these results, we decided to try to obtain a pure fraction of Mg47. Different 
chromatographic procedures were tried from normal phase to reverse phase column 
chromatography and repeated crystallizations from water and a variety of organic 
solvents. The best procedure consisted on the purification in preparative TLC with 
normal silica gel, using CH2Cl2/hexane/pyridine (1:1:0.5%) as eluent. Yet, with this 
procedure we were not able to afford a complete pure fraction. A mixture of Mg47 and 
traces of tetra thio-pyridine derivative was obtained. 
Then we studied the synthesis of hexa(thio-pyridine) Pc–SA conjugates Mg48 
and Zn48. For the synthesis of Mg48 - second route (Figure 3.11 - green) - Pht 25 was 
reacted with 4,5-di(pyridylsulfanyl)phthalonitrile (40) in DMF in the presence of 
Zn(AcO)2, at 120-150 ºC. After 12 hours, the color of the reaction mixture changed 
from yellowish to blue-green. Still in the TLC, different spots could be observed 
inducing that we would be in the presence of a mixture of Pcs. After mass spectrometry 
analysis it was possible to conclude that, from this reaction, we only afford the 
octa(thio-pyridine) derivative which was not our goal. 
To overcome these difficulties, we drew a synthetic route (Figure 3.11 - red) in 
which 4,5-difluorophthalonitrile and Pht 25 were converted in the Pc–hexafluoroSA 
conjugates Zn49. Then, after purification, this Pc would be converted, by a nucleophilic 
aromatic substitution, in the desired Pc–hexa(pyridylsulfanyl)-SA conjugate Zn48. The 
idea with this procedure was to reduce the polarity of the Pcs obtained making the 
purification of these compounds easier. For that, 4,5-difluorophthalonitrile and Pht 25 
were reacted in a statistical condensation in chloronaphthalene and in the presence of 
Zn(AcO)2. After purification the desired hexafluoroPc (Zn49) was obtained and its 
structure confirmed in 1H NMR and mass spectrometry. In 1H NMR spectrum is 
observed the protons corresponding to the methyl and methylene groups at δ 1.15 
and 3.24 ppm, respectively. In the aromatic region, at δ 7.03 ppm is shown the peak 
corresponding to H2, at δ 7.49 ppm the peak corresponding to the α-protons and at δ 
7.81 ppm the resonances for protons H3. The structure was also confirmed by MS in 
which the ion [M+Na]+ was observed at m/z 1163.4. 
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Figure 3.11: 1H NMR spectrum of {9,10,16,17,23,24-[hexafluoro-2,3-bis(4- 
diethylaminosulfonyl)phenoxy]phthalocyaninato]zinc(II) (Zn49) in CDCl3. 
Next, we tried the reaction of Zn49 with 4-mercaptopyridine in DMF in the 
presence of cesium carbonate. Different reaction temperatures were tried. The reaction 
was stirred from room temperature to 90 ºC. following the procedures described in the 
literature for the nucleophilic aromatic substitution of fluoro-Pors and fluoro-
phhalocyanines.149–152 However, no differences in the TLC were observed.  
3.2.3 Encapsulation of phthalocyanine–sulfonamide conjugates 
in PVP micelles 
Some of the conjugates obtained were chosen to be encapsulated in PVP 
micelles in order to be soluble in aqueous media. The encapsulation procedure is quite 
simple and practical. The encapsulation within the water soluble PVP was performed 
with Pcs 41–44, 46 and Zn41–Zn46 in an incubator at 50 ºC overnight, obtaining 
complete blue-green solutions. 
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3.3 Conclusions 
This chapter describes the work developed for the synthesis of Pc–SA 
conjugates. To that end, firstly, neutral conjugates were synthesized. It was obtained 
new Phts mono-substituted with SO2NEt2 (9) and di-substituted with SO2NH-isopropyl 
(26) and SO2NH-thiazol-2-yl (27) that were used for the synthesis of Pc-SA conjugates. 
Furthermore, the synthesis of precursors for cationizable Pc-SA conjugates were also 
accessed. 
With the synthetized Phts we were able to obtain, for the first time, the Pc-SA 
conjugates Mg42–Mg44, 42–44, Zn42–Zn43, Mg46, 46 and Zn46. These results 
consisted on an upgrade of a work developed in our group in 2009.62 Furthermore, we 
were also able to identify the presence of a new cationizable Pc-SA conjugate Mg47 in 
a mixture of Pcs. The synthesis of cationic conjugates turned out to be very demanding 
but these results are very promising for future studies involving the synthesis of cationic 
Pc-SA conjugates. 
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Chapter 4  Evaluation of phthalocyanine–sulfonamide 
conjugates as photosensitizers in PDT and as carbonic 
anhydrase inhibitors 
This chapter reports on the work developed in collaboration with the group of 
Doctor Jon Golding from the Health Sciences, Faculty of Science, Technology, 
Engineering & Mathematics, The Open University (UK) and Doctor Etelvina Figueira 
from the Biology Department, University of Aveiro. This is an ongoing work from 
which the most recent results will be presented. 
Taking advantage of Pc outstanding properties as PSs and SAs potentialities as 
antitumor agents, this work had the purpose of testing the hypothesis of a additive effect 
between Pcs and SAs. In this sense, these two active moieties were coupled in one 
molecule and evaluated as PS in the inactivation of cancer cells. 
Pc–SA conjugates were assessed as PSs by photophysical, photochemical and in 
vitro photobiological studies. Solubility, photostability/stability and singlet oxygen 
generation of these compounds were determined and their photodynamic activities were 
investigated on HSC3 oral squamous cell carcinoma and HaCaT ‘normal’ keratinocytes. 
Four of these compounds were encapsulated in PVP micelles and the differences on 
photophysical, photochemical and photobiological properties of these compounds were 
also accessed. In addition, the properties of these compounds as modulators of the 
activity of the enzyme CA were evaluated. 
The Pc–SA conjugates used in this work are indicated in Scheme 4.1. In the case 
of compounds Zn41, Zn44, Zn45 and Zn46 an encapsulation in PVP micelles was 
performed.153–160 The procedures involved in the synthesis of all compounds and 
encapsulation of the selected compounds (Zn41(PVP), Zn44(PVP)-Zn46(PVP)) are 
described in chapter 3. 
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Scheme 4.1: Structure of the phthalocyanine–sulfonamide conjugates. 
From the results it was possible to confirm that Pc–SA conjugates are important 
compounds to be considered as photosensitizes for PDT. The PVP encapsulation turned 
out to be a very good approach to enhance solubility of these compounds in aqueous 
media and consequently increase singlet oxygen generation. Furthermore, it was also 
possible to highlight Pc–SA conjugate Zn41(PVP) as the PS with higher cytotoxicity 
for the lowest uptake, probably due to the selectivity to the inactivation of the enzyme 
CA. 
4.1 Introduction 
Photodynamic therapy represents a new treatment opportunity for several 
diseases. Although still emerging, it is already being successfully used in the treatment 
of malignant and non-malignant diseases. Since 1985, when some Pcs were 
demonstrated as efficient PSs of mammalian cells, the interest of these compounds in 
photobiology increased considerably.2,161–164 
During the last decades, great attention has been paid to photodynamic therapy. 
One of the main challenges of this technique is the performance of the PS which should 
preferentially accumulate in malignant tissues relative to normal tissues, while having a 
good solubility in aqueous media and a also high singlet oxygen generation.161,165–168 
The functionalization and metallation of Pcs have been studied in order to obtain 
compounds with better properties, such as increased solubility in biological fluids, 
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transport, selectivity, singlet oxygen production, as well as clearance after 
photoinactivation. To overcome low solubility of phthacyanines in aqueous media, 
several approaches have been explored. One example is the encapsulation in a drug 
delivering vehicle. There are several micelles encapsulation possibilities reported in 
literature.153–160,169,170 One example is the encapsulation in PVP micelles that, as Pcs are 
concerned, it is described in the literature as reducing aggregation and consequently 
improving solubility in aqueous media and singlet oxygen generation yield.169 
Furthermore, SAs have been studied as antitumor drugs. There are a variety of 
mechanisms by which SAs have antitumor action such as disruption of microtubule 
assembly, functional suppression of the transcriptional activator NF-Y, or angiogenesis 
(matrix metalloproteinase, MMP) inhibition.91 But there are two that are more studied: 
One of them is related with the inhibition of CAs IX and XII. These enzymes are 
responsible for maintaining pH within viability values in cells and are known to be 
overexpressed in several tumours.73 The other mechanism is the regulation of cell cycle 
at the G1 phase through inhibition of cyclin-dependent kinases.90 
4.1.1 Brief historical perspective of photodynamic therapy 
Going back over 4,000 years it is possible to trace the attempts to use light in the 
treatment of diseases.171–173 It was firstly applied in Ancient Egyptian, Indian, and 
Chinese civilizations where light was used to treat various diseases including rickets, 
psoriasis, skin cancer and vitiligo.174 In the late nineteenth century, first reports of 
contemp orary PDT appeared during the investigations led by Finsen when he found 
that exposure of red light can prevent the formation and discharge of smallpox 
pustules.175 In addition, he also demonstrated that phototherapy could be used to 
successfully treat cutaneous tuberculosis, for which he won the Nobel Prize in 
Physiology and Medicine in 1903.162 
Chemical sensitization of tissue by light was reported in 1900 by Raab et al.,176 
who discovered that a combination of acridine red and light could kill a species of 
Paramecium. In the same year, using eosin (a brominated derivative of fluorescein) 
orally in the treatment of epilepsy, Prime, a French neurologist, discovered that this 
treatment induced dermatitis in sun-exposed areas of skin,175 leading to the first 
therapeutic medical application of PDT.46 
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The basic concept of photodynamic therapy was disclosed and the term 
‘photodynamic action’ (‘photodynamische Wirkung’) was introduced in 1904 by 
Tappeiner and Jesionek.46 Ten years later, a German doctor Friedrich Meyer-Betz inject 
himself with 200 mg of hematoporphyrin (Hp). When exposed to sunlight, adverse 
reactions like extreme swelling occurred and photosensitivity persisted for several 
months.177 Upon these observations, Lipson and co-workers3 prepared hematoporphyrin 
derivative (Hpd) by reacting Hp with acetic acid and sulfuric acid (9:1). During this 
reaction, apart from the formation Hp and related dehydration analogues, a completely 
unexpected product, was formed in about 50% yield, which was named Hpd. In the late 
1960s and early 1970s Hpd starts becoming known as an important drug for diagnosis. 
Several groups during the 1970s, upon in vitro and in vivo studies, recognized the 
potential utilization of Hpd coupled to light for tumor destruction. In 1978, Dougherty 
et al.178 reported an extensive pre-clinical study in which a series of 25 patients were 
treated with Hpd following photodynamic therapy showed partial or complete response 
in 111 of 113 tumors. These results were very important in PDT area but only in 1980 
Hpd was purified and Photofrin® was partially identified as a fraction of Hpd. Hpd is a 
mixture of dimers and higher oligomers in which the Por units are joined by ether, ester 
and carbon-carbon bonds.10 The first approval of using Photofrin® for PDT by the Food 
and Drug Administration (FDA) in the United States was obtained in 1995 for palliation 
of obstructive esophageal cancer.175 Since Photofrin® discovery increased worldwide 
interest in this treatment modality took place and several other PSs have been developed 
and studied, some of them with Pc-base structure.8 
Nowadays, there is a large variety of potent PSs and some of them are under 
investigation in clinical trials or already used in clinic.8,165,168,171,175,179 
4.1.2 Basic components of photodynamic therapy 
PDT is a 3-stage procedure which consists on the administration and distribution 
of a non-toxic drug - light-sensitive PS - systemically, locally, or topically to a patient 
bearing a lesion (first stage), which is frequently, but not always cancer, followed by an 
incubation period (second stage) and photodynamic inactivation by irradiation with a 
light of appropriate wavelength (third stage). Virtually, photodynamic inactivation can 
occur in any organ in the body using flexible fibrotic devices.180 The first key step of 
PDT is the accumulation of the PS in malignant tissue after the administration of the PS, 
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which can be taken orally or introduced in the body by intravenous administration. 
Accumulation must be as selective as possible. The second and crucial step is singlet 
oxygen production after PS illumination with light of an appropriate wavelength 
creating a photochemical reaction called photodynamic effect. This effect, third step, 
results in tissue destruction. The description of the interaction with light with the PS and 
the generation of reactive oxygen species (ROS) including singlet oxygen is described 
in the modified Jablonski diagram (see section 0).165,181,182 
In this technique, the combination of the selectivity of the PS and precise 
delivery of light is decisive for the success of this technique. When irradiated with light, 
the PS will produce singlet oxygen, damaging tumor cells, leading to death and 
elimination of cancer cells (Figure 4.1).3,165 As Pcs are concerned, it is usually used red 
visible light (620–690 nm).8 
 
Figure 4.1: Principles of photodynamic therapy (adapted from Agostinis et al.).165 
The use of PDT as cancer therapy is particularly attractive because of its 
potential specificity. This is due to the fact that the PS can be localized in the malignant 
tissue. When the light is directly focused on the lesion, the ROS that are generated 
during photo-sensitization result in cellular destruction in that particular region. In 
recent years, PDT has become a subject of intense investigation as a possible treatment 
modality for various forms of cancer.165,175,179 
PDT can be a complementary treatment to chemotherapy, radiotherapy, or 
surgery and can be used either before or after, without compromising these therapeutic 
procedures. The currently used PSs do not accumulate in cell nuclei and do not present 
the adverse effects of chemotherapy or radiation, beyond that it is an excellent 
technology for the treatment of patients with skin cancers and do not present significant 
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changes in tissue temperature, preserving connective tissue leading to minimal 
fibrosis.165 
As previously referred, one key step of PDT is the accumulation of the PS in 
malignant tissue which can be influenced by many factors such as hydrophobicity, pH, 
lymphatic drainage and lipoprotein binding. In addition, it is known that pH of 
interstitial fluids in malignant tumors is by tendency lower than that of normal tissues. 
This phenomenon is due the elevated production of lactic acid by tumor cells because of 
its high metabolic rates. Other factor that influences PS accumulation is lymphatic 
clearance that in tumors generally is poor due to underdevelopment of lymphatic system 
and due to lymphatic obstruction. Thus, the difference between poor lymphatic drainage 
of tumors and normally enhanced tumor vasculature permeability and hypervascularity 
are considered to be the main reasons for the accumulation of proteins and 
macromolecules in tumors. Serum protein binding is a phenomenon well described for 
several drugs. It is known that some tetrapyrrolic compounds like Pors bind to proteins, 
especially albumin, which is an important carrier of endogenous Por in the 
blood.165,175,183 
4.1.3 Photosensitizers 
PSs are compounds that when irradiated with light have the capability to absorb 
light in a specific wavelength and transform photons into other forms of energy.179 PSs 
play a crucial role in PDT, indeed they are the crucial parameter in this technique. 
The demand for new compounds with improved photo-physical and photo-
biological properties has led to the development of several generations of PSs. 
However, there are challenges to be addressed, in particular in terms of specificity to the 
target and enhanced ability to be carried to the target site. Although there are a variety 
of natural photosensitizing compounds such as methylene blue, rose bengal, and 
acridine also used as PSs in PDT, the majority of the PSs are cyclic tetrapyrroles and 
their analogues, with enhanced photobiological properties. In this group we can 
highlight Pors, chlorins, bacteriochlorins, expanded Pors, and Pcs.179 
Pors, first-generation PSs, have been successfully applied in PDT since the 
1970s, in the photodynamic therapy of detection of neoplasic tissues and photodynamic 
inactivation of viral pathogens present in the blood plasma. In addition, already on the 
market there are some active principles with approval for this therapy. First-generation 
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PSs Photofrin® presented some disadvantages. Out of these, the prolonged skin 
photosensitivity, low selectivity towards the tumor tissue and the poor band of 
absorption (630 nm - out of red zone), stand out. Moreover, like Photofrin®, most of 
these PSs are mixtures because it is virtually impossible to isolate and characterize the 
main active compounds.162,165,184 
In the attempt to improve the first-generation PSs, new and more effective PSs 
have been developed (second-generation PSs), with activity and selectivity improved in 
relation to those already commercially available. These molecules exhibit some 
differences when compared to the first-generation compounds. They differ in the 
intervals between administrations, in the intervals of irradiation, in the dose 
administered and light requirements to cause necrosis. The synthesis of these PSs has 
been established of the ideal characteristics for a compound to be used in PDT. Some 
relevant properties of an ideal PS should include: 
• adequate solubility in body fluids, which affects transport and retention time; 
• high selectivity for tumor tissue compared to normal tissue; 
• negligible toxicity in the absence of light; 
• absorption near to red visible spectrum (λ > 650nm), for better tissue penetration; 
• high yield of singlet oxygen generation; 
• stability upon exposure to light, since this can affect singlet oxygen quantum yield; 
• simplicity of synthesis with high yields; 
• purity and stability of composition; 
• rapid clearance from normal tissues; 
• stability and solubility in the injectable solvents (formulation); 
• inducer of cell death neoplasic tissues.184 
meso-Tetraphenylporphyrin (TPP) was the first Por to be used as second-
generation It was an important improvement from Photofrin® and the first Por-based PS 
as a single compound. TPP has an absorption maximum of 630 nm and is an efficient 
generator of 1O2 but has limited solubility in biological media. However, some 
modification of the molecule with suitable substituents, have been done in order to 
enhance the hydrophilicity.179 
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Apart from Pors and in particular TPP, some second-generation PSs with Por 
related structures were developed, such as reduced Por derivatives (chlorins, 
bacteriochlorins), benzoporphyrines, Pcs and naphthalocyanines. These compounds 
have the desirable photophysical properties. Chlorins and bacteriochlorins have 
absorption bands between 660–690 nm and 730 nm, respectively, and Pcs and 
naphthalocyanines have an intense band at 670 nm and 820 nm, respectively.162,184 Due 
to the four additional peripheral benzene rings, Pcs absorb at longer wavelengths 
compared with other second-generation PSs. The use of PSs which absorb at longer 
wavelength gives rise to a higher penetration of light and consequently to an increased 
therapeutic effect. A recent example of a Pc-based PS used clinically is the so called 
Photosens®, which is a mixture of sulfonated aluminum Pcs with various degrees of 
sulfonation. This PS was developed in General Physics Institute in Russia. Photosens® 
is activated by 675 nm red light and has already been used in photodynamic therapy 
trials. It has also been tried on age-related macular degeneration.2,179,185 
Recently, third-generation PSs have been developed. Photosensitizers bearing 
targeting moieties or encapsulate in a drug delivery vehicle, such as nanoparticles or 
polymeric or lipoic micelles have been develop and a huge improvement of 
photodynamic properties have been observed.186 
Some clinically used PSs are summarized in Table 4.1. When compared with 
Photofrin®, Pcs have high molar-extinction coefficient (e = ∼ 105) and red-shift 
absorption maximum around 680 nm. Furthermore, Pcs are excellent singlet oxygen 
generators and when chelated with a metal ion such as zinc or aluminum singlet oxygen 
efficiently increases to nearly 100%. So, metal complexes of Pcs became very 
interesting for PDT.2 
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Table 4.1: Clinically used photosensitizers.179 
Photosensitizer Structure Wavelength (nm) Cancer types 
Porfimer sodium 
(HPD) (Photofrin®) 
Porphyrin 630 
Lung, esophagus, 
bile duct, bladder, 
brain, ovarian 
5-aminolevulinic 
acid (ALA) 
Porphyrin precursor 635 
Skin, bladder, brain, 
esophagus 
ALA esters Porphyrin percursor 635 Skin, bladder 
Temoporfin 
(Foscan®) 
Chlorin 652 
Head and neck, lung, 
brain, skin, bile duct 
Verteporfin Chlorin 690 
Ophthalmic, 
pancreatic, skin 
HPPH Chlorin 665 
Head and neck, 
esophagus, lung 
SnEt2 (Purlytin®) Chlorin 660 Skin, breast 
Talaporfin Chlorin 660 Liver, colon, brain 
Ce6-PVP 
(Fotolon®), Ce6 
derivatives 
Chlorin 660 
Nasopharyngeal, 
sarcoma, brain 
Silicon Pc (Pc4) Phthalocyanine 675 
Cutaneous T-cell 
lymphoma 
Padoporfin 
(TOOKAD®) 
Bacteriochlorin 762 Prostate 
Motexafin lutetium 
(Lutex®) 
Texaphyrin 732 Breast 
Photosens® Phthalocyanine 675 nd 
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Apart from the outstanding photophysical and photochemical properties of 
Pcs,12,187 their properties can be changed through rational modification of the 
substituents either on the periphery of the macrocycle or at the axial positions linked to 
the metal center. There are several studies in which PSs are covalently attached to 
various molecules that have some affinity for neoplasia, to receptors expressed on 
specific tumors or to specific metabolic receptors. The intention is to control the 
localization where PS will be attached. These vehicles can be monoclonal antibodies, 
antibody fragments, peptides, proteins, low density lipoproteins (LDL), various 
carbohydrates, somatostatin, and folic acid, among others.165Observations that neoplasic 
tissues have affinity for Pcs was already reported before,2 but was only in 1985 by Ben-
Hur and Rosenthal164 that Pcs became interesting, as PSs for PDT. 
Singlet oxygen generation capacity is also affected by the tendency of Pcs to 
aggregate which shortens the singlet excited state lifetime and hence decreases the 
singlet oxygen quantum yield by dissipating energy through internal 
conversions.188Apart from the modulation of the periphery of the macrocycle with large 
substituents, this problem can also be circumvented by encapsulating the Pc in 
emulsifying agents (liposomes),183 polymer-drug conjugates,189 polymeric micelles190,191 
or nanoparticles.192 
4.1.4 Light sources 
The longer the wavelength the greater the penetration into living tissues. The 
best region for light penetration in tissues is between 600 and 1200 nm and is often 
called the optical therapeutic window of the tissue. Nevertheless, after 800 nm light is 
not appropriated to generate singlet oxygen because the energy required to initiate a 
photodynamic reaction is low. Therefore, the ideal light source and light wavelength 
choice should be based on the type of PS used and its photophysical properties 
(fluorescence excitation and action spectra). It should also take into account the 
localization, size, accessibility of the tumor, tissue characteristic and cost (Figure 
4.2).165 
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Figure 4.2: Light penetration though tissues. 
4.1.5 Photophysics and photochemistry 
Luminescence is the phenomena in which a substance emits light, and occurs by 
a transition between electronically excited states to a less energetic state. Depending on 
the nature of the excited state, luminescence is formally divided into two categories: 
fluorescence and phosphorescence. Fluorescence is the emission of light by a substance 
that has absorbed light or other electromagnetic radiation. This excited state is very 
unstable and emits excess energy as fluorescence and/or heat, returning to the ground 
state. When allowed, it can also occur rapidly by emission of a photon. Typically, 
fluorescence emission rates are 108 S-1. Phosphorescence is the emission of light from 
triplet excited states, in which the electron in the excited orbital has the same spin 
orientation as the ground-state electron. Transitions to the ground state are forbidden 
and the emission rates are slower than in fluorescence. After light exposure, the 
phosphorescence substances glow for several minutes. 
Fluorescence spectroscopy is an optical spectroscopy technique that analyses 
fluorescence emitted by type specimens. It involves the use of a light source, usually 
UV-Vis, which excites the electrons of the molecules in the sample and cause emission 
of light of lower energy, typically but not necessarily visible light. This optical 
apparatus is used to analyze PSs fluorescence and phosphorescence.42,47 
The events experienced by a molecule since it absorbs radiation until it returns 
to the ground state can be illustrated in a Jablonski diagram (Figure 4.3), which 
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represents the energy states of a molecule and transitions between them. Aleksander 
Jablonski was one of the pioneers of molecular photophysics and is regarded as the 
father of fluorescence spectroscopy. Jablonski diagrams are often used as the starting 
point for discussing light absorption and emission.166 
 
Figure 4.3: Modified Jablonski diagram. 
The absorption of light of appropriate wavelengths (photons) by a population of 
molecules induces the passage of electrons from the ground electronic state - singlet 
state (S0) - to an excited state Sn, where n > 1. The molecule Sn returns to the lowest 
energy short-lived excited state S1 emitting energy to the outside environment, in the 
form of heat.42 
From the lowest energy excited state S1, the molecule returns to S0 state via four 
different competitive processes. It can be by photon emission (fluorescence) or 
dissipating the absorbed energy to the environment by heat. This type of energy is non-
radiative. A third route is described when the excited molecules pass some energy to 
another molecule located in the vicinity through collisions or energy transfer; and 
finally, the excitation can proceed by transient passage due to the passage of energy 
from the S1 state to an excited triplet state of lowest energy T1. This phenomenon is 
referred as inter-system crossing (ISC).42,47 
Then, the energy is transferred from the triplet state T1 to the ground state S0. 
This is driven by three similar ways to the state transition from S1 to S0, which may 
occur throw emission of a photon (phosphorescence), by non-radiative energy 
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dissipation (heat), and may also occur, by energy transfer to a close molecule (collision) 
or to a short distance molecule.42 
A chromophore (part of the molecule or functional group which is responsible 
for color) which emits photons is called a fluorophore. Many are not necessarily 
fluorescent chromophores. In this case, the absorbed energy is dissipated to the 
environment as thermal energy, energy of collision with the molecules of the solvent 
and also by energy transferred to other molecules. For example, the heme group absorbs 
energy but it is not fluorescent. The lack of fluorescence results from the total energy 
transfer from the Por to the metal ring.42 
The ground state of an oxygen molecule can be described as a triplet in which 
two higher-energy electrons are unpaired and each occupies a degenerate orbital. When 
an oxygen molecule is excited the two highest energy electrons pass to be located in a 
single orbital, getting paired. An oxygen molecule in this state is called singlet oxygen, 
whose state is the highest energy and is therefore less stable.42,47 
The triplet or singlet designations are the result of the spin quantum number (s). 
An electron rotates around itself with a movement quantified by a spin quantum 
number. The singlet and triplet states depend on this number. According to the Pauli 
Exclusion Principle, two electrons in a same defined orbital may not have the same 
quantum numbers including spin quantum number. Two spins are assigned to an 
electron, + 1/2 and – 1/2. Thus, two electrons must have opposite spin to belong to the 
same orbital.42 
The multiplicity (m) of that two electron states is defined by m = 2|s1+s2|+1, and 
refers to the number of possible states with the same energy. When the spins are 
antiparallel (m = 1), we have the singlet state (S). When the spins are parallel (m = 3), 
we have the triplet state (T).Most molecules are in the singlet state. Oxygen is in the 
triplet state and, when excited, passes to a singlet excited state. In triplet oxygen state 
there are in total three possible spin orientations for the two higher-energy electrons. 
While in singlet oxygen there is only one possible spin orientation.47 
The rotation speed of an electron around its axis is very small compared with the 
speed of light. Thus, the magnetic contribution to the absorption can be neglected 
compared to the contribution of the magnetic field. During absorption, electronic 
transition results from the interaction between the electrons and the electric field 
generated by radiation. For this reason, during absorption, there is no change in the 
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number of electron spin. This way, only the transitions S0 → Sn are possible and 
transitions S0 → Tn are forbidden.42 
In many organic molecules, the internal conversion from the higher excited state 
to the lowest energy state occurs much faster than the decay of the lowest energy 
excited state to the ground state. Thus, fluorescence takes place mainly from the excited 
state to the lowest energy state, even if the initial molecule has an excited state of higher 
energy.42 
The photosensitization by a tetrapyrrolic compound, like Pc, is a photodynamic 
reaction in which oxygen is required for the reaction. This process may follow by a type 
I or type II mechanism. In both mechanisms, there is a generation of a long-lived triplet 
state. In a type I mechanism the PS in a triplet state undergoes a primary reaction with a 
target biomolecule in its vicinity, leading to an hydrogen atom abstraction or an electron 
transfer process which results in the formation of a radical. This radical will react with 
molecular oxygen to produce multiple oxidized products, usually called as ROS, such as 
superoxide, hydroperoxyl and hydroxyl radicals and hydrogen peroxide. In a type II 
mechanism, the excited Pc triplet state directly interacts with molecular oxygen. In this 
interaction, the electronically excited singlet state oxygen (1O2) is formed via energy 
transfer. Singlet oxygen will react with an electron-rich region of biomolecules to 
produce oxidized species.42 It is generally accepted that the type II photodynamic 
mechanism prevails during the process and that the singlet oxygen is the most important 
cytotoxic species. However, the type I mechanism may become more significant in 
environments with low oxygen concentration. Probably there are many cases in which 
the two processes act accordingly. But more important than all this, is that both 
mechanisms trigger oxidative reactions that induce cell death and lead to a higher tumor 
destruction.42,166 
4.1.6 Biological mechanisms of photodynamic therapy 
It is now known that photodynamic treatment can go through three different 
mechanisms:29 direct tumor cell destruction, vascular destruction, and recruitment of an 
antitumor immune response. These three mechanisms are not independent and can 
influence each other. 
As direct damage and cell death is concerned, ROS generated during PDT can 
kill tumor cells directly. By PDT, the elimination of tumor cells can occur by at least 
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two types of cell death processes: necrosis or apoptosis.3,30,31 Necrosis is a violent and 
immediate form of degeneration that results from extensive cellular damage. It is 
characterized by the release of intra-cellular contents into the extracellular compartment 
resulting from the destruction of organelles and disruption of the plasma membrane. 
Apoptosis is a mechanism in which genetically programmed death of old or damaged 
cells occurs. It involves a common sequence of morphological and biochemical 
changes, including condensation of chromatin and formation of apoptotic bodies.166 
The viability of a tumor depends on the amount of nutrients supplied by blood 
vessels. In this sense, vessels around the tumor are very important. There are a number 
of reports of PDT that can induce damage to tumor microvasculature leading to post-
PDT tumor hypoxia/anoxia and nutrient deficiency, which is lethal to the tumor.166 This 
mechanism by which tumor microvasculature is damaged includes vascular occlusion, 
vessel constriction/collapse, macromolecular leakage, leukocyte adhesion, blood flow 
stasis, and thrombus formation.193 
PDT can also trigger inflammatory and immune responses, by photodynamically 
induced changes in the plasma membrane and membrane organelles, which can activate 
multiple signal transduction pathways. This includes the activation of a variety of 
protein kinase signalling cascades leading to an inflammatory or immune response and, 
ultimately, to cell death.161,193 In the late 1980s and early 1990s several studies have 
reported the infiltration of lymphocytes, leukocytes, and macrophages into PDT-treated 
tissue which indicates an activation of the immune response.180,194 The initiated 
inflammatory response can have differences in the nature and intensity between normal 
and cancerous tissues that may be an additional contribute to the selectivity of PDT.29 
Mitochondria, plasma membranes, lysosomes and nuclei have been proposed as 
subcellular structures targets of the photodynamic effect. Additionally, it has also been 
reported that photodynamic treatment can also result in, direct or indirectly, DNA 
damage. In the case of Photofrin®, it is believed that the major mechanism of tumor 
necrosis is due to damage of tumor vasculature that leads to blood stasis and 
consequently starving the tumor of oxygen and nutrients. Furthermore, it is believed 
that in the initial phase after irradiation, the plasma membranes and the membranes of 
mitochondria and lysosomes start to disintegrate. After this phase, there is a continuous 
depletion of the ATP pool with drastic consequences for all energy-consuming process. 
Joining to this, the membrane breakdown can cause rapid liberation of phospholipids, 
  
84 
 
such as arachidonic acid, leading to the release of vasoactive and inflammatory 
mediators like thromboxanes, prostaglandins and leukotrienes. All these inflammatory 
mediators initiate an acute inflammatory process with massive edema and vascular 
damage. This vascular damage leads to a local hypoxia and initiation of a necrotic 
process by nutrient deprivation. In response to this hemorrhage, platelets aggregation 
and adhesion to damaged tissue is activated and are released IL-1β, IL-2 and TNF-α 
increasing the pathological effect of the eicosanoids. However, other mechanisms of 
tumor necrosis have also been proposed like direct cell killing and 
apoptosis.161,165,166,172,184 
It is believed that PSs, with high partition coefficients (increased 
hydrophobicity), are more likely to accumulate in malignant tissue by preventing drugs 
from entering or continuing on blood circulation, and it is important for membrane 
penetration. Lipophilicity has proven to be a very important molecular descriptor and is 
often well correlated with bio-activity of chemical entities. On the other hand, 
hydrophilicity is vital for a proper PS distribution in biological fluids, thus a proper 
balance between hydrophobicity and hydrophilicity is important.162,167,179 
4.1.7 Applications of phthalocyanines in PDT 
In medicals sciences, the major utilization of Pcs is as PSs in PDT to 
inhibit/eliminate cancer cells. There are several examples of such applications.195–197 In 
a study by Fadel et al.,43 nanoparticles formulated from the biodegradable copolymer 
poly(lactic-coglycolic) acid (PLGA) containing zinc phthalocyanine (ZnPc) were 
investigated as a drug delivery systems to enhance tissue uptake, permeation, and 
targeting for photodynamic therapy. These nanoparticles were prepared with different 
sonication time in order to study the effect on nanoparticle shape, encapsulation and size 
distribution, in vitro release, and in vivo photodynamic efficiency in tumor-bearing 
mice. This study revealed that tumor-bearing mice injected with Pc nanoparticles 
exhibited significantly smaller mean tumor volume, delay tumor growth and enhanced 
survival, compared with the control group and with the group injected with free ZnPc 
during the time course of the experiment. This was attributed to the increase of the 
solubility and dissolution rate, allowing sustained drug release.43 One year later, 
Maduray et al.44 performed in vitro toxicity testing of zinc tetrasulfoPcs in fibroblast 
and keratinocyte cells for the treatment of melanoma cancer by photodynamic therapy. 
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With this in vitro study, they were able to show that ZnTSPc mediated photodynamic 
therapy (50 µg/ml) with a light dose of 4.5 J/cm2, represented and effective therapeutic 
option for melanoma, by selectively destroying melanoma cells via apoptosis with low 
killing effects on healthy normal skin cells. In the same year, Lim and coworkers45 used 
an indocyanine green PS with 785 nm LED light to treat cancer from oral region. With 
this methodology Lim et al. were able to conclude that focused and increased depth of 
penetration due to longer wavelength are not required to an effective treatment. These 
results will be important to enhance the treatment of one of the most difficult cancers 
due to its late diagnoses. 
In 2012, tetrasubstituted carboxy aluminum phthalocyanines (AlC4Pc) were 
covalently encapsulated in silica shells and used as PSs in magnetic resonance imaging 
and photodynamic therapy of liver cancer cells. The nanoparticles obtained showed 
uniformity in size, stability against PS leaching, and also showed high efficient in 
photogenerating cytotoxic singlet oxygen under near-infra-red light.55 Also in 2012, 
using the same Pc, Manono et al.15 determined the subcellular localization of ZnTSPc 
and its effect on two cancer cell lines - human colon (DLD-1) and lung (A549) 
carcinoma cells. ZnTSPc was activated at a wavelength of 680 nm with 5 J/cm2 and 
subcellular localization was determined by fluorescence microscopy. Alongside, 
toxicity of PS alone and combination of light was determined by cell morphology, 
viability, proliferation and cytotoxicity. With this procedure cell death was induced in 
both cell lines. PS was localized in vital organelles such mitochondria and lysosomes. A 
collaboration involving the University of Aveiro, the Universidad Autonoma de Madrid, 
Memorial Sloan-Kettering Cancer Centre in New York and the University of Erlanger, 
in Germany,198 glycoPcs were tested as PSs for triggering mitotic catastrophe and 
apoptosis in cancer cells. In this study, the photodynamic-effect of three symmetric and 
asymmetric Pcs with D-galactose on HeLa carcinoma cells was analyzed. This work 
revealed that asymmetric glycoPc with the sugar in only one side of the Pc is very 
efficient and selective, producing higher photo-cytotoxicity on cancer cells than in 
nonmalignat HaCaT, probably due to its amphiphilic character. The other example is the 
utilization in PDT and magnetic resonance imaging (MRI) in cancer cells of 
Lanthanide-doped up conversion nanoparticles with a AlC4Pc. In vitro studies indicated 
that these nanoparticles could effectively kill cancer cells upon near-infrared (NIR) 
irradiation (700-1000 nm), which affords deep light penetration, low auto-fluorescence 
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and photo-damage, and reduced light scattering. Furthermore, the nanoparticles also 
demonstrated good MRI contrast, both in aqueous solution and inside cells. The third 
work from 2012 was carried out by Korbelik et al.199 in which it was developed a 
poly(D,L-lactic-co-glycolic acid)-nanoparticles (PLGA-NPs) preparation of 
hypocrellin-based derivative SL052. In collaboration with Quest PharmaThech Inc., 
Edmonton, AB, Canada, Korbelik used this new formulation in preclinical and clinical 
tests in photodynamic therapy. The nano formulation encapsulating SL052 into 
biodegradable polymer PLGA was developed using single-emulsion solvent 
evaporation technique and characterized in terms of particle size and loading of the 
photosensitizing agent. 
An interesting field of PDT is the utilization of antibodies coupled with Pcs 
which has been study in newer years. To give an example, in 2011, Stuchinskaya et al.16 
developed and studied the utilization of anti-HER2 monoclonal antibodies-Pc-
polyethylene glycol-gold nanoparticle to target photodynamic therapy of breast cancer 
cells. The nanoparticle conjugates showed low aggregation, and under irradiation with 
visible red light efficiently produced cytotoxic singlet oxygen. Cellular experiments 
demonstrated that the nanoparticle conjugates selectively target breast cancer cells that 
over-express the HER2 epidermal growth factor cell surface receptor, and that they are 
effective photodynamic therapy agents. However, the large size of monoclonal 
antibodies (mAbs) hinders tissue penetration and lowers cellular uptake when used in 
vivo has been created some concern. Furthermore, the attachment of PSs to mAbs may 
also reduce the antigenic specificity of the mAbs. As a result, smaller antibody 
fragments have been used as alternative carriers. An alternative strategy involves the 
utilization of peptides with appropriate sequences which can specifically bind to 
different surface markers of cancer cells and tumor vasculatures. This biding is achieved 
by the formation of a triazole by a click reaction.17 
Photodynamic therapy has been showing promising results in the treatment of 
atherosclerosis acting on vascular walls. Recent experiments in animal samples 
provided a solid evidence for successful use of photodynamic therapy for preventing 
and reducing the intimal hyperplasia.22–24 Borshch et al. in 201223 used a silicon Pc and 
a commercial phthalocyaninic PS (Photosens - sodium salt of sulfonated 
hydroxyalumino) on the treatment of atherosclerosis by inducing the apoptosis of the 
cellular population of atherosclerotic plaques. Heckenkamp et al.24 using as PS 
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chloroaluminum sulfonated Pc, achieved an inhibition of intimal hyperplasia, with 
better results in comparison to the treatment with γ-irradiation. The same research 
group, using the same PS, designed a study to test the hypothesis that PDT alters the 
vascular wall matrix thereby inhibiting invasive cell migration, and as such, provides an 
important barrier mechanism to favorably alter the vascular injury response. With this 
protocol, Heckenkamp and colleagues were able to observe a 52% reduction of invasive 
SMCs and a reduction up to 59% in fibroblast migration, but not significant effects on 
the secretion of matrix metalloproteinases. Additionally, PDT induced collagen matrix 
changes, including cross-linking, which resulted in resistance to protease digestion, and 
led to a durable 45% reduction in pepsin digestion susceptibility of treated arteries and 
inhibition of periadventitial cell migration into the media.22 
Also using a sulfonated MPc, Ranyuk et al.28 labelled a series of ZnPcSn with 
64Cu in good yields. Tumor-bearing mice were injected with the 64Cu-labeled products 
and subjected to 3 hours dynamic positron emission tomography (PET). The 
[64Cu]CuPcSn complexes demonstrate to be suitable for PET imaging, allowing the 
rapid generation of preliminary biodistribution data with only a few animals. However, 
only some Pcs with amphiphilic groups like [64Cu]CuPcS2 and [64Cu]CuPcC6 showed 
biodistribution patterns and highest tumor-to-back-ground rations. In another study, 
hexyn-1-yl-trisulfophthalocyanine (ZnPcS3C6) and hexyn-1-yl-trisulfobenzo-
mononaphthalo-porphyrazine (ZnNPS3C6) were also used as testing PS for PET. 
Cauchon et al.27 combined PET with the constant infusion of 2-deoxy-2-[18F]fluoro-D-
glucose (FDG) as a tracer to monitor in real-time transient metabolic chances resulting 
from photodynamic therapy in animals bearing a tumor. 
4.1.8 Sulfonamides as antitumoral agents 
The antitumoral activity of SAs is, in general, associated with arrestment of 
activity CDKs in the regulation of the cell cycle200,201 and inhibition of CA in tumor 
membrane.73 
The inhibition of growth of human cancer cells in culture by direct action of 
specific SA CA inhibitors was first reported by Chegwidden and Spencer,202 who drew 
attention to their therapeutic potential in the treatment of cancer. This work 
demonstrated that potent CA inhibitors such as acetazolamide, methazolamide and 
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ethoxzolamide, strongly inhibit the growth of human lymphoma cells with GI50 values 
of 0.5 μM for ethoxzolamide and 0.25 mM for acetazolamide. 
CAs (also known as carbonate dehydratases) are a class of ubiquitous metallo-
enzymes that catalyze the reversible hydration of carbon dioxide to the bicarbonate ion 
(Scheme 4.2).203 This reaction is the basis for the regulation of acid–base balance in 
organisms.204,205 Fifteen different CA isoforms have been identified in humans (Table 
4.2 and Figure 4.4), and these proteins are also present in prokaryotes and eukaryotes.206 
 
Scheme 4.2: Reaction catalyzed by the enzyme carbonic anhydrase. 
CAs are involved in crucial physiological processes related with respiration and 
transport of CO2 between metabolizing tissues and the lungs. The primary function of 
the enzyme in animals is in the interconversion of carbon dioxide and bicarbonate to 
maintain acid-base balance in blood and other tissues, a reversible reaction that occurs 
relatively slowly in the absence of a catalyst. CA  is also related with pH homeostasis, 
bone resorption, calcification, production of body fluids, gluconeogenesis, lipogenesis, 
electrolyte secretion in a variety of tissues/organs, biosynthetic ureagenesis and 
tumorigenicity.207–209 CA-related proteins (CA-RP VIII, CA-RP X and CA-RP XI) are 
acatalytic forms due to the default of one or more histidine residues which are essential 
for the binding of the zinc ion in the active site.207 The zinc ion, essential for catalysis, 
is coordinated by the imidazole rings of 3 histidine residues, His94, His96, and His119. 
CA XV is the most recent discover isoenzyme that is absent in humans and monkeys 
but is expressed in a number of other species.203,209 Recently, CA IX closed association 
with tumors was revealed and CA XII were found to be overexpressed in renal 
carcinoma.203 
Hypoxia is key feature in many tumors. An inadequate supply of oxygen is a 
crucial pathophysiological consequence of structurally and functionally disturbed 
microcirculation and deteriorated oxygen diffusion processes. It seems that tumor 
hypoxia is strongly associated with tumor propagation, malignant progression, and 
resistance to chemotherapy and radiotherapy. In a hypoxia environment there is an 
overexpression of CA IX. CA IX expression is strongly increased in many types of 
tumors.209 
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CAs are encoded by four evolutionarily unrelated gene families: α-CAs (in 
vertebrates, bacteria, algae and cytoplasm of green plants), β-CAs (predominantly in 
bacteria, algae and chloroplasts), γ-CAs (in archaea and some bacteria), δ-CAs (were 
found in marine diatoms), ζ-CAs (exclusively found in bacteria in few chemolithotrophs 
and marine cyanobacteria), and, finally, η-CAs (in organisms of the genus 
Plasmodium). In plants, CA helps raise the concentration of CO2 and it is crucial in 
photosynthesis.206,210–218 In fact, CA inhibitors reserved special attention to fight 
infection caused by microorganisms such as protozoa, fungi or bacteria.209 
Two main classes of CA inhibitors are known: metal-complexing anions and 
unsubstituted SAs and their bioisosteres such as sulfamates and sulfamides compounds. 
CA inhibition by aromatic and heterocyclic SAs has been exploited clinically for half a 
century in the treatment of glaucoma, epilepsy, congestive heart failure, mountain 
sickness, gastric and duodenal ulcers and diuretic agents. From this class can be 
highlighted acetazolamide, methazolamide and ethoxzolamide. In particular 
acetazolamide is a well-known strong inhibitor of several CA isoforms and it is a 
potential modulator of anticancer therapies due of increase of hypoxia of intra-tumoral 
environment ensued after CA inhibition.207,219–223 
An interesting example of the application of SAs as antitumoral agents was 
reported in 2017 by Jung et al.224. In that work, the additive effect of a SA 
(acetazolamide) and a BODIPY PS was evaluated. The conjugate was designed to take 
advantage of the two active subunits: the acetazolamide ligand to provide both CA IX 
inhibition and efficient tumor targeting, and a BODIPY moiety to serve both a singlet 
oxygen-producing PS and to allow fluorescence-based tracking of cellular uptake and 
distribution by combining the benefits of anti-angiogenesis therapy with PDT. In the in 
vitro studies with Human breast cancer cells (MDA-MB-231 cells) it was observed an 
accumulation of the conjugate in mitochondria of cancer cells that overexpress CA IX 
and the highest singlet oxygen generation was achieved at 660 nm. In vivo studies in 
xenograft mouse models revealed notable tumor suppression. Furthermore, a parallel 
gene expression study showed a decrease of various angiogenesis factors. 
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Table 4.2: CA isoforms and sub-cellular location.207 
Isozyme Sub-cellular location Tissue location 
CA I Cytosol 
Red blood cell and GI 
tract 
CA II Cytosol Almost ubiquitous 
CA III Cytosol 
8% of soluble protein in 
Type I muscle 
CA IV Membrane-bound 
GI tract, kidney, 
endothelium 
CA V Mitochondria Liver 
CA VI Secreted to saliva Saliva and breast milk 
CA VII Cytosol Widely distributed 
CA-RP VIII Probably cytosolic nda 
CA IX Membrane-bound 
Normal GI tract, several 
cancers 
CA-RP X nda nda 
CA-RP XI Membrane-bound nda 
CA XII Membrane bound Kidney, certain cancers 
CA XIII Cytosol Widely distributed 
CA XIV Membrane-bound 
Kidney, heart, skeletal 
muscle, brain 
CA XV Membrane-bound 
Not expressed in human 
tissues 
and: not determined 
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Figure 4.4: Crystal structure of catalytic domain of human carbonic anhydrase isozyme 
XII with inhibitor.225 
4.2 Results 
In this work we studied the applicability of Pc–SA conjugates and Pc–SA 
conjugates encapsulated in PVP micelles as PSs in PDT. Firstly, photophysical and 
photochemical parameters were accessed (subsections 4.2.1, 4.2.2 and 4.2.3). Then, an 
in vitro test was performed in Doctor Jon Golding laboratory (subsections 4.2.4 and 
4.2.5). Finally, by an adaptation of Doctor Etelvina Figueiras procedure around the 
determination of CA activity an enzymatic assay was conduct (subsection 4.2.6). Herein 
will be presented the results obtained. 
4.2.1 UV-Vis absorption spectroscopic properties 
The electronic absorption of compounds 42, Zn41(PVP), Zn43, Zn44, 
Zn44(PVP), Zn45(PVP) and Zn46 was recorded at increasing concentrations (1, 3, 6, 9 
and 12 µM) in DMSO or phenol red-free Dulbecco's Modified Eagle's Medium 
(DMEM) to determine if the Pc–SA conjugates and corresponding Pc–SA conjugates 
encapsulated in PVP micelles, at this concentration range, followed the Beer-Lambert 
law. The spectra of Pcs 42, Zn43, Zn44 and Zn46 in DMSO (Figure 4.5) display B 
bands around 350-370 nm, vibronic band around 610-620 nm and Q-bands around 660-
720 nm. For Pcs Zn43, Zn44 and Zn46 the intense, single and narrow Q band is typical 
of monomeric metallated Pcs. On the other hand, the spectrum of Pc 42 shows two Q 
bands, typical of metal-free Pcs.226 The graphics obtained from the plotting of the Q 
band intensity versus Pc concentration in DMSO show a linear regression for all Pcs 
under study, indicating that no significant aggregation occurred in DMSO. 
  
92 
 
In contrast to the well-defined absorbance spectra in DMSO, the spectra of the 
Pcs in DMEM + 0.08% DMSO show a broadened Q band with much lower absorbance 
when compared with the spectra in DMSO at equivalent concentration. This suggests 
that these Pcs aggregate in DMEM + 0.08% DMSO media (data not shown), as had 
been previously observed.169 Nonetheless, the absorbance values at the studied 
concentration range (1, 3, 6, 9 and 12 µM), at fixed wavelengths, gave almost straight 
line graphs obeying the Beer-Lambert law, suggesting that a proportion of each 
compound remained as a monomer in DMEM + 0.08% DMSO, in agreement with 
Liang et al..169 
Figure 4.6 represents the spectra in DMEM of the Pc–SA conjugates 
encapsulated in PVP micelles Zn41(PVP), Zn44(PVP)–Zn46(PVP). Except for 
Zn45(PVP), the values of absorbance obtained at a fixed wavelength, at the 
concentration range under study, in the line graph obey the Beer-Lambert law, 
suggesting that in DMEM, no significant aggregation occurred. This is due to the 
presence of the long alkyl chains that hamper solubilisation in DMEM, forming a turbid 
solution (observed by naked eye). As a control, PVP UV-Vis spectrum was also 
obtained confirming, as expected, that it does not absorb in the wavelength recorded. 
4.2.2 Fluorescence spectroscopic properties 
Fluorescence spectra of all Pc–SA conjugates and Pc–SA conjugates 
encapsulated in PVP micelles under study were recorded at 15 µM in phenol red-free 
DMEM + 0.08% DMSO for Pc–SA conjugates and in water and phenol red-free 
DMEM for encapsulated compounds, at excitation wavelength of 610 nm (Figure 4.7). 
4.2.3 Singlet oxygen generation 
The ability of these PSs to generate singlet oxygen was qualitatively evaluated 
following the photo-oxidation of 1,3-diphenylisobenzofuran (DPBF) when irradiated 
with light at a fluence rate of 9 mW/cm (Table 4.3). The generation of singlet oxygen 
was recorded in three different solvents: DMF, phenol red-free DMEM + 0.08% DMSO 
and phenol red-free DMEM for the Pc–SA conjugates encapsulated in PVP micelles. 
The reactions were followed spectrophotometrically by observing the decrease of the 
absorption peak of DPBF at 415 nm as a function of irradiation time. 
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Figure 4.5: UV-Vis spectra of compounds 42, Zn43, Zn44 and Zn46 in DMSO at different concentrations. The linear regression graphics plotted 
the Q-band absorbance versus the concentrations in DMSO. 
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Figure 4.6: UV-Vis spectra of PVP and compounds Zn41(PVP), Zn44(PVP)–Zn46(PVP) in DMEM at different concentrations. The linear 
regression graphics plotted the Q-band absorbance versus the concentrations in DMEM.
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a)
 
b)
 
 
c) 
 
Figure 4.7: Fluorescence spectra in a) DMEM, b) DMEM + 0.08% DMSO, c) water of 
the Pc–SA conjugates under study (exc.: 610 nm). 
The results confirm that all compounds are good singlet oxygen generators, 
causing a decay of DPBF absorption higher than 90% after 7 minutes of irradiation 
(Table 4.3). The decay caused by Pc–SA conjugate 42 is higher than for the other Pcs. 
For phenol red-free DMEM + 0.08% DMSO and DMEM + PVP, as was already 
described by Liang et al.169 and also observed in the results obtained in the 
photodynamic inactivation of microorganisms (see chapter 5), it is possible to observe 
that there is a large enhancement on the efficiency of singlet oxygen production after 
encapsulation in of Pc–SA conjugates Zn41(PVP), Zn44(PVP)–Zn46(PVP), when 
compared with singlet oxygen generation by the Pcs in phenol red-free + 0.08% DMSO. 
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Table 4.3: Photooxidation of DPBF by singlet oxygen generated by the Pc–SA 
conjugates and Pc–SA conjugates encapsulated in PVP micelles. 
Sample PVP 42 Zn41 Zn43 Zn44 Zn45 Zn46 
DPBF decay 
(%) (after 7 
minutes of 
irradiation) 
DMF nda 99.6 94.8 98.9 99.4 99.0 93.5 
DMEM + 
0.08% 
DMSO 
nda 4.0 7.1 0.3 3.1 1.8 3.5 
DMEM + 
PVP 
4.0 nda 68.8 nd 79.9 61.1 73.7 
anot determined in the encapsulated conjugate 
4.2.4 Cellular uptake and accumulation of PSs 
Conjugates 42, Zn43, Zn44, Zn46, Zn41(PVP) and Zn44(PVP)–Zn46(PVP) 
were used as PSs in PDT of HSC3 oral squamous cell carcinoma and HaCaT ‘normal’ 
keratinocytes, as cellular models (Figures 4.8 and 4.9). The cellular uptake and 
accumulation of the PSs were assessed after 1, 2 and 4 hours on HSC3 and HaCaT cells. 
The second-generation PS Foscan was used as a positive control. Foscan was kindly 
provided from Doctor Alexandre McRobert, University College of London, London. 
Comparing the Pc–SA conjugates uptake on the two cell models, a similar 
pattern can be found. Conjugates Zn44 and Pc Zn46 are clearly the PSs with the highest 
cellular uptake, for both cell lines. 
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Figure 4.8 Cellular uptake of Pc–SA conjugates 42, Zn43, Zn44, Zn46, Zn41(PVP), 
Zn44(PVP)–Zn46(PVP) at 1, 2 and 4 hours in HaCaT cells. 
 
Figure 4.9 Cellular uptake of Pc–SA conjugates 42, Zn43, Zn44, Zn46, Zn41(PVP), 
Zn44(PVP)–Zn46(PVP) at 1, 2 and 4 hours in HSC3 cells. 
4.2.5 Cytotoxicity studies 
The effect of the Pc–SA conjugates 42, Zn43, Zn44, Zn46, Zn41(PVP), 
Zn44(PVP)–Zn46(PVP) on HSC3 and HaCaT cells viability and cell number in the 
absence of light (dark toxicity - DT) and after PDT treatment (phototoxicity - PDT) 
were investigated and compared with Foscan. In this section, cells were loaded for 2 h 
with 0, 3, 10 and 15 µM with the selected PSs.  
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4.2.5.1 Morphology 
After light exposure, microscopic observations of the cell cultures were made. 
Cell viability was quantified by microscopic observations of the cells under test and 
controls. A simple, quantitative and preliminary scale was developed in which cell 
detachment and change in morphology was taking in count. The scale consists on: no 
toxic (there are no differences in cell detachment or cell morphology when compared to 
controls), slight toxic (there are some differences on cell detachment when compared to 
controls), toxic (there are differences in cell detachment and cell morphology when 
compared to controls) and very toxic (there are unmistakable and sharp differences in 
cell detachment and cell morphology). 
Microscope observations showed that only conjugate 42 produce slight dark 
toxicity in HaCaT cells in the highest concentration (data not shown). The results of the 
PDT assays show that only the highest concentration produced toxicity on the two cell 
models. At the concentration 3 µM, none of the PSs under study produced any obvious 
dark toxicity.  
For Pc–SA conjugates Zn41(PVP), 42, Zn43, Zn44 and Zn44(PVP), light 
exposure induced toxicity at the highest concentration of PS. A slight toxicity was also 
observed at 10 μM concentration for Pcs Zn44(PVP) and Zn46(PVP). No dark toxicity 
was observed on HSC3 cells (data not shown). Under light conditions, at the highest PS 
concentrations, all Pcs under study were cytotoxic and Pcs Zn43 and Zn44 were very 
toxic. At 10 μM Pcs 42, Zn43, Zn44, Zn44(PVP)–Zn46(PVP) also caused cytotoxic 
effects. Microscope observations of both cell models in the presence of PVP under dark 
and light condition were also performed but no toxic effects were detected. 
With these results it is possible to highlight Pc–SA conjugates Zn44 and 
Zn45(PVP) as phototoxically selective for HSC3 cells. 
4.2.5.2 Cell viability 
Cell viability was quantified by MTS assay and the results were expressed as a 
percentage of the total cell population (Figures 4.10-4.12). 
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Figure 4.10: Dark toxicity and phototoxicity effect of Pc–SA conjugates 42, Zn43, 
Zn44, Zn46, Zn41(PVP), Zn44(PVP)–Zn46(PVP) and PVP, and the positive control 
Foscan on HSC3 and HaCaT cells viability at 3 µM concentration. 
 
Figure 4.11: Dark toxicity and phototoxicity effect of Pc–SA conjugates 42, Zn43, 
Zn44, Zn46, Zn41(PVP), Zn44(PVP)–Zn46(PVP) and PVP, and the positive control 
Foscan on HSC3 and HaCaT cells viability at 10 µM concentration. 
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Figure 4.12: Dark toxicity and phototoxicity effect of Pc–SA conjugates 42, Zn43, 
Zn44, Zn46, Zn41(PVP), Zn44(PVP)–Zn46(PVP) and PVP, and the positive control 
Foscan on HSC3 and HaCaT cells viability at 15 µM concentration. 
In the dark, the treatment of HSC and HaCaT cells with 3, 10 and 15 µM of the 
Pc–SA conjugates under study did not affect cell viability over a period of 2 hours 
duration, compared with no Pc control in the dark. Under white light, at 3 µM 
concentration, it is not observed for all Pc–SA conjugates under study large differences 
when compared with the dark for HaCaT cells, suggesting that there is a cytotoxic 
selectivity at this concentration for HSC3 cells. At 10 and 15 µM Zn41(PVP) was 
highlight as very cytotoxic for both cells under study. Pc–SA conjugates Zn45(PVP) 
and Zn46(PVP) also caused a decrease in cells viability.  
4.2.6 Carbonic anhydrase assay 
In the presence of encapsulated Pc–SA conjugate Zn41(PVP), a lower pH 
variation was observed when compared with standard activity control (Figure 4.13), 
meaning that it is taking place a decrease of CA activity. So, with this result is 
suggested that Zn41(PVP) is working as an inhibitor of this enzyme. On the other hand, 
the higher CA activity (indicated by the higher value of ΔpH) was observed for 
conjugate Zn45(PVP). 
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Figure 4.13: Carbonic anhydrase assay results for Pc–SA conjugates 42, Zn43, Zn44, 
Zn46, Zn41(PVP), Zn44(PVP)–Zn46(PVP) and PVP at 15 µM concentration. Results 
are shown as the ΔpH for the same red cells extract total protein quantity. 
4.3 Discussion 
PSs with SAs have been recently tested.227–229 For this work, Pc–SA conjugates 
were developed and their photophysical properties and possible applications were 
evaluated.61,62 The aim of this study was to evaluate the PDT efficiency of these 
compounds (42, Zn43, Zn44, Zn46, Zn41(PVP), Zn44(PVP)–Zn46(PVP)) using 
HSC3 oral squamous cell carcinoma and HaCaT ‘normal’ keratinocytes as cell models. 
Furthermore, we also intended to evaluate the activity of these compounds, in particular 
the SA moiety, as modulators of CA activity. 
Aggregation of Pcs in aqueous media is well-known in Pc chemistry.3 
Photosensitization efficiency of Pcs changes dramatically as a result of aggregation. 
Therefore it is important to evaluate the aggregation behaviour of the Pcs under study. 
Aggregation have been examined in DMSO, phenol red-free DMEM + 0.08% DMSO 
and phenol red-free DMEM. As expected, the best aggregation results were obtained for 
PVP-encapsulated Pc–SA conjugates in DMEM, in which an effective decrease on 
aggregation is observed. This decrease in the aggregation can be due to a 
monomerization state of the Pcs molecules increasing the solubility in aqueous medium 
(DMEM). This phenomenon have already been observed in other studies.169 
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Furthermore, an increase in singlet oxygen generation was also observed, due to the 
better homogenization of the solution. 
In the in vitro assay, using equimolar concentrations (3, 10 and 15 µM) of each 
compound and standardized illumination conditions (10 J/cm2 halogen white light), it 
was evident that Zn41(PVP) was the most cytotoxic to HSC3 oral squamous cell 
carcinoma and HaCaT ‘normal’ keratinocytes. These results are in line with the ones 
obtained for the well-known PS (positive control) Foscan, especially for the PS 
concentration of 15 µM. Furthermore, this conjugate (Zn41(PVP)) was the PS that 
showed the lowest uptake values. For the same concentration and time light exposure, 
Zn41(PVP) was the PSs that shown the highest cytotoxicity for the lowest uptake, 
resulting in the most effective PS under study. 
For the CA assay, the compounds under study were compared with a standard 
activity which was obtained by the exposure of the enzyme lysate with the subtract 
(CO2) without the presence of any compound. From this study Pc Zn41(PVP) was 
highlighted as the compound that caused lowest differences in pH and therefore the one 
with higher capability to reduce the activity of the enzyme CA.  
In addition, it was also possible to highlight PVP-encapsulated conjugate 
Zn45(PVP) as the compound that caused the higher difference in pH. Since we 
obtained for Zn45(PVP) a high variation in PVP. These results suggest that Zn45(PVP) 
as CA activator properties. 
From these results, conjugate Zn41(PVP) showed the higher cytotoxicity effect 
for the lowest uptake, probably due to the additive effect of the photodynamic effect of 
the Pc and the inactivation effect of the enzyme CA by the SA present in this 
compound. 
4.4  Conclusions 
This study highlights, for the first time, the potential of Pc–SA conjugates as PSs 
for PDT. It was also possible to evaluate the difference in aggregation, and 
consequently singlet oxygen production, of some of these compounds without PVP and 
encapsulated in PVP micelles in phenol red-free DMEM. Zn41(PVP) was the conjugate 
with the highest cytotoxicity effect for HSC3 oral squamous cell carcinoma and HaCaT 
‘normal’ keratinocytes. This result can be explained by the capacity of this compound, 
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through the SA moiety, to inactivate the enzyme CA as shown in the enzymatic assay 
conducted in this study. 
As already mentioned, this is an ongoing work in collaboration with the group of 
Doctor Jon Golding from the Health Sciences, Faculty of Science, Technology, 
Engineering & Mathematics, The Open University, Milton Keynes, and Doctor Etelvina 
Figueira from the Biology Department, University of Aveiro. The relation between PDT 
efficacy and CA inhibition is still being studied. After these final experiments, these 
results will be integrated in an article that will be submitted for publication. 
This work opens a new window for further work in the future. New SA moieties 
can be study in order to better adjust SA structure–inactivation effect in CA activity. 
Furthermore, different Pcs properties and drug delivering vehicles can be explored. 
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Chapter 5  Photodynamic inactivation of Gram-negative and 
Gram-positive bacteria with phthalocyanine–sulfonamide 
conjugates 
SAs are frequently used as antimicrobials230–232 acting by inhibition of the 
enzyme DHPS in the folic acid pathway. Antimicrobial SAs exhibit a broad spectrum of 
action, covering all organisms that have to synthetize de novo folic acid through the 
folate biosynthetic pathway.4 This biosynthetic pathway is present in plants, fungi, 
certain protists, most bacteria and, crucially, it is absent in mammals,4 which makes the 
folate pathway attractive as an antimicrobial drug target. In recent years SAs have also 
been tested as inhibitors and activators of different enzymes in different biological 
systems.90,233–247 
Considering that unsubstituted Pcs are generally not soluble in water and in most 
organic solvents, several strategies to overcome this disadvantage have been developed, 
such as the fine-tuning via the addition of suitable substituents, which can enhance the 
solubility3. As an alternative, Pcs can be encapsulated in drug delivery vehicles like 
polymeric micelles, conjugated polymer nanoparticles or inorganic nanoparticles. 
Water-soluble PVP micelles are one of these types of drug vehicles that have been 
successfully used in many studies.153–155,157–159,169,248 
Considering the potential of Pcs as PSs and SAs as antimicrobial molecules, 
with this work we intended to use Pc–SA conjugates, either in solution or encapsulated 
in PVP micelles, as PSs for photodynamic antimicrobial therapy, taking advantage of 
the additive effect of the two components of the PS molecule and of the encapsulation 
system. 
The efficiency of Pc–SA conjugates in the photodynamic inactivation of Gram-
negative (Escherichia coli) and Gram-positive (Staphylococcus aureus) bacteria was 
evaluated. Zinc Pc–SA conjugates with simpler structures (N,N-diethylsulfonamide, N-
isopropylsulfonamide, methoxylsulfonamide) caused stronger inactivation than Pcs with 
heterocyclic structures (thiazol-2-ylsulfonamide) or long chains (dodecylsulfonamide), 
in both bacteria. Furthermore, the encapsulation within PVP polymeric micelles, used as 
drug delivery vehicles, enhanced the inactivation efficiency. As already discussed, the 
results show that encapsulated Pc–SA conjugates are a promising class of PSs to be 
used in photodynamic antimicrobial therapy. 
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The compounds used in this work are described in Scheme 5.1. The synthesis of 
these compounds and encapsulation in PVP micelles are described in chapter 3. 
 
Scheme 5.1: Photosensitizer used in this study 
5.1 Introduction 
PDI has been studied during the last decade as an approach for the inactivation 
of pathogenic microorganisms, in order to circumvent the problem of drug resistance.18 
The first observation of photo-toxicity against microorganisms was in 1900 
when Oskar Raab observed that the toxicity of acridine hydrochloride against 
Paramecium caudatum was dependent on the amount of light.176 In addition, his teacher 
Hv Tappeiner also reported that the toxic effects in the presence of light are not due to 
heat, and after further experiments, light was excluded as the main influence factor.46 
Additional investigations demonstrated that oxygen is the crucial molecule in the 
inactivation of bacteria because the antibacterial activity of fluorescent dyes against the 
facultative anaerobic species Proteus vulgaris could not be demonstrated in the absence 
of oxygen.249 
Since the discovery of antibiotics, in the middle of the last century, antimicrobial 
photodynamic therapy was put aside. However, after the worldwide rise in antibiotic 
resistance, PDI re-emerged as alternative to these drugs. 
In order to follow the process of photodynamic inactivation of bacterial 
pathogens, different methods were developed. The more conventional methods 
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frequently involve in vivo animal sacrifice, removal of the infected tissue, 
homogenization, serial dilution, plating and colony counting. In vitro, the studied 
organism is cultured in liquid media, after irradiation an aliquot is planted in solid 
media, and the colonies are counted. Colony-counting method is still commonly used 
nowadays. Bioluminescence-based methods have emerged has reliable, fast, sensitive, 
and effective options. These methods only allow the detection of active or viable cells 
and do not need administration of substrates to obtain light emission.250,251 
Bioluminescence consists on the process of visible light emission by living 
organisms through the intervention of an enzyme catalyst. With this method, an indirect 
assessment of cell viability is made by the measurement of the intensity of 
bioluminescence. This method is usually used to monitor PDI.250–255 
The resistance of Gram-negative bacteria to photosensitization by macrocyclic 
dyes as Pors or Pcs is still an important challenge to antibacterial PDI. In 1880, 
Christian Gram classified bacteria as Gram-positive or Gram-negative, due to their 
different staining on Gram staining. The difference in staining is due to structural 
differences on bacteria outer cell membrane of the wall (Figure 5.1a). Gram-positive 
bacterial cell is thicker (15-80 nm) than the Gram-negative ones. The first one contains 
up to 100 peptidoglycan layers and a small quantity of lipids or proteins. Gram-positive 
bacteria wall presents a rather high degree of porosity. This way, several 
macromolecules from 30 to 57 kDa can easily diffuse to the inner plasma membrane. 
On the other hand, Gram-negative bacteria (Figure 5.1b) wall has an additional layer, 
the outer membrane, external to the peptidoglycan layer, presenting an asymmetric lipid 
structure composed by strongly negative charged lipopolysaccharides, phospholipids, 
lipoproteins and proteins. In this type of bacterial cell, only relatively hydrophilic 
compounds with molecular weight lower than 600-700 Da can diffuse through the porin 
channels. Thus, Gram-negative outer membrane is a very effective permeability barrier 
that confers resistance against host cellular and humoral defence factors.76,256 Cationic 
PSs have provided promising results by establishing electrostatic interactions with 
negatively charged sites of the outer membrane. Some compounds, such as 
ethylenediaminetetraacetic acid (EDTA) or polymixin B nanopeptide have been used to 
enhance the activity of neutral or anionic PSs by altering and disorganizing the outer 
membrane and enhancing the penetration of PSs to inner cell compartments. The 
attachment of poly-L-lysine chains to the PS has also been tested, since this 
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oligopeptide is positively charged at physiological pH and dramatically increases the 
ability of photodynamic inactivation of Gram-negative bacteria.257–259 
 
a) Gram-positive 
 
b) Gram-negative 
Figure 5.1: Schematic representation of bacteria cell wall(adapted from Black et al.260). 
5.1.1 Applications of microbial photodynamic inactivation 
In 2009, Alves et al.261 reported the effect of PS charges on the efficiency of PDI 
of Gram-negative and Gram-positive bacteria with cationic meso-substituted Pors. In 
this study, the Gram-positive model Enterococcus faecalis and the Gram-negative 
model Escherichia coli were used. The number of positive charges and charge 
distribution in Pors' structure seems to have an important influence on the PDI 
efficiency of both bacterial models. In that study, Alves and co-workers were also able 
to identify the cationic Por Tri-Py+-Me-PF as the most efficient PS. In 2010,262 the same 
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group used the cationic Por Tri-Py+-Me-PF against Vibrio fisheri and recombinant 
bioluminescent strain of Escherichia coli. With this study, Tavares and coworkers 
showed that the PS Tri-Py+-Me-PF can be a promising option for efficiently destroying 
Gram-negative bacteria. 
Tri-Py+-Me-PF was also used against non-enveloped virus (bacteriophages) with 
promising results.263 Using cationic ZnPcs, Soncin et al.264 achieved inactivation of both 
wild-type and methicillin-resistant Staphylococcus aureus strains. These PSs, in 0.1 µM 
concentration, showed to be efficient photoantimicrobial agents by causing a 4-5 log 
decrease in bacterial viability upon short irradiation times. Furthermore, by carefully 
adjusting experimental parameters to low Pc concentrations and low light doses, Soncin 
and co-workers were able to conclude that it is possible to inactivate these pathogens 
without damaging host tissues, taking human fibrosarcoma cells and keratinocytes as 
host models for skin and mucosa. 
As already mentioned, Pcs can be substituted in order to fine-tune their 
properties. Concerning PDT and PDI, Pcs must be properly substituted with specific 
molecules with affinity to cell targets. SAs will be described in the next section as 
possible substituents of Pcs. 
5.1.2 Sulfonamides as DHPS inhibitors 
A SA moiety can be found in several groups of drugs. Still, the primary clinical 
application of these compounds is as antimicrobial agents. 
Every single cell, whether prokaryotic or eukaryotic, requires reduced folate 
cofactor for the biosynthesis of a diverse range of cellular components. Tetrahydrofolate 
is an important carbon donor in a variety of biosynthetic processes through the 
formation of methionene, purines and thymine. Furthermore, tetrahydrofolate can be 
used as cofactor in many reactions, especially in the metabolism of amino acids and 
nucleic acids, and in degradative reactions as acceptor of one carbon unit. In spite of 
being a universal requirement, the way cells obtain folate differs between prokaryotes 
and eukaryotes. Unlike plants and most microorganisms, in which folate must be 
synthesized through the folate biosynthesis pathway, mammals possess an active 
transport system making them resistant to any compound that disrupts the folate 
pathway. This difference between mammals and microorganisms in obtaining folate is 
very important in the design of antimicrobial drug targets.4 
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Folate biosynthetic pathway (Scheme 5.2) consists of the transformation of 
guanosine triphosphate (GTP) in 7,8-dihydrofolate in six enzyme-catalyzed steps. In the 
first step, GTP is converted in 7,8-dihydroneopterin triphosphate by the enzyme GTP 
cyclohydrolase I, which forms the pterin. Next, there is a cascade of kinase, aldolase 
and pytophosphokinase step adding by the production of an activated 
pyrophosphorylated intermediate (6-pyrophosphomethyl-7,8-dihydropterin – DHPPP). 
In the fifth step, DHPS catalyzes the formation of a C-N bond (7,8-dihydropteroate) by 
joining the pterin ring moiety to pABA. Finally, with addition of a L-glutamate moiety 
to 7,8-dihydropteroate, the synthesis of 7,8-dihydrofolate is completed, which will after 
be transformed in tetrahydrofolate by the enzyme dihydrofolate reductase (DHFR).4 
SAs with antimicrobial effect were the first drugs which could be used 
systematically to selectively act on bacteria. They act as structural analogues of pABA 
and appear to be competitive inhibitors of the enzyme DHPS. It has been shown that 
SAs can act as alternative substrate for DHPS effectively depleting the folate pool and 
in that way, inhibit cell growth. Therefore, SAs act as bacteriostatic agents, inhibiting 
the growth and multiplication of bacteria. Furthermore, the final enzyme of the 
pathway, DHFR, can be inhibited by diaminopyrimidine antibiotics. In some cases, 
clinical treatment uses a combination of both SA and diaminopyrimidine antibiotics. To 
give an example, a combination of SA and trimethoprim (a diaminopyrimidine) was 
used to treat urinary tract infections.4 This combination overcame the problem of target 
organism resistance, although nowadays some resistance to this combined therapy has 
also been observed.265 
DHPS crystalline structure has been solved from E. coli, S. aureus, and M. 
tuberculosis, and adopts a classic TIM2 barrel fold, consisting of an eight-stranded 
central parallel β-sheet, bounded by α-helices (Figure 5.2). DHPS structure is a ternary 
complex, in which analogues of pterin substrate, like SA or sulfanilamide, can bind in 
the active site. The active site is located at the C-terminal end of the central β-sheet.4 
The binding site of DHPP is well identified by ligand soaking and co-
crystallization studies. In his pocket, DHPP is rotated in a way that its ring system sits 
parallel with the axis plane of the eight-stranded beta-sheet binding with hydrophilic 
residues (Asp66, Asn115, Asp185 and Lys221, E. coli sequence numbering). On the 
other hand, structural information on the second substrate, pABA, is more limited. It is 
known that E. coli DHPS will use SAs and sulfanilamide as substrates, forming 
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dihydropterinsulfonamide products.4 The crystal structure of ternary complex of these 
bindings was reported by Achari et al..266 
The folate pathway is a validated target for antibacterial drugs. Recent structural 
information obtained specially for DHPP binding site has been important to correlate 
structural binding sites modifications with resistance to SAs. SA resistance mutation, in 
the dhps gene from several pathogenic organisms, has been mapped as alteration on the 
residues surrounding the binding sites of both substrates. In different organisms, the 
mutation is concentrated in Loop2, which appears to play a role in recognition of the 
pyrophosphate moiety in 6-hydroxymethyl-7,8-dihydropterin pyrophosphate (DHPPP). 
Furthermore, in bacteria like E. coli and N. meningitidis resistance mutation have been 
observed of a single Phe to Leu or Ile in Loop1. This alteration will not directly alter 
substrates binding but will indirectly influence the way substrate binds through 
interactions with residues in Loop2. Furthermore, alterations in positions within the 
Loops 4, 5 and 6 have also been associated with resistance mutations.4 
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Scheme 5.2: Folic acid pathway.4 
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The SA chemical moiety is also present in other drugs that do not have 
antimicrobial activity. That is the case of thiazide diuretics, loop diuretics, 
sulfonylureas, COX-2 inhibitors, antitumoral, anti-inflammatory, among others.4 
 
Figure 5.2: DHPS crystal structure.4 
5.2 Results 
In this work, the applicability of Pc–SA conjugates as PSs in the PDI of E. coli 
(subsection 5.2.4) and S. aureus (subsection 5.2.5) were evaluated under white and red 
light. For that, subsection 5.2.3 describes the correlation between bioluminescence and 
viable counts for the bioluminescent E. coli strain. In addition, the solubility (subsection 
5.2.1), photostability and singlet oxygen generation (subsection 5.2.2) of the conjugates 
under studied were assessed. 
5.2.1 Phthalocyanine solubility 
The solubility of selected Pc–SA conjugates and the corresponding encapsulated 
in PVP conjugates in DMSO and phosphate-buffered saline (PBS) + 10% DMSO in the 
case of Pcs and PBS for Pcs(PVP), was analyzed by UV-Vis spectroscopy. The 
measurements were made in concentrations between 2.5 and 25 µmol/L in order to 
determine if the Pcs, at this concentration range, follow the Beer-Lambert law. The 
graphics were obtained by the plotting of the Q-band intensity versus Pc concentration 
in DMSO. A linear relation was observed for all zinc and metal-free Pcs under study, 
confirming a low aggregation of these compounds in organic solvents. In PBS + 10% 
DMSO the relation was not linear. 
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A similar approach was used to test the solubility of Pc–SA conjugates 
encapsulated within PVP in PBS. A linear relation was observed for all encapsulated 
conjugates (Figure 5.3). 
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Figure 5.3: UV-Vis spectra of Pc–SA conjugates 41(PVP), 42(PVP), 44(PVP) and Zn41(PVP)–Zn46(PVP) in PBS at different concentrations. 
The linear regression graphics plotted the Q-band absorbance versus the concentrations in PBS.
  
116 
 
5.2.2 Photostability and singlet oxygen generation 
The results of the photostability studies conducted during 30 min with a fluence 
rate of 150 mW/cm2 indicated that, in aqueous media and under white and red light, 
none of the Pcs suffered pronounced changes in the residual absorbance (Table 5.1), and 
were photostable under the conditions of the experiments. 
Table 5.1: Photostability and stability by Pc–SA conjugates and encapsulated Pc–SA 
conjugates under study. L – Light, D – Dark. 
 Photostability and stability (%) 
Compound 
White Red 
Compound 
White Red 
L D L D L D L D 
41 71 71 98 98 41(PVP) 98 98 98 98 
42 64 65 97 97 42(PVP) 95 95 96 96 
44 58 58 99 99 44(PVP) 89 89 89 88 
Zn41 58 58 96 96 Zn41(PVP) 94 96 98 95 
Zn42 74 74 66 61 Zn42(PVP) 99 99 99 99 
Zn43 40 45 96 96 Zn43(PVP) 87 88 90 95 
Zn44 75 75 99 99 Zn44(PVP) 96 96 84 84 
Zn45 68 69 89 90 Zn45(PVP) 65 65 78 78 
Zn46 74 74 95 95 Zn46(PVP) 97 97 95 97 
 
The results of the evaluation of the singlet oxygen generation by each PS, 
measured as the photo-oxidation of DPBF when irradiated with light at a fluence rate of 
9.0 mW/cm2, showed that they were able to generate singlet oxygen but in different 
ranges (Table 5.2). All Pcs in DMF showed a high generation of singlet oxygen. 
However, in the aqueous medium PBS + 10% DMSO there was a strong decrease of 
singlet oxygen generation for all Pcs under study. All encapsulated Pc–SA conjugates in 
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PBS showed a high generation of singlet oxygen and PVP-free samples a low 
generation of singlet oxygen. 
Table 5.2: Relative photo-oxidation of DPBF by singlet oxygen generated by Pc–SA 
conjugates and encapsulated Pc–SA conjugates. 
Compound 
DPBF decay (%)b 
DMF PBS + 10% DMSO PBS + PVP 
PVP nda nda nda 
41 92.7 0.9 68.1 
42 95.9 3.5 73.7 
44 92.3 4.1 58.6 
Zn41 94.8 5.3 78.9 
Zn42 99.6 1.0 80.1 
Zn43 98.9 4.9 84.9 
Zn44 99.4 4.7 77.5 
Zn45 99.0 5.2 91.0 
Zn46 93.5 6.2 70.5 
anot determined, bafter 7 minutes of irradiation. 
5.2.3 Relation between bioluminescence and concentration of 
viable cells 
A significant linear correlation between bioluminescence and viable counts for 
the bioluminescent E. coli strain was observed (R2 = 0.9526) (Figure 5.4). 
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Figure 5.4: Linear correlation between the bioluminescence signal and colony counts of 
overnight cultures of recombinant bioluminescent E. coli serially diluted in PBS. 
Bacterial counts are expressed in colony forming units (CFU)/ml and bioluminescence 
in relative light units (RLU). 
5.2.4 Photodynamic inactivation of E. coli 
The results of the photodynamic inactivation experiments showed that the 
viability of the recombinant bioluminescent E. coli was neither affected by light alone 
(light control) nor by the direct effect of the tested PSs (dark controls).  
Significant differences in the inactivation profiles obtained with the different PS 
were observed (Figures 5.5–5.8). 
Upon irradiation with white light in presence of 10 µM of PS (Figure 5.5), 42 
and 44 and Zn41, Zn42, Zn44 and Zn46 caused stronger inactivation (3.9, 4.0, 3.7, 3.0, 
3.0 and 3.7 logs of reduction in bioluminescence emission, respectively) than 41 and 
Zn43 and Zn45 (1.5, 0.9 and 0.2 logs reduction in bioluminescence emission, 
respectively), after 180 min of irradiation. The differences between the controls and the 
test result are significant (p < 0.05) for all Pcs (41, 44, Zn41–Zn45 and Zn46). 
Under red light (Figure 5.6), similar inactivation profiles were obtained with 42 
and 44, and Zn41, Zn42, Zn43 and Zn46, that caused stronger inactivation (2.9, 2.8, 
3.4, 3.7, 2.6 and 4.1 logs of reduction in bioluminescence emission, respectively) than 
41 and Zn43 and Zn45 (1.8, 0.7 and 0.3 logs reduction in bioluminescence emission, 
respectively). 
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a) ZnPcs 
 
b) 2HPcs 
Figure 5.5: Photodynamic inactivation of bioluminescent E. coli in the presence of 10 
µM of a) ZnPcs and b) 2HPcs under white light (150 mW/cm2) for 0, 15, 30, 60, 90, 120 
and 180 min. Each value represents the average of three measurements in a single assay. 
LC – Light control; DC – Dark control; T – Test. Error bars indicate the standard 
deviation. Lines just combine the points. Small bars are overlapped by the symbols. 
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a) ZnPcs 
 
b) 2HPcs 
Figure 5.6: Photodynamic inactivation of bioluminescent E. coli in the presence of 10 
µM of a) ZnPcs and b) 2HPcs under red light (150 mW/cm2) for 0, 15, 30, 60, 90, 120 
and 180 min. Each value represents the average of three measurements in a single assay. 
LC – Light control; DC – Dark control; T – Test. Error bars indicate the standard 
deviation. Lines just combine the points. Small bars are overlapped by the symbols. 
In the case of 42 and 44, Zn42, Zn43 and Zn44 the differences between controls 
and test are significantly different (p < 0.05). 
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Similarly to what was observed in the concentrations of 10 µM, at 20 µM 
concentration, the viability of bioluminescent E. coli was not affected by the PS, in the 
dark. Table 5.3 contains a summary of the logarithmic reduction of this Gram-negative 
bacteria with 20 µM of each PS. Furthermore, 42 and Zn41, Zn42, Zn44 and Zn46 
were effective against E. coli (Figure 5.7) causing 2.4, 3.0, 3.9, 2.9, 3.2 logs reductions, 
respectively, after 180 min of exposure to white light. Pcs 41 and 44, Zn43 and Zn45 
caused a less pronounced effect (0.0, 0.6, 0.5 and 1.1 logs reduction in bioluminescence 
emission, respectively). For 42, 44 and Zn42–Zn44 significant differences between 
controls and test (p < 0.05) were observed.  
Table 5.3: Systematization of the results obtained in the photoinactivation of E. coli 
under white and red light at 20 µM. 
Reduction 
(log) 
PVP 41 42 44 Zn41 Zn42 Zn43 Zn44 Zn45 Zn46 
White nda 0.0 2.4 0.6 3.0 3.9 0.5 2.9 1.1 3.2 
White 
Pc(PVP)b 
0.1 1.0 0.3 0.6 3.1 4.4 1.1 4.2 2.1 3.6 
Red nda -0.2 2.2 0.7 4.5 4.0 1.0 3.8 2.2 3.5 
Red 
Pc(PVP)b 
-0.5 -0.5 0.4 -0.5 1.9 4.4 -0.4 3.9 0.9 2.0 
anot determined; bPc(PVP) refers to the encapsulated Pc indicated in the first row of this 
table. 
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a) ZnPcs 
 
b) 2HPcs 
Figure 5.7: Photodynamic inactivation of bioluminescent E. coli in the presence of 20 
µM of a) ZnPcs and b) 2HPcs under white light (150 mW/cm2) for 0, 15, 30, 60, 90, 120 
and 180 min. Each value represents the average of three independent assays. LC – Light 
control; DC – Dark control; T – Test. Error bars indicate the standard deviation. Lines 
just combine the points. Small bars are overlapped by the symbols. 
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In the assays with red light (Figure 5.8), 42, Zn41, Zn42, Zn44, Zn45 and Zn46 
caused 2.2, 4.5, 4.0, 4, 3.8, 2.2 and 3.5 log reductions, respectively. 44 and Zn43 caused 
log reductions of 0.7 and 1.0 respectively. Conjugate 41 failed to cause significant 
inactivation. For 42, 44, Zn43 and Zn45 there were significant differences for a p value 
< 0.05. 
The results of the assays conducted with the encapsulated Pc–SA conjugates 
under white light at a 20 µM concentration of PS (Figure 5.9) showed that Zn41(PVP), 
Zn42(PVP), Zn44(PVP) and Zn46(PVP) were the most effective (log reductions of 
3.1, 4.4, 4.2 and 3.6, respectively), while 41(PVP), 42(PVP), 44(PVP), Zn42(PVP) 
and Zn45(PVP) were less effective (1.0, 0.3, 0.6, 1.1 and 2.1 log reductions, 
respectively). Differences between controls and tests were significant for 44(PVP) and 
Zn41(PVP)–Zn46(PVP), considering a p value < 0.05. 
Upon irradiation with red light (Figure 5.10), Zn41(PVP), Zn42(PVP), 
Zn44(PVP) and Zn46(PVP) caused log reductions of 1.9, 4.4, 3.9, 2.0, respectively and 
Zn45(PVP) was less effective with 0.9 log reductions. Pc–SA conjugates 41(PVP), 
44(PVP) and Zn43(PVP) failed to inactivate. For 42(PVP), 44(PVP), and for all 
encapsulated conjugates significant differences between controls and tests were 
observed (p < 0.05). 
PVP (Pc unloaded control) caused a negligible effect either with white or red 
light. 
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a) ZnPcs 
 
b) 2HPcs 
Figure 5.8: Photodynamic inactivation of bioluminescent E. coli in the presence of 20 
µM of a) ZnPcs and b) 2HPcs under red light (150 mW/cm2) for 0, 15, 30, 60, 90, 120 
and 180 min. Each value represents the average of three independent assays. LC – Light 
control; DC – Dark control; T – Test. Error bars indicate the standard deviation. Lines 
just combine the points. Small bars are overlapped by the symbols. 
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a) ZnPcs(PVP) 
 
b) 2HPcs(PVP) 
Figure 5.9: Photodynamic inactivation of bioluminescent E. coli in the presence of 20 
µM of a) ZnPcs(PVP) and b) 2HPcs(PVP) under white light (150 mW/cm2) for 0, 15, 
30, 60, 90, 120 and 180 min. Each value represents the average of three independent 
assays. LC – Light control; DC – Dark control; T –Test. Error bars indicate the standard 
deviation. Lines just combine the points. Small bars are overlapped by the symbols. 
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a) ZnPcs(PVP) 
 
b) 2HPcs(PVP) 
Figure 5.10: Photodynamic inactivation of bioluminescent E. coli in the presence of 20 
µM of a) ZnPcs(PVP) and b) 2HPcs(PVP) under red light (150 mW/cm2) for 0, 15, 30, 
60, 90, 120 and 180 min. Each value represents the average of three independent assays. 
LC – Light control; DC – Dark control; T – Test. Error bars indicate the standard 
deviation. Lines just combine the points. Small bars are overlapped by the symbols. 
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5.2.5 Photodynamic inactivation of S. aureus 
Inactivation of S. aureus was evaluated upon irradiation with white and red light 
(150 mW/cm2) for 0, 10, 20 and 30 min, at a concentration of PS of 20 µM, using 
colony counts as an estimate of cell survival. Similarly to what was observed in the 
inactivation of bioluminescent E. coli, the viability of S. aureus was not affected by 
light alone (light control) nor by the direct effect of the tested PS (dark controls). Such 
as observed in the assays with E. coli, clear differences in the inactivation efficiency of 
the different PS were observed. The log reductions obtained in the photodynamic 
inactivation assays with S. aureus are summarized in Table 5.4. 
Table 5.4: Systematization of the results obtained in the photoinactivation of S. aureus 
under white and red light. 
Reduction 
(log) 
PVP 41 42 44 Zn41 Zn42 Zn43 Zn44 Zn45 Zn46 
White nda 4.1 2.9 2.6 7.0 7.9 2.0 6.3 4.1 6.8 
White 
Pc(PVP)b 
0.5 0.5 0.4 3.0 9.5 9.5 3.2 5.9 5.6 7.9 
Red nda 4.0 3.0 3.3 7.0 7.5 1.0 6.8 3.8 5.1 
Red 
Pc(PVP)b 
0.3 5.3 3.0 4.3 9.4 9.0 3.8 7.9 4.3 7.1 
anot determined; bPc(PVP) refers to the encapsulated Pc indicated in the first row of 
this table. 
Under white light (Figure 5.11), Zn41, Zn42, Zn44 and Zn46 caused 
significantly higher inactivation (7.0, 7.9, 6.3 and 6.8 log reductions, respectively) than 
41, 42, 44, Zn43 and Zn45 (4.1, 1.9, 2.6, 2.0 and 3.8 log reductions, respectively). The 
differences between controls and test groups are significant for 42, 44 and Zn41–Zn45. 
Upon irradiation with red light (Figure 5.12), Zn41, Zn42, Zn44 and Zn46 were 
more effective (7.0, 7.5, 6.8 and 5.1 log reductions, respectively) than 41, 42, 14, Zn13 
and Zn45 (4.0, 3.0, 3.3, 1.0 and 3.8, respectively). There are significant differences for 
41, Zn44 and Zn46, considering a p value < 0.05, comparing to the controls. 
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a) ZnPcs 
 
b) 2HPcs 
Figure 5.11: Photodynamic inactivation of S. aureus in the presence of 20 µM of a) 
ZnPcs and b) 2HPcs under white light (150 mW/cm2) for 0, 10, 20, 30 min. Each value 
represents the average of three independent assays. LC – Light control; DC – Dark 
control; T – Test. Error bars indicate the standard deviation. Lines just combine the 
points. Small bars are overlapped by the symbols. 
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a) ZnPcs 
 
b) 2HPcs 
Figure 5.12: Photodynamic inactivation of S. aureus in the presence of 20 µM of a) 
ZnPcs and b) 2HPcs under red light (150 mW/cm2) for 0, 10, 20, 30 min. Each value 
represents the average of three independent assays. LC – Light control; DC – Dark 
control; T – Test. Error bars indicate the standard deviation. Lines just combine the 
points. Small bars are overlapped by the symbols. 
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efficiency than the former, reducing the concentration of viable cells by 0.5, 0.4, 3.0, 3.2 
and 5.6 log, respectively. Zn41(PVP) showed significant differences between controls 
and test group considering a p value < 0.05. 
 
a) ZnPcs(PVP) 
 
b) 2HPcs(PVP) 
Figure 5.13: Photodynamic inactivation of S. aureus in the presence of 20 µM of a) 
ZnPcs(PVP) and b) 2HPcs(PVP) under white light (150 mW/cm2) for 0, 10, 20, 30 min. 
Each value represents the average of three independent assays. LC – Light control; DC 
– Dark control; T – Test. Error bars indicate the standard deviation. Lines just combine 
the points. Small bars are overlapped by the symbols. 
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Upon irradiation with red light (Figure 5.14), Zn41(PVP), Zn42(PVP), 
Zn44(PVP) were also the most effective causing significant inactivation of S. aureus 
(9.4, 9.0, 7.9 and 7.1 log reductions, respectively). Pc–SA conjugates 41(PVP), 
42(PVP), 44(PVP), Zn43(PVP) and Zn45(PVP) caused log reduction of 5.3, 3.0, 4.3, 
4.3, 3.8 and 4.3, respectively. Significant differences between controls and test group 
were observed for 41(PVP) and 44(PVP), and for all Zn encapsulated Pc–SA 
conjugates. 
PVP (Pc unloaded control), similarly to what was obtained for E. coli, caused a 
negligible effect under either white or red light. 
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a) ZnPcs(PVP) 
 
b) 2HPcs(PVP) 
Figure 5.14: Photodynamic inactivation of S. aureus in the presence of 20 µM of a) 
ZnPcs(PVP) and b) 2HPcs(PVP) under red light (150 mW/cm2) for 0, 10, 20, 30 min. 
Each value represents the average of three independent assays. LC – Light control; DC 
– Dark control; T – Test. Error bars indicate the standard deviation. Lines just combine 
the points. Small bars are overlapped by the symbols. 
1.00E-01 
1.00E+00 
1.00E+01 
1.00E+02 
1.00E+03 
1.00E+04 
1.00E+05 
1.00E+06 
1.00E+07 
1.00E+08 
1.00E+09 
1.00E+10 
0 10 20 30
Lo
g	
CF
U/
m
l
Irradiation	time	(min.)
LC
DC	PVP
DC	Zn41(PVP)
DC	Zn42(PVP)
DC	Zn43(PVP)
DC	Zn44(PVP)
DC	Zn45(PVP)
DC	Zn46(PVP)
T	PVP
T	Zn41(PVP) 
T	Zn42(PVP) 
T	Zn43(PVP) 
T	Zn44(PVP) 
T	Zn45(PVP) 
T	Zn46(PVP) 
1.00E+00 
1.00E+01 
1.00E+02 
1.00E+03 
1.00E+04 
1.00E+05 
1.00E+06 
1.00E+07 
1.00E+08 
1.00E+09 
1.00E+10 
1.00E+11 
0 10 20 30
Lo
g	
CF
U/
m
l
Irradiation	time	(min.)
LC
DC	PVP
DC	41(PVP) 
DC	42(PVP) 
DC	44(PVP) 
T	PVP
T	41(PVP) 
T	42(PVP) 
T	44(PVP) 
  
133 
 
5.3 Discussion 
Pcs have emerged as reliable compounds to be used as PS for the inactivation of 
pathogenic microorganisms in the clinical context due to their interesting photophysical 
properties, namely the absorbance of light in the red region of the electromagnetic 
spectrum, the photostability and high singlet oxygen generation yield. This justifies the 
effort to study new possible modulations of the Pc core with specific groups, like SAs, 
in order to further enhance their performance for photodynamic antimicrobial 
therapeutic applications.  
In this work, Pc-SA conjugates were tested as PSs in the photodynamic 
inactivation of E. coli and S. aureus. In addition, differences in the photosensitization 
efficiency related with the encapsulation in a drug delivery vehicle (PVP) were also 
assessed. 
The compounds exhibited four or eight peripheral substituents units which 
makes them different in structure and in physico-chemical properties, namely their 
solubility in different media. The stability, photostability and the singlet oxygen 
generation for each conjugate was evaluated. 
In the literature it is possible to find several examples of modulation of Pcs such 
as by sulfonation,267–269 conjugation with chondroitin sulfate,270 with cationic 
groups,148,271,272 glycosylation,273,274 or conjugation with peptides.275,276 
The encapsulation of the synthesized Pcs in the drug delivery vehicle -PVP-, 
intended to improve the solubility of the Pcs in aqueous media, was a successful 
strategy since, in addition to an improvement, differences in singlet oxygen generation 
was observed: the DPBF decay increased from 0.9-6.2% in free-PVP compounds to 
58.6-91.0% with Pc(PVP). These results are due to the accommodation of the Pcs 
within polymer micelles in the monomeric state, confirming that the encapsulation in 
PVP strongly improves the solubility of these Pcs in aqueous media. This effect had 
already been observed by Liang et al.169 that reported the preparation of a 
multifunctional delivery vehicle, which involved a PS - ZnPc - and a targeting agent 
(folic acid) encapsulated within PVP micelles and which were used as PSs in in vitro 
and in vivo studies. In addition, the interaction of PVP with derivatives of chlorin e6 
bearing one α-amino acids or 6-aminohexanoic acid as substituent was also 
demonstrated, confirming PVP an interesting useful drug carrier to be used in PDT and 
consequently in PDI.153 
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Furthermore, as observed in the singlet oxygen generation studies, this 
monomerization largely enhanced singlet oxygen production, as was already described 
by Lian and Coll.169 This feature highlights the improvement that PVP encapsulation 
brings to the photosensitization process, in particular with Pcs with low solubility in 
aqueous media are used. Singlet oxygen generation by Pc(PVP) in aqueous medium was 
interestingly high, with percentages of DPBF oxidation similar to the ones obtained for 
the Pcs in DMF. 
In addition, the procedure for the encapsulation is simple enough to be done 
overnight making this method more practical and less expensive than others, such as 
silica or gold nanoparticles. On the other hand, the differences between the values of 
oxygen generation of the Pcs and the encapsulated compounds can be somewhat 
underestimated because of the presence of DMSO, a well-known quencher, in the 
measurements without PVP.277 
After assessing the photophysical properties of the new Pc–SA conjugates, in 
vitro assays were performed in order to appraise their potential as PSs for the 
inactivation of E. coli and S. aureus. In an overall analysis, none of the compounds 
showed significant toxicity in the absence of light, as inferred from low log reduction in 
the dark controls. According to the photosensitization efficiency, two groups of Pc–SA 
conjugates were defined: Pcs Zn41, Zn42, Zn44 and Zn46 showed high potential to be 
used as antimicrobial PS under white and red light in both bacteria under study 
(inactivation factor > 2.0 for E. coli and 5.0 for S. aureus) whereas 41, 42, Zn43, 44 and 
Zn45 caused very small or insignificant inactivation of either bacteria. 
Pcs Zn41, Zn42, Zn44 and Zn46 are zinc Pcs, a group that is very well 
documented in the literature as particularly suitable for photodynamic inactivation 
applications due to the presence of the zinc atom enhancing the generation of singlet 
oxygen.2,40 On the other hand, simpler structures with smaller chains and less variety of 
atoms seemed to show greater photosensitization capacity. Pcs 41, 42 and 44 are metal-
free Pcs known to cause milder photosensitization effects. In fact, when coordinated 
with diamagnetic ions like Zn and Al, Pcs have higher singlet oxygen generation than 
with paramagnetic ions. In association with the fact that aggregation follows the order 
Cu > H > Fe > VO > Zn > Co > Al, in which AlPcs were found to be almost in a 
monomeric form,40 Pcs coordinated with Zn and Al are firstly consider to be evaluated 
as PSs. 
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Pcs Zn43 and Zn45 have “atypical” SAs. In particular, Zn45 has a large alkyl 
group that reduces water solubility, which can influence the photodynamic process in 
physiological conditions. For this PS in particular, a lipoic drug delivery vehicle could 
have been more adequate.278 
After one preliminary assay at 10 µM in, three independent assays, a 20 µM 
assay of each PS, corresponding to the concentration used in previous works,148,279 were 
conducted. 
The group of the best-performing Pc–SA conjugates showed a similar effect on 
both bacterial models. E. coli is a Gram-negative, hence less susceptible to 
photosensitization than Gram-positive bacteria in general. This limitation is usually 
overcome by using cationic PS that more easily interact with the negatively charged cell 
wall.279 Yet, in this work it was possible to achieve viability reductions of 2-4 logs with 
the neutral Pcs Zn41, Zn42, Zn44 and Zn46 and the corresponding encapsulated Pc–
SA conjugates, under white or red light, with the exception of Zn41(PVP) that was only 
effective with white light. Although complete inactivation was not attained, some of 
these molecules (42, Zn41, Zn42, Zn46, Zn41(PVP), Zn42(PVP), Zn44(PVP) and 
Zn46(PVP)) already cause a reduction of > 3 log in the concentration of viable cells, 
thus meeting the ASM minimum requirement for a new antimicrobial approach.280 
These are the promising Pcs that could be used as the base for subsequent synthetic 
modifications in order to improve photosensitization of Gram-negative bacteria. 
Moreover, comparing the PDI efficiency obtained under the two light conditions, there 
is no evidence that photodynamic inactivation efficiency was improved under red light. 
In fact, under red light, the photodynamic inactivation of bioluminescent E. coli in the 
presence of 20 µM 41(PVP), 44(PVP) and Zn43(PVP) was insignificant. 
When tested against S. aureus, Pcs Zn41, Zn42, Zn44 and Zn46 and 
encapsulated Pc–SA conjugates Zn41(PVP), Zn42(PVP), Zn44(PVP) and Zn46(PVP) 
were also the most effective, in parallel with the results of the PDI tests with E. coli. As 
expected, being a Gram-positive, S. aureus was more susceptible to photosensitization 
than the bioluminescent E. coli and inactivation factors of 6-9 logs were obtained. These 
results point out Pc–SA conjugates as compounds with high potentiality to be used as 
PSs of Gram-positive bacteria, which are in line with the results obtained with other Pc 
bearing other moieties in the photodynamic inactivation of S. aureus, and other Gram-
positive bacteria at equivalent PS concentrations.281–285 
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Looking closely at the PSs structures under study, a variety of SA moieties, from 
less complex SAs like N,N-diethylsulfonamide (compounds 41, Zn41 and Zn46) or N-
isopropylsulfonamide (42 and Zn42) to more complex structures like 
dodecylsulfonamide (Zn45), methoxylsulfonamide (44 and Zn44) and thiazol-2-
ylsulfonamide (Zn43) were tested. The structure of the molecule is an important 
determinant of the photosensitization efficiency. The structure of the SA can not only 
affect the specificity for the enzyme DHPS in the folic acid pathway, but can also have 
an influence in the affinity towards other important components in the cell membrane 
like polysaccharides, lipids and transport proteins, that will ultimately determine the 
efficiency of binding of PS molecules to the cell outer structures and the rate of 
translocation to the intracellular compartment. Pc–SA conjugates containing ‘simple’ 
SA structures such as N,N-diethylsulfonamide or N-isopropylsulfonamide seemed a 
better selection to be used as PSs in the PDI of E. coli and S. aureus. 
5.4  Conclusions 
This work demonstrates that Pc–SA conjugates are promising PS for the 
inactivation of microorganisms. The efficient photosensitization of E. coli and S. aureus 
as Gram-negative and Gram-positive bacterial models was demonstrated. Different SA 
moieties linked to metal-free and ZnPcs were tested. A comparative analysis of the 
performance of the free and the PVP-encapsulated forms of Pc-SA conjugates was also 
established. The performance was highly variable between molecules with or without 
metal and with different SA moieties. Pcs Zn41, Zn42, Zn44 and Zn46 stand out as 
particularly promising PSs. In addition, PVP monomerization effect enhanced singlet 
oxygen production and consequently efficiency of inactivation. 
The results of this work confirm the potential of Pc derivatives for microbial 
photodynamic inactivation of Gram-negative and Gram-positive bacteria. Furthermore, 
it opens a new window for the study of the utilization of Pc-SA conjugates as PSs in a 
additive effect of the Pc PS properties and biocidal properties of SAs. This additive 
effect is seen as a way of enhancing PS selectivity. SAs as well-known antimicrobials 
have the ability to be taken up by bacteria and outer membranes and inhibit DHPS 
enzyme in the periplasm or cytosol.266 The binding of this specific type of molecules to 
the Pc (PS) result in an enhancement of selectivity of these PSs to the target.286–288 
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Taking into consideration the promising results obtained with the tested Pc-SA 
conjugates, it may be interesting to explore different SA structures in the perspective of 
enhance antimicrobial effects. Thus, DHPS enzymatic studies by computational 
simulations technics or in in vitro assays can be performed. Biochemical properties of 
these compounds are an important point to be assessed in the future, by understanding 
to which cell membrane components these compounds are more likely to attach to. 
On the other hand, Pc properties can also be designed. For example, a 
meticulous comparison between the PDI results obtained in this work, in the same 
comparable conditions, by using equivalent Pc-SA conjugates but with cationic moieties 
can be done. Likewise, different drug delivering vehicles can be tested and the 
susceptibility of other bacterial pathogens needs to be explored. 
The results of this work strongly motivates serious attention to Pc-SA conjugates 
as PS as a new therapeutic approach against bacterial infections and are described in an 
article that will be submitted for publication. 
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Chapter 6  Major findings and further work 
Photodynamic therapy is a powerful technique with wide range of applications 
in medicine. Photodynamic inactivation of microorganisms, in particular, it has been 
proved to be a reliable method to substitute or complement the effect of antibiotics that 
have become ineffective on the treatment of several multidrug-resistant 
microorganisms. 
PDT efficiency is influenced by different parameters, namely the intensity and 
wavelength of the light used, the ability of the PS to produce singlet oxygen, and 
affinity towards target cells or tissues. To determine the effect of all this factors in the 
outcome of the photosensitization process, different chemical, photochemical, 
photobiological, photophysical and biological studies have been developed and highly 
interdisciplinary approaches have been followed. However, the type of PS is still a 
crucial factor of the success of photodynamic inactivation protocols. 
In this work, the main effort was put in the achievement of a more selective and 
specific PS with optimized photobiological characteristics. We intended to obtain Pc–
SA conjugates, which could act as antimicrobial and antitumoral PSs. This increased 
efficiency would be achieved not only by the excellent ability of Pcs to produce singlet 
oxygen and to absorb at a wavelength within the optical window CA in tumor cells and 
DHPS in microorganisms that produce folic acid. 
The direct functionalization of Pcs is difficult and leads to the formation of 
complex mixtures. So, the synthesis of Pcs bearing substituents in well-defined 
positions requires the use of adequately substituted precursors, such as Phts. In this 
work was implemented that approach. The synthesis of mono substituted N-acyl SAs 
involved the use of the sulfo-click reaction but this transformation turned out to be quite 
demanding. After testing various experimental conditions, it was possible to obtain a 
Pht– N-acyl-SA conjugate. However, with this method we were not able to obtain the 
corresponding Pc–N-acyl-SA conjugate as intended. Additionally, new Pcs with ethynyl 
groups were produced. This new acetylene containing compounds are versatile 
substrates for further structural modifications. In fact, in collaboration with Brazilian 
researchers, we are studying the possibility of coupling ethynyl Pcs to AZT derivatives. 
The resulting compounds may be useful in HIV/AIDS treatment and to be used as 
antitumoral drugs. 
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Following the sulfo-click reactions discussed in chapter 2, the possibilities of 
affording Pc-SA conjugates were explored. Chapter 3 reports on the development of 
new Pc–SA conjugates. 
Some of the conjugates obtained in this study were used for biological 
evaluation as PSs for the photodynamic inactivation of bacteria and tumor cells. It 
demonstrated for the first time the additive effect of the photosensitizing properties of 
the Pcs and biocidal and antitumoral properties of SAs (chapters 4 and 5). 
This work allowed us to highlight, for the first time, the potential of Pc-SA 
conjugates as PSs in PDT. In addition, the capacity of these compounds to inactivate the 
enzyme CA was also studied. Besides, the capacity of the Pc-SA conjugates to be used 
in the PDI of Gram-positive and Gram-negative bacteria was demonstrated for the first 
time. Furthermore, PVP-encapsulated forms of Pc-SA conjugates were also tested and a 
comparative analysis between these compounds and the corresponding PVP-free 
derivatives were performed. 
From this doctoral work, three articles will be produced for publication. A 
review article on new developments of the synthetic strategies to afford SAs is nearly 
ready. Another manuscript on the synthesis of Pc-SA conjugates and PDI studies has 
been already submitted. Finally, an article with the results obtained in the PDT of HSC3 
oral squamous cell carcinoma and HaCaT ‘normal’ keratinocytes and on the CA 
enzymatic assays in collaboration with Doctor Jon Golding and Doctor Etelvina 
Figueira will be written. 
This work is well tuned with the future challenges expected for medicine. One 
of the most challenging diseases is cancer. PDT is a reliable and powerful approach to 
treat cancer. Pc-SA conjugates contribute to the pursuit for better PSs with the most 
selective and enhanced properties. This work represents an initial step but a long way 
still has to be covered before the results of can be transposed to clinical applications. 
However, the impressive build-up of bacterial resistance to antibiotics, that just recently 
were still effective, sheds a new perspective to innovative tools to control infections. 
PDI stands out as one of the most promising alternatives to traditional antimicrobial 
chemotherapy and with this work, Pc-SA conjugates are unequivocally confirmed as 
promising PSs for PDI. 
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Chapter 7  Experimental section 
7.1 General information 
The organic solvents used in this work were dried according to standard 
methods by distillation over drying agents and stored under nitrogen. All commercially 
available reagents were used as acquired. The progress of reactions was followed by 
TLC performed on silica gel-coated plastic sheets (Merck). TLC plates were visualized 
under UV light (λ=254 nm). Column chromatography was performed using silica gel 
(Merck, 35-70 mesh). Deuterated solvents such as CDCl3 and DMSO-d6 were used for 
1H and 13C NMR spectra. 
1H and 13C NMR spectra were acquired on Bruker DRX AC 300 or 500 
instruments CDCl3 and DMSO-d6 solutions. The frequencies used were 300.13 and 
500.13 MHz for 1H and 75.47 and 125.77 MHz for 13C. Chemical shifts are reported as 
δ-values in part per million (ppm) in relation to tetramehylsilane. Coupling constants (J) 
are in Hz. 
Mass spectra were obtained using Q-TOF (QTOF 2, Micromass, Manchester, 
UK), MALDI-TOF-TOF Applied Biosystems MDS Sciex 4800 and ultrafleXtreme 
mass spectrometer (Bruker, Bremen, Germany) controlled by Compass for flex Series 
1.4, using chloroform as solvent and with DHB matrix. The mass spectra data are 
expressed in terms of the ratio of m/z. 
The UV-Vis spectra (steady-state absorption spectra) were recorded on a 
spectrophotometer UV-2501 PC, Shimadzu, using glass or quartz cell of 1 cm. Steady-
state emission spectra were recorded with a Fluoromax- 3-spectrometer (HORIBA 
Jobin Yvon). 
HSC3 oral squamous carcinoma cells were purchased from ATCC and HaCaT 
‘normal’ keratinocytes cells were a gift of Erik Walbeehm at Erasmus Medical Centre, 
Rotterdam. 
7.2  Synthesis 
7.2.1 4-(4-chlorosulfonylphenoxy)phthalonitrile (2) 
4-Phenoxyphthalonitrile 1 (1.65 g, 5.29 mmol, 1 eq.) was added to 
chlorosulfonic acid (2.49 ml, 37.45 mmol, 5 eq.) cooled in an ice bath. The reaction 
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mixture was stirred for 15 minutes at a temperature between 5 and 10 ºC and then the 
temperature was allowed to rise to room temperature for 15 minutes. After 30 minutes, 
thionyl chloride (1.08 ml, 14.9 mmol, 2 eq.) was added and the reaction was left for 
more 30 minutes at the same temperature. Then, the reaction mixture was poured onto 
ice (300 g) and the solid formed was filtered and washed with cold water. The 
compound was dried under vacuum and used in the following reactions without further 
purification. 
7.2.2 4-(4-(diethylaminosulfonyl)phenoxy)phthalonitrile (9) 
Pht 2 (1.00 g, 3.13 mmol, 1 eq.) was dissolved in acetonitrile (5 ml) and the 
solution was cooled to 0 °C. Diethylamine (0.69 ml, 9.41 mmol, 3 eq.) was added 
slowly to the reaction mixture. The reaction mixture was then stirred at room 
temperature for 2 hours and poured into ice (~ 200 g). The resulting solid was filtered 
off and crystallized from CH2Cl2/Hexane and drying under vacuum at 60 ºC. 
 
yield: 0.870 g white powder (78.0%). 1H NMR (300 MHz, CDCl3): (ppm) = δ 1.18 (t, J 
= 7.1 Hz, 6 H), 3.29 (q, J = 7.1 Hz, 4 H), 7.14 – 7.21 (m, 2 H), 7.31 (dd, J = 2.4, 8.7 Hz, 
1 H), 7.38 (d, J = 2.4 Hz, 1 H), 7.80 (d, J = 8.7 Hz, 1 H), 9.91 (m, 2H). 13C NMR (75 
MHz, CDCl3) δ 14.26, 42.19, 110.35, 114.66, 115.05, 118.02, 120.38, 122.41, 122.60, 
129.85, 135.71, 138.09, 156.97, 160.17. ESI-MS: 355.3 ([M]+). 
7.2.3 4-acetylbenzenesulfonyl azide (11) 
A solution of sodium azide (0.019 g, 0.029 mmol, 1.5 eq.) in water was added 
drop-wise to a solution of acetylbenzenesulfonyl chloride 10 (0.054 g, 0.024 mmol, 1 
eq.) in acetone. The mixture was stirred during 2 hours under an inert atmosphere. 
During this period, the reaction was kept below 0 ºC using an ice-salt bath. After that 
time the mixture was extracted with dichloromethane and the organic layer was dried 
over NaSO4. After filtration of the NaSO4, the solution was evaporated under reduced 
pressure at low temperature to prevent decomposition. The white powder obtained was 
dried under vacuum. 
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yield: 0.039 g white powder (69.7 %). 1H NMR (300 MHz, CDCl3): δ (ppm) = 2.69 (s, 
3 H), 8.05–8.09 (m, 2 H), 8.15–8.19 (m, 2 H). 13C NMR (75 MHz, CDCl3): δ (ppm) = 
26.95, 127.85, 129.38, 141.52, 141.94, 195.26. ESI-MS: 219.3 ([M+H]+). 
7.2.4 4-(3-ethynylphenoxy)phthalonitrile (13) 
A mixture of 4-nitrophthalonitrile (0.50 g, 2.89 mmol, 1 eq.), 3-ethynylphenol 
(0.38 ml, 0.41 g, 3.47 mmol, 1.2 eq.) and potassium carbonate (0.48 g, 3.47 mmol, 1.2 
eq.) in 5 ml of dry DMF was stirred at room temperature overnight. The desired product 
was precipitated in warm water, and the solid obtained was filtered and washed with 
several additions of water and hexane. The product was purified by chromatography on 
a silica gel column using dichloromethane as eluent and recrystallized from 
CH2Cl2/hexane. Product 13 was dried in a vacuum pump during several hours at 60 ºC 
and stored at 55 ºC to eliminate residual water. 
 
yield: 0.055 g white powder (79.0 %). 1H NMR (300 MHz, CDCl3): δ (ppm) = 4.34 (s, 
1 H), 7.24–7.33 (m, 2 H), 7.40–7.45 (m, 2 H), 7.86 (d, J = 2.6, 1 H), 8.12 (d, J = 8.8, 1 
H). ESI-MS: 245.4 ([M + H]+). 
7.2.5 Ethynyl-phthalocyanines 
The 4-(3-ethynylphenoxy)phthalonitrile (13) (0.20 g, 0.81 mmol, 1 eq.) and 4-
tert-butylphthalonitrile (0.754 g, 4.09 mmol, 5 eq.) in DMAE (5 ml) was maintained 
overnight at reflux (140 ºC) under a nitrogen atmosphere, in the presence of zinc acetate 
(0.30 g, 1.64 mmol, 2 eq.). Then, the mixture was precipitated in water/methanol (1:1) 
and the resulting crude was washed several times with the same solvent mixture. The 
various Pcs formed in this statistical condensation were separated on a silica gel column 
using hexane/1,4-dioxane (4:1) as eluent. Finally, the Pc fractions were dried under 
vacuum atmosphere during 2 h at 60 ºC. 
Mono-ethynyl tBuZn Phthalocyanine (14) 
yield: 0.190 g blue-greenish powder (27.5 %). 1H NMR (300 MHz, CDCl3): δ (ppm) = 
4.34 (s, 1 H), 7.93–7.37 (m, 8 H), 9.30 (m, 8 H). MALDI-MS: 860.2 (M+). UV-Vis: 343 
nm (ε = 120 000), 679 nm (ε = 4 500 000). Fluorescence quantum yield: Φ = 0.04. 
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Di-ethynyl tBuZn Phthalocyanine (15) 
yield: 0.071 g blue-greenish powder (10.3 %). 1H NMR (300 MHz, CDCl3): δ (ppm) = 
4.34 (s, 1 H), 4.37 (s, 1 H), 7.81–7.44 (m, 12 H), 9.33–8.82 (m, 8 H). MALDI-MS: 
920.2 (M+). UV-Vis: 348 nm (ε = 120 000), 678 nm (ε = 5 100 000). Fluorescence 
quantum yield: Φ = 0.07. 
Di-ethynyl tBuZn Phthalocyanine (16) 
yield: 0.097 g blue-greenish powder (14.1 %). 1H NMR (300 MHz, CDCl3): δ (ppm) = 
4.34 (s, 1 H), 4.37 (s, 1 H), 7.80–7.44 (m, 12 H), 9.31–8.80 (m, 8 H). MALDI-MS: 
920.2 (M+). UV-Vis: 3453 nm (ε = 120 000), 679 nm (ε = 5 900 000). Fluorescence 
quantum yield: Φ = 0.09. 
7.2.6 4-[3-(4-acetamidophenyl)sulfonylamino-2-
carboxylmethyl)phenoxy]phthalonitrile (17) 
In a boiling flash with a magnetic stir bar copper(I) cyanide (0.08 mg, 0.01 
mmol, catalytic concentration) and compound 13 (0.367 g, 15.2 mmol, 1 eq.) was added 
in the presence of distilled water and 4-acetamidobenzenesulfonyl azide (0.085 g, 15.2 
mmol, 1 eq.) was added at room temperature. 
To this stirred mixture, triethylamine (1,647 ml, 152 mmol, 10 eq.) was slowly 
added via syringe over one min at room temperature. The mixture was then stirred open 
to air for 4 hours at room temperature. The reaction was quenched by addition of a 
saturated aqueous ammonium chloride solution. Methanol was added, and then the 
mixture was stirred for an additional 20 min at the same temperature. The resulting 
mixture was filtered through a Celite pad, and the pad was washed with methanol (5 × 2 
ml). The filtrate was concentrated to half volume using a rotary evaporator, and then the 
resulting solid was collected by suction filtration with aid of distillated water. The solid 
was washed with a pre-cooled (0 ºC) mixture of diethyl ether and isopropyl alcohol 
followed by diethyl ether. After evaporation the light yellowish solid was dissolved in 
boiling methanol and crystallized upon storage in −4 ºC refrigerator for 3 days. The 
crystalline product was collect by suction filtration and was washed with pre-cooled (0 
ºC) methanol. Then the white solid was dried under vacuum at room temperature. 
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yield: 0.192 mg white powder (52.4%). 1H NMR (300 MHz, CDCl3): δ (ppm) = 2.09 (s, 
3 H), 3.60 (m, 2 H), 6.96 (s,1 H), 7.03–7.12 (m, 2 H), 7.32 (dd, J = 8.8, 2.5 Hz, 1 H), 
7.40 (t, J = 7.9 Hz, 1 H), 7.85 – 7.72 (m, 5 H), 8.09 (d, J = 8.7 Hz, 1 H), 10.39 (s, 1 H), 
12.24 (s, 1 H). 
7.2.7 N-((4-acetamidophenyl)sulfonyl)-2-phenylacetamide (22) 
Similar to compound 17, a flash equipped with a magnetic stir bar was charged 
with copper(I) cyanide (0.08 mg, 0.01 mmol, catalytic concentration) and 4-
acetamidobenenesulfonyl azide (0.240 g, 1 mmol, 1 eq.). Distilled water was added to 
the flash, and then phenylacetylene (0.102 g, 1 mmol, 1 eq.) was added via syringe at 
room temperature. 
To this stirred mixture, triethylamine (0.167 ml, 1.2 mmol, 10 eq.) was slowly 
added via syringe over one min at room temperature. The mixture was then stirred open 
to air for 4 hours at room temperature. The reaction was quenched by addition of a 
saturated aqueous ammonium chloride solution. Methanol was added, and then the 
mixture was stirred for an additional 20 min at the same temperature. The resulting 
mixture was filtered through a Celite pad, and the pad was washed with methanol (5 × 2 
ml). The filtrate was concentrated to half volume using a rotary evaporator, and then the 
resulting solid was collected by suction filtration with aid of distillated water. The solid 
was washed with a pre-cooled (0 ºC) mixture of diethyl ether and isopropyl alcohol 
followed by diethyl ether. After evaporation the light yellowish solid was dissolved in 
boiling methanol and crystallized upon storage in −4 ºC refrigerator for 3 days. The 
crystalline product was collect by suction filtration and was washed with pre-cooled (0 
ºC) methanol. Then the white solid was dried under vacuum at room temperature. 
 
yield: 0.203 mg white powder (64.5%). 1H NMR (300 MHz, CDCl3): δ (ppm) = 2.09 (s, 
3 H), 3.53 (m, 2 H), 7.16–7.12 (m,2 H), 7.20–7.32 (m, 3 H), 7.79 (q, 4 H), 10.39 (s, 1 
H), 12.24 (s, 1 H). 
7.2.8 4,5-bis(4-(isopropylaminosulfonyl)phenoxy)phthalonitrile (26) 
Pht 26 was obtained by the reaction of the compound 4,5-bis(4-
chlorosulfonylphenoxy)phthalonitrile 24 (1.54 g, 3.02 mmol, 1 eq.) with slowly 
added isopropylamine (1.49 ml, 18.12 mmol, 6 eq.) in acetonitrile. The mixture 
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was stirred for 1 hour at room temperature under nitrogen atmosphere. The 
desired product was obtained after filtration of the solid formed in water and 
recrystallization from CH2Cl2/hexane.  
 
yield: 0.370 g white powder (23.0%). 1H NMR (300 MHz, CDCl3) δ 7.94–7.89 
(m, 4 H), 7.44 (s, 2 H), 7.08–7.02 (m, 4 H), 3.57–3.46 (m, 2 H), 1.12 (d, J = 6.5 
Hz, 2 H) 13C NMR (126 MHz, CDCl3) δ 23.89, 46.34, 112.77, 114.23, 118.65, 
125.14, 129.73, 138.35, 150.42, 157.58. ESI-MS: 555.1 ([M+H]+). mp: 117-123 
ºC. 
7.2.9 4,5-bis(4-(thiazol-2-ylaminosulfonyl)phenoxy)phthalonitrile 
(27) 
Compound 27 was obtained by reaction of the compound 4,5-bis(4-
chlorosulfonylphenoxy)phthalonitrile 2 (1.00 g, 1.96 mmol, 1 eq.) with 2-aminothiazole 
(0.196 g, 1.96 mmol, 1 eq.) in acetonitrile in the presence of slowly added 4 eq. of 
triethylamine. The mixture was stirred for 2.5 hours at room temperature under nitrogen 
atmosphere. The desired product was purified by chromatography over a silica gel 
column using a mixture of CH2Cl2/hexane (3:1) and crystallization from 
CH2Cl2/hexane.  
 
yield: 0.200 g yellow powder (16.2%). 1H NMR (300 MHz, DMSO) δ 7.07 (d, J = 5.2 
Hz, 2 H), 7.33 (d, J = 7.9 Hz, 4 H), 7.56 (dd, J = 1.3, 7.9 Hz, 4 H), 7.75 (d, J = 5.2 Hz, 2 
H), 8.49 (s, 2H). ESI-MS: 554.6 ([M]+). mp: 250-253 ºC. 
7.2.10 4-(benzylsulfanyl)phthalonitrile (33) 
4-Nitrophthalonitrile (0.100 g, 5.77 mmol, 1 eq.)  and phenylmethanethiol (0.08 
g, 6.93 mmol, 1.2 eq.) were reacted at room temperature in DMF and in the presence of 
cesium carbonate (0.094 g, 2.88 mmol, 0.5 eq.). When 4-nitrophthlonitrile was totally 
consumed, the reaction was stopped with cold water. The resulting solid was filtered 
and washed with cold water and hexane. The solid obtained was dried at room 
temperature in a desiccator. 
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yield: 0.124 g white powder (86.1%). 1H NMR (300 MHz, DMSO) δ 4.25 (s, 2 H), 
7.32–7.37 (m, 4 H), 7.49 (dd, J = 8.4, 1.9 Hz, 1 H), 7.58 (d, J = 1.8 Hz, 1 H), 7.61 (d, J 
= 8.4 Hz, 1H). ESI-MS: 251.1 (M+H]+).  
7.2.11 {2,3,9,10,16,17,23,24-[Octakis(4-
isopropylaminosulfonyl)phenoxy]phthalocyaninato}magnesi
um(II) (Mg42) 
Magnesium turnings (9.27 mg) were added to pentan-1-ol (0.5 ml) and the 
suspension was heated to 150 °C (reflux) and maintained at that temperature until 
the complete formation of the alkoxide (overnight). Octan-1-ol (1 ml) was added 
to the suspension, followed by Pht 26 (0.100 g, 0.189 mmol). The reaction 
mixture was stirred at 160 °C overnight and, after cooling to room temperature, it 
was poured onto a 5:1 methanol/water mixture (20 ml). The resulting precipitate 
was isolated by filtration and washed several times with methanol.  
 
yield: 0.087 g blue powder (82.0%). 1H NMR (300 MHz, DMSO): δ 1.11 (d, J = 
6.5 Hz, 48 H), 3.44-3.55 (m, 16 H), 7.02 (d, J = 8.8 Hz, 16 H), 7.59 (d, J = 9.7 
Hz, 8 H), 7.87 (d, J = 8.8 Hz, 16 H). MALDI: 2242.5 ([M]+), 2265.5 ([M+Na]+). 
mp: > 300 ºC. 
7.2.12 {2,3,9,10,16,17,23,24-[Octakis(4-thiazol-2-
ylaminosulfonyl)phenoxy]phthalocyaninato}magnesium(II) 
(Mg43) 
Magnesium turnings (9.27 mg) were added to pentan-1-ol (0.5 ml) and the 
suspension was heated to 150 °C (reflux) and maintained at that temperature until 
the complete formation of the alkoxide (overnight). Octan-1-ol (1 ml) was added 
to the suspension, followed by Pht 27 (0.100 g, 0.157 mmol). The reaction 
mixture was stirred at 160°C overnight and, after cooling to room temperature, it 
was poured onto a 5:1 methanol/water mixture (20 ml). The resulting precipitate 
was isolated by filtration and washed several times with methanol.  
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yield: 0.078 g blue powder (78.3%). 1H NMR (500 MHz, CDCl3):  δ 6.89-7.11 
(m, 24 H), 7.33-7.55 (m, 16 H), 7.56-7.86 (m, 16 H). MALDI: 2557.1 ([M]+); 
mp: > 300 ºC. 
7.2.13 {2,9(10),16(17),23(24)-[Tetrakis(4-
diethylaminosulfonyl)phenoxy]phthalocyaninato}magnesiu
m(II) (Mg46) 
Magnesium turnings (9.27 mg) were added to pentan-1-ol (0.5 ml) and the 
suspension was heated to 150 °C (reflux) and maintained at that temperature until 
the complete formation of the alkoxide (overnight). Octan-1-ol (1 ml) was added 
to the suspension, followed by Pht 9 (100 mg, 0.281 mmol). The reaction mixture 
was stirred at 160 °C overnight and, after cooling to room temperature, it was 
poured onto a 5:1 methanol/water mixture (20 ml). The resulting precipitate was 
isolated by filtration and washed several times with methanol. 
 
 yield: 0.0874 g blue powder (86.3%). 1H-NMR (500 MHz, CDCl3): δ 1.13-1.19 
(m, 24 H), 3.21-3.30 (m, 16 H), 7.11-7.20 (m, 4 H), 7.45-7.98 (m, 24 H). 
MALDI: 1444.4 ([M]+) mp: > 300 ºC. 
7.2.14 Metallation of phthalocyanines with Zn2+: general 
procedure 
The MgPc (Mg42, Mg43 or Mg46) were dissolved in dry THF (20 ml) in 
a 50 ml three flask equipped with a water condenser. Trifluoroacetic acid (2 ml) 
was added and the mixture was heated at 50 ºC for 3 hours. The removal of the 
coordinated metal cation was monitored by UV-Vis spectroscopy and TLC 
analysis. The reaction mixture was cooled to room temperature and water (ca. 10 
ml) was added until a precipitate was formed. Methanol (2 ml) was added leading 
to further precipitation. Each metal-free Pc 12, 13 and 16 were then collected by 
filtration. After re-dissolving in a minimal amount of DMF, the solution was 
transferred to a sealed tube and 2.5 eq. of zinc acetate was added. The mixture 
was left overnight at 150 ºC. The metallation was confirmed by UV-Vis analysis. 
The reaction mixture was cooled to room temperature and water (ca. 10 ml) was 
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added until a precipitate was formed. Methanol/water 5:1 (2 ml) was added and 
the product was extract with dichloromethane/methanol. After drying with 
anhydrous sodium sulfate the ZnPc (Zn42, Zn43 and Zn46) was crystalized from 
dichloromethane/hexane and the crystals were dried in vacuum. 
7.2.15 {9,10,16,17,23,24-[hexafluoro-2,3-bis(4-
diethylaminosulfonyl)phenoxy]phthalocyaninato}zinc(II) 
(Zn49) 
4,5-Difluorophthalonitrile (0.214 g, 12.7 mmol, 6 eq.) and Pht 25 (0.051 g, 2.8 
mmol, 1 eq.) were reacted in a statistical condensation in chloronaphthalene and in the 
presence of Zn(AcO)2 (0.088 g, 4,80 mmol, 2.2 eq.) overnight. The reaction was 
stopped by precipitation with methanol/H2O (1:1) and the solid obtained was filtered 
and washed with methanol. After purification by chromatography over a silica gel 
column using a mixture of THF/hexane (6:1) and crystallization in THF/hexane the 
desired product was obtained. 
 
yield: 25.2% blue powder. 1H-NMR (300 MHz, CDCl3): δ 1.15 (t, J = 7.1 Hz, 1 H), 
3.24 (q, J = 7.1 Hz, 1 H), 6.99–7.06 (m, 1 H), 7.36–7.61 (m, 1 H), 7.83–7.76 (m, 1 H). 
MALDI: 1163.4 ([M+Na]+); mp: > 300 ºC. 
7.3 Encapsulation of phthalocyanines in polyvinylpyrrolidone 
micelles 
1 mM of stock solutions of Pc 41–44, 46 and Zn41–Zn46 in dichloromethane 
were prepared and 0.5 ml of these solutions were placed in sample ports with 100 mg of 
PVP (40 kDa). As a control, one of the sample ports was prepared in the same way as 
the others but containing only PVP. The resulting solutions were evaporated in N2 until 
oil formation. The sample ports were left at 55 ºC overnight. The resulting polymers 
were dissolved in 1 ml of distilled water and solubilized using ultra-sounds. 
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7.4 Photophysics and photochemistry 
7.4.1 Solubility 
The solubility of Pc–SA conjugates and the respective Pc–SA conjugates 
encapsulated in PVP micelles in DMSO and PBS was assessed by UV–Vis 
spectroscopy. Concentrations between 0.625 and 25 µmol/L obtained by the addition of 
aliquots of each Pc–SA conjugate, were analyzed. The intensity of the Q-band versus 
conjugate concentration was plotted in a graphic for linear regression to check the 
compliance of the Beer–Lambert law. 
7.4.2  Photostability 
The photobleaching rates of Pc–SA conjugates and the respective Pc–SA 
conjugates encapsulated in PVP micelles were determined by irradiating 2 ml of a 
diluted solution of each Pc–SA conjugate in PBS under the same conditions used in the 
biological assays (150 mW/cm2). During irradiation, the solutions were magnetically 
stirred and kept at room temperature. The concentration of the Pc–SA conjugates was 
quantified by visible absorption spectroscopy at regular time intervals. UV–Vis 
spectroscopy was used to determine the intensity of the Q-band at different intervals of 
time and the photostability (%) was expressed as It ⁄ I0*100 (It = intensity of the band at 
given time of irradiation, I0 = intensity of the band before irradiation). Similar assays 
were performed in the dark to account for the effect of aggregation as a source of light-
independent decay. 
7.4.3  Singlet oxygen generation 
The ability of each Pc–SA conjugates and PVP-encapsulated Pc–SA conjugates 
to generate singlet oxygen was qualitatively evaluated following the photooxidation of 
DPBF, a singlet oxygen quencher.72 Stock solutions of each PS at 0.5 mmol/L in DMF 
and a stock solution of DPBF at 50 mmol/L in DMF ⁄ H2O (9:1) were prepared. The 
reaction mixtures of DPBF and each Pc–SA conjugate were irradiated, with white light 
filtered through a cut-off filter for wavelengths < 550 nm, at a fluence rate of 9.0 
mW/cm2. The absorption decay of DPBF at 415 nm was measured at irradiation 
intervals of 1 min, during 7 min. The percentage of the DPBF absorption decay, 
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proportional to the production of 1O2, was assessed by the difference between the initial 
absorbance and the absorbance of DPBF after a given period of irradiation. 
7.5  Photodynamic inactivation 
A recombinant bioluminescent strain of Escherichia coli was used as a model 
for Gram-negative bacteria.289 Before each photodynamic inactivation assay, one 
isolated colony from a culture growing on tryptic soy agar (TSA, Merck) amended with 
the antibiotics ampicillin (100 mg/ml) and chloramphenicol (25 mg/ml) was aseptically 
inoculated on tryptic soy broth (TSB) with both antibiotics and grown overnight at 26 
°C under stirring (130 rpm). An aliquot of this primary culture was sub-cultured in TSB 
with antibiotics (ampicillin and chloramphenicol), grown overnight under stirring (130 
rpm) at 26 °C and used to prepare the cell suspensions for the PDI assays. 
To confirm the correlation between the bioluminescent signal (in relative light 
units, RLU) of E. coli and the concentration of CFU, two independent assays were 
carried out. An overnight culture (~107 CFU/ml) of bioluminescent E. coli was serially 
diluted (101 to 107) in PBS. Light emission of the non-diluted and diluted aliquots was 
read on a luminometer (Turner Designs – 20 ⁄ 20). Viable counts were determined by 
pour-plating 2 replicates of each dilution in TSA medium. After 24 h of incubation at 37 
°C, the number of colonies was counted in the most convenient dilution series. Three 
independent assays were conducted. 
Staphylococcus aureus was used as a model for Gram-positive bacteria.290–292 
Stock cultures in TSA, Merck, were kept at 4 ºC. Fresh cultures were prepared before 
each assay by inoculating an isolated colony in 30 ml of TSB, Merck. The cultures were 
incubated for 24 hours at 37 ºC under stirring (130 rpm). An aliquot of this primary 
culture was sub-cultured in TSB, grown overnight under stirring (130 rpm) at 37 °C to 
obtain fresh cultures for the PDI assays. 
Fresh liquid cultures were 10-fold diluted in PBS and allowed to stabilize under 
stirring for 10 minutes, at room temperature. Aliquots of 0.1 ml were distributed into 1 
ml vials and added of convenient volumes of DMSO stock-solutions of the Pc–SA 
conjugates or aqueous suspensions of PVP-encapsulated conjugates, to achieve final 
concentrations of 20 µM of Pcs. One sole preliminary assay was conducted with E. coli 
at the concentration of 10 µM. The experiments with PS concentrations of 20 µM were 
conducted in 3 independent assays. After adding the PS, the suspensions were pre-
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incubated in the dark, at 37 ºC, for 30 min for adsorption of the PS to the cells and 
further irradiated with white light (400–800 nm) or red light (620–750 nm) delivered by 
an illumination system LC-122 LumaCare equipped with a halogen ⁄ quartz 250 W lamp 
coupled to two different interchangeable optic fiber probes (400–800 nm and 620–750 
nm). The fluence rate was set to 150 mW/cm2 and confirmed with an energy meter 
Coherent FieldMaxII-Top combined with a Coherent PowerSensPS19Q energy sensor. 
Irradiation was conducted for 180 minutes for bioluminescent strain E. coli and for 30 
minutes for S. aureus. Aliquots were periodically retrieved for measurement of 
bioluminescence, in the case of E. coli, or to determine the concentration of viable cells 
by colony counting, in the case of S. aureus. Bioluminescence was measurement in 
triplicate aliquots in a luminometer (TD-20⁄20 Luminometer; Turner Designs, Inc.). To 
determine the concentration of viable cells, the suspension of S. aureus was serially 
diluted in PBS and triplicates of the convenient dilutions were pour-plated in TSA. The 
cultures were incubated at 37 ºC for 24 h. Colonies were counted in the replicates of the 
most suitable dilution and the concentration of viable cells was expressed as CFU/ml. 
Light (without PS) and dark (protected from light) controls were included in all 
experiments. 
7.5.1 Statistical analysis 
Statistical analysis was performed with SPSS package (SPSS 24.0 SPSS Inc.). 
Normal distribution was verified by the Kolmogorov–Smirnov test. The significance of 
irradiation time and type of PS on bacterial inactivation between controls (light control - 
without PS and dark control - protected from light) and the test groups in which the 
bacteria was irradiate with the proper light in the presence of the PS was assessed by 
non-parametric univariate analysis of variance (non-parametric ANOVA) model with 
the Kruskal-Wallis test. A value of p < 0.05 was considered significant. 
7.5.2 Cell cultures 
HSC3 and HaCaT cells were maintained as monolayers in 25 mM glucose 
DMEM supplemented with 100 µU/ml penicillin, 100 µU/ml streptomycin (1% 
penicillin/streptomycin) and 10% heat-inactivated fetal bovine serum, in a humidified 
5% CO2 atmosphere at 37 ºC. For experiments, cells were grown in 24-well tissue 
culture plates in triplicate in 500 µL 5 mM glucose DMEM supplemented with 1% 
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pen/strep and 10% heat-inactivated fetal bovine serum at a density of 1 x 105 cells per 
well and allowed to attach for 24 h to attain ~100% confluence. 
7.5.3 PS loading and PDT treatment 
All manipulations prior to PDT were performed under subdued lighting. Before 
irradiation, the medium  containing serum was replaced with 500 µL serum-free 
medium containing the 3 µM, 10 µM and 15 µM respectively of each PS and cells were 
incubated in the dark at 37 ºC and 5% CO2 for 2 h. Cells were then washed three times 
with PBS and covered with phenol red-free DMEM. Test samples were immediately 
exposed to 10 J/cm2 halogen white light (from a 500 W bulb) for 5 min and 15 sec, heat 
filtered through 5 cm of water in a T175 flask (Nunc 156502) (or maintained in the 
dark, for dark cytotoxicity experiments). A negative control with PVP and three positive 
controls with Foscan (kindly provided by Dr. Alexandre McRobert, UCL, London), at 
the same concentrations used for the PS under study, were also used. Samples were then 
left in a culture incubator overnight in the dark, and then assayed for viability. 
7.5.4 Cell viability analysis 
Cell viability was assessed by MTS assay as described in the technical bulletin. 
20,000 cells/well were incubate for 2 hours with 50 μL of each PS in serum-free 
DMEM. Then, the adhesive cells were washed three times with warm PBS and the 
medium was changed to 100 μL of DMEM + Serum. Each well was irradiated with 
white light (10 J/cm2) for 5 minutes and 15 seconds. Dark toxicity wells were lived 
away from light. Finally, 20 μL of pre-warmed CellTiter MTS was added and the cells 
were incubated for 4 hours. The absorbance was read at 492 nm. 
7.5.5 PS uptake 
The uptake of the PSs in the total cell population was determined by 
fluorescence spectroscopy as described previously.226 10 µM PS in serum-free DMEM 
were incubated for 1 to 4 h and cells were washed three times with warm Hank’s salt 
(HBSS). Then, cells were incubated with DMSO:PBS (1:9) and shaken for 10 min 
(tyrosinase cells from 3x control wells in 100 µL TE for haemocytometer). In a different 
plate, a 10-fold dilution series of each PS in 250 µL DMSO:PBS (1:9) was prepared, 
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starting at 10 µM (10-5 M). PS in the supernatant was assayed by measuring the 
fluorescence using a FLUOstar Optima plate reader (λex = 355 nm, λem = 680 nm). 
7.6 Carbonic anhydrase activity 
Swine blood was collected with 10% (v/v) anticoagulant (0.1 M Tris buffer with 
3.8% sodium citrate). Total non-coagulated blood was centrifuged twice at 3500 rpm 
for 10 min. Plasma was removed and the pellet was resuspended in Tris HCl (0.1 M) 
and vortexed. The suspension was frozen (-80 ºC) and thawed (37 ºC) three times in 
order to disrupt red cell membranes. Lyses were confirmed under a microscope for > 
90% of the cells. A biuret assay was conducted to assess the total protein in the lysate 
that was further stored at -20 ºC. 
An adaptation of the method developed by Moreira et al. was used for the 
determination of CA activity.293 Aliquots of 20 µL of lysate 1:200 diluted in Tris HCl 
buffer (pH 8.3) were transferred to microplate wells, with 80 µL TRIS buffer (0.1 M) 
containing 20 ppm bromothymol blue, and 7.5 µL of each Pc–SA conjugate or PVP-
encapsulated Pc–SA conjugate (15 µM). 200 µL of CO2 saturated distilled H2O 
(obtained by bubbling CO2 gas in distilled H2O for 10 min, and considered saturated 
when pH < 3.5) was added to each sample. A standard control (without Pc–SA 
conjugate or PVP-encapsulated Pc–SA conjugate) was included. Bromothymol blue 
conversion to yellow, indicating CO2 was converted to bicarbonate + protons, was 
immediately measured at 436 nm on a microplate reader (Multiskan GO, VWR) during 
20 min in eight independent assays. All samples and reagents were kept and mixed at 4 
ºC. 
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